Exhibit 99.1
EXECUTION COPY
--------------------------------------------------
PURCHASE AGREEMENT
by and among
E.I. DU PONT DE NEMOURS AND COMPANY,
DUPONT PHARMA, INC.,
DUPONT PHARMACEUTICALS COMPANY,
DUPONT ELECTRONIC MATERIALS, INC.,
DUPONT DIAGNOSTICS INC.
and
XXXXXXX-XXXXX SQUIBB COMPANY
Dated as of June 7, 2001
------------------------------------------------------
TABLE OF CONTENTS
Page
----
ARTICLE I -- DEFINITIONS
1.1 Definitions....................................................2
ARTICLE II -- THE PURCHASE AND SALE
2.1 Purchase and Sale.............................................25
2.2 Purchase Price................................................27
2.3 The Closing...................................................27
2.4 Purchase Price Adjustment.....................................29
2.5 Allocation of Purchase Price..................................33
ARTICLE III -- REPRESENTATIONS AND WARRANTIES OF DUPONT
3.1 Organization, Etc.............................................34
3.2 Authority Relative to this Agreement, Etc.....................34
3.3 Capitalization................................................35
3.4 Consents and Approvals; No Violations.........................36
3.5 Financial Statements..........................................37
3.6 Absence of Certain Changes....................................38
3.7 Compliance with Law, Permits..................................40
3.8 No Undisclosed Liabilities....................................42
3.9 Litigation....................................................42
3.10 Taxes.........................................................43
3.11 Employee Benefit Plans; ERISA.................................45
3.12 Environmental Matters.........................................51
3.13 Real Property.................................................52
3.14 Intellectual Property.........................................53
3.15 Assets........................................................55
3.16 Brokers and Finders...........................................56
3.17 Inventories...................................................56
3.18 Contracts.....................................................56
3.19 Shared Services...............................................59
3.20 Agreements Restricting Affiliates.............................60
i
Page
----
ARTICLE IV -- REPRESENTATIONS AND WARRANTIES OF BUYER AND BUYER SUB
4.1 Corporate Organization; Etc...................................60
4.2 Authority Relative to this Agreement, Etc.....................60
4.3 Consents and Approvals; No Violations.........................61
4.4 Brokers and Finders...........................................61
4.5 Financing.....................................................62
4.6 Securities Act................................................62
ARTICLE V -- COVENANTS
5.1 Conduct of Business...........................................62
5.2 Access to Information.........................................66
5.3 Consents and Approvals........................................67
5.4 Further Assurances............................................69
5.5 Intercompany Accounts and Arrangements........................69
5.6 Provision of Corporate Records................................71
5.7 Names.........................................................72
5.8 Intellectual Property.........................................73
5.9 Post-Closing Cooperation......................................77
5.10 Pending Litigation............................................78
5.11 Employee Matters..............................................78
5.12 Post-Closing Access to Information............................89
5.13 Production of Witnesses and Individuals.......................90
5.14 Retention of Records..........................................90
5.15 Confidentiality...............................................91
5.16 Privileged Matters............................................93
5.17 Mail and Other Communications; Accounts.......................95
5.18 Compliance with WARN Act and Similar Statutes.................96
5.19 Shared Contracts..............................................96
5.20 Certain Matters Relating to Intellectual Property and
Agreements with Merck & Co. Inc............................97
5.21 Section 754 Election..........................................98
5.22 Responsibility for Subsidiaries...............................98
5.23 Maintenance of Partnership Existence..........................99
5.24 Delivery of Financial Statements..............................99
5.25 Certain Real Estate Matters..................................100
ii
Page
----
ARTICLE VI -- TAX MATTERS
6.1 Tax Indemnification..........................................101
6.2 Closing of Current Taxable Year, Etc.........................102
6.3 Tax Returns..................................................103
6.4 Contest Provisions...........................................104
6.5 Transfer Taxes...............................................105
6.6 Certain Post-Closing Settlement Payments and Post-
Closing Actions.........................................106
6.7 Mutual Cooperation...........................................108
6.8 Maintenance of Books and Records.............................108
6.9 Miscellaneous................................................109
ARTICLE VII -- CONDITIONS TO THE SALE
7.1 Conditions to the Obligations of the Sellers to Effect the
Sale....................................................109
7.2 Conditions to the Obligations of Buyer to Effect the Sale....110
ARTICLE VIII -- TERMINATION AND ABANDONMENT; INDEMNIFICATION
8.1 Termination..................................................112
8.2 Procedure and Effect of Termination..........................112
8.3 Survival of Representations, Warranties and Covenants........113
8.4 Indemnification..............................................114
8.5 Environmental Matters........................................119
ARTICLE IX -- MISCELLANEOUS
9.1 Amendment and Modifications..................................122
9.2 Extension; Waiver............................................122
9.3 Representations and Warranties; Etc..........................123
9.4 Entire Agreement; Assignment.................................123
9.5 Validity.....................................................123
9.6 Notices......................................................123
9.7 Governing Law................................................124
9.8 Specific Performance.........................................125
9.9 Publicity....................................................125
9.10 Jurisdiction; Forum, Etc.....................................125
9.11 Descriptive Headings.........................................126
9.12 Counterparts.................................................127
9.13 Expenses.....................................................127
iii
Page
----
9.14 Parties in Interest..........................................127
9.15 Interpretation...............................................127
9.16 Schedules....................................................127
iv
PURCHASE AGREEMENT
PURCHASE AGREEMENT (this "AGREEMENT"), dated as of June 7, 2001, by
and among E.I. du Pont de Nemours and Company, a Delaware corporation
("DUPONT"), DuPont Pharma, Inc., a Delaware corporation ("DPI"), DuPont
Pharmaceuticals Company, a general partnership formed under the laws of the
State of Delaware ("DPC"), DuPont Electronic Materials, Inc., a Delaware
corporation ("DEMI"), DuPont Diagnostics Inc., a Delaware corporation ("DDI"),
and Xxxxxxx-Xxxxx Squibb Company, a Delaware corporation ("BUYER").
WHEREAS, in addition to its other businesses, DuPont is engaged
through DPC, DuPont Pharma, Ltd., a corporation organized under the laws of
Bermuda ("DPL"), DuPont Pharmaceutical Research Labs, Inc., a Delaware
corporation ("DPRL"), and DuPont Contrast Imaging, Inc., a Delaware corporation
("DCI"), and their Subsidiaries (as defined herein) in the research,
development, manufacturing, distribution, marketing and sale of human
pharmaceutical and radiopharmaceutical products and similar product lines; and
WHEREAS, DPC is the direct or indirect record and beneficial owner
of all of the issued and outstanding capital stock of DuPont Pharma SA, a
corporation formed under the laws of Belgium ("PHARMA BELGIUM"), Du Pont
Pharmaceuticals Limited, a corporation formed under the laws of the United
Kingdom ("PHARMA UK"), DuPont Pharma Inc., a corporation formed under the laws
of Canada ("PHARMA CANADA"), DuPont Pharma S.A., a corporation formed under the
laws of France ("PHARMA FRANCE"), DuPont Pharma Italia s.r.l., a corporation
formed under the laws of Italy ("PHARMA ITALY"), DuPont Pharma GmbH, a
corporation formed under the laws of Germany ("PHARMA GERMANY"), Du Pont Sankyo
Pharmaceuticals Co., Ltd, a corporation formed under the laws of Japan ("PHARMA
JAPAN"), Du Pont Farmaceutica, Ltda., a corporation formed under the laws of
Brazil ("PHARMA Brazil"), and DuPont Pharma S.A., a corporation formed under the
laws of Spain ("PHARMA SPAIN")(the "CONTROLLED FOREIGN SUBSIDIARY SHARES"),
other than directors' qualifying shares; and
WHEREAS, DuPont and DPI are the record and beneficial owners of all
of the outstanding general partnership interests in DPC (the "DPC INTERESTS");
and
WHEREAS, DuPont is the record and beneficial owner of all of the
issued and outstanding shares of capital stock of DCI (the "DCI SHARES"); and
WHEREAS, DPI is the record and beneficial owner of all of the issued
and outstanding shares of capital stock of DPRL (the "DPRL SHARES"); and
WHEREAS, DEMI and DDI are the record and beneficial owners of all of
the issued and outstanding shares of capital stock of DPL (the "DPL SHARES");
and
WHEREAS, DuPont is the record and beneficial owner of the all of the
Transferred Equipment (as defined herein); and
WHEREAS, the parties hereto desire that (i) immediately prior to any
transactions described in clauses (ii) through (v) below, DPC sell, convey,
assign, transfer and deliver to one or more Subsidiaries of Buyer (collectively,
the "FOREIGN BUYER SUBS"), all of the Controlled Foreign Subsidiary Shares owned
by DPC, and that DPC immediately distribute the proceeds of such sales to DuPont
and DPI, (ii) DuPont sell, convey, assign, transfer and deliver to a Subsidiary
of Buyer ("BUYER SUB 1") the DPC Interests held by DuPont, the DCI Shares and
the Transferred Equipment, (iii) DPI sell, convey, assign, transfer and deliver
to another Subsidiary of Buyer ("BUYER SUB 2") the DPC Interests held by DPI,
(iv) DPI sell, convey, assign, transfer and deliver to Buyer Sub 1 the DPRL
Shares, and (v) DEMI and DDI sell, convey, assign, transfer and deliver to Buyer
Sub 1 the DPL Shares; and
WHEREAS, at or prior to the Closing (as defined herein), DuPont,
DPC, DPL and Buyer or its Affiliates will enter into the Related Agreements (as
defined herein); and
WHEREAS, the respective Boards of Directors of DuPont, DPI, DEMI,
DDI and Buyer, and of DuPont and DPI in their capacities as general partners of
DPC, have approved and declared advisable this Agreement, the Related Agreements
and the consummation of the transactions contemplated hereby and thereby.
NOW, THEREFORE, in consideration of the foregoing and the mutual
representations, warranties, covenants and agreements herein contained, the
parties hereto hereby agree as follows:
ARTICLE I
DEFINITIONS
1.1 DEFINITIONS. The terms defined in this Article I, whenever used
herein, shall have the following meanings for all purposes of this Agreement:
2
"Action" shall mean any action, claim, suit, arbitration, subpoena,
discovery request, proceeding or investigation by or before any court or grand
jury, any Governmental Authority or arbitration tribunal.
"Additional Transferred Assets" shall mean the Transferred Assets
described in clauses (ii)-(v) of the definition of "Transferred Assets".
"Affiliate" shall mean, with respect to any specified Person, a
Person that, directly or indirectly, through one or more intermediaries,
controls, or is controlled by, or is under common control with, such specified
Person. For purposes of this definition, "control", when used with respect to
any specified Person, means the power to direct the management and policies of
such Person, directly or indirectly, whether through ownership of voting
securities, by Contract or otherwise; and the terms "controlling" and
"controlled" have meanings correlative to the foregoing.
"Agent" shall have the meaning set forth in Section 9.10(b).
"Agreement" shall have the meaning set forth in the recitals.
"Antitrust Laws" shall mean and include (i) the Xxxxxxx Act, as
amended, the Xxxxxxx Act, as amended, the HSR Act, the Federal Trade Commission
Act, as amended, and the EC Merger Regulations and (ii) all other Federal, state
or foreign statutes, rules, regulations, orders, decrees, administrative and
judicial doctrines and other laws that are designed or intended to regulate
competition or investment or to prohibit, restrict or regulate actions having
the purpose or effect of monopolization or restraint of trade.
"Applicable Buyer Plan" shall have the meaning set forth in Section
5.11(b).
"Asset" shall mean, with respect to any Person, any and all of such
Person's title and ownership interest in and to all of the properties, assets,
claims, Contracts and businesses of every kind, character and description,
whether real, personal or mixed, whether tangible or intangible, whether
accrued, contingent or otherwise, and wherever located, including, without
limitation, the following: (i) all Cash, notes and accounts receivable (whether
current or non-current); (ii) all real properties, including plants, buildings
and other structures and improvements (including construction in progress)
located thereon, fixtures contained therein and appurtenances thereto
(including, in the case of the Transferred Business Companies, the Real
Property); (iii) all leases and subleases and all machinery, Equipment
(including all transportation and office equipment), fixtures, trade fixtures
and furniture; (iv) all office supplies, production supplies, spare parts, other
miscellaneous
3
supplies and other tangible property of any kind; (v) all capital stock,
partnership interests and other equity or ownership interests or rights,
directly or indirectly, in any Subsidiary or other entity; (vi) all raw
materials, work-in-process, finished goods, consigned goods and other
inventories; (vii) all Intellectual Property; (viii) all rights existing under
all Contracts; (ix) all rights (including ownership rights or rights arising
under Contracts) relating to all computer hardware, software, computer programs,
systems and documentation relating thereto; all databases and reference and
resource materials; (x) all prepayments, deposits, performance bonds or prepaid
expenses and, to the extent they constitute an asset and not a liability of such
party, deferred tax accounts; (xi) all claims, causes of action, choses in
action, rights of recovery and rights of set-off of any kind; (xii) all customer
lists and records pertaining to customers and accounts, personnel records, all
lists and records pertaining to suppliers and agents, and all books, ledgers,
files and business records of every kind; (xiii) all advertising materials and
all other printed or written materials, including purchase orders, forms,
labels, shipping materials, catalogues, sales brochures, operating manuals, and
instructional documents; (xiv) all permits, licenses, approvals and
authorizations, to the extent transferable, of Governmental Authorities or third
parties relating to the ownership, possession or operation of the Assets; (xv)
all goodwill as a going concern and all other intangible properties; (xvi) all
employee contracts, including, without limitation, the right thereunder to
restrict an employee from competing in certain respects; and (xvii) all trucks,
automobiles and other vehicles.
"Assumed Liabilities" shall mean, except in each case as otherwise
expressly provided in Article VI, any and all Liabilities, arising after the
Closing Date, of DuPont, the Transferred Business Companies or any of their
Affiliates, Subsidiaries or divisions, solely to the extent relating to,
resulting from or arising out of the ownership or use of the Additional
Transferred Assets, other than in any case any Retained Liabilities.
"Audited Financial Statements" shall have the meaning set forth in
Section 5.24(a).
"Audited 1999 Financial Statements" shall have the meaning set forth
in Section 5.24.
"Audited 2000 Financial Statements" shall have the meaning set forth
in Section 5.24.
"Balance Sheet" shall have the meaning set forth in Section 3.5.
"Basket" shall have the meaning set forth in Section 8.4(h).
4
"Belgian Pension Plan" shall have the meaning set forth in Section
3.11(r)(vi).
"Business Day" shall mean any day other than a Saturday, a Sunday or
a day on which United States banks are closed generally.
"Buyer" shall have the meaning set forth in the recitals.
"Buyer Business Material Adverse Effect" shall mean any actual or
prospective change, event or effect that, individually or in the aggregate with
all other such adverse actual or prospective changes, events or effects, is
materially adverse to the business, prospects, Assets, results of operations or
condition (financial or otherwise) of Buyer and its Subsidiaries, taken as a
whole.
"Buyer Caribe DC Plan" shall have the meaning set forth in Section
5.11(h).
"Buyer Environmental Liabilities" shall have the meaning set forth
in Section 8.5(d).
"Buyer Indemnified Parties" shall have the meaning set forth in
Section 8.4(a).
"Buyer Material Adverse Effect" shall mean any actual change, event
or effect that, individually or in the aggregate with all other actual changes,
events and effects, impairs, hinders or adversely affects in any material
respect the ability of Buyer and its Subsidiaries to consummate the Sale or the
other material transactions contemplated hereby.
"Buyer Shared Know-how" means all trade secrets and confidential
business information, including confidential ideas, research and development,
know-how, discoveries, improvements, formulas, manufacturing and production
processes and techniques, technical data, designs, drawings, and specifications
owned by the Transferred Business Companies at the Closing and used by DuPont or
the Retained Subsidiaries in the conduct of the Retained Business as of the
Closing; PROVIDED that, for the avoidance of doubt, Buyer Shared Know-how shall
not include any (x) Patents or (y) applied for or registered Trademarks or
Copyrights.
"Buyer Sub 1" shall have the meaning set forth in the recitals.
"Buyer Sub 2" shall have the meaning set forth in the recitals.
"Buyer Tax Act" shall have the meaning set forth in Section 6.1(a).
5
"Cap" shall have the meaning set forth in Section 8.4(i).
"Caribe DC Plan" shall mean the DuPont Pharma (Puerto Rico) Savings
Plan.
"Cash" shall mean all (i) cash and cash equivalents (including,
without limitation, certificates of deposit and bankers acceptances) and (ii)
marketable debt instruments that mature within three months or less.
"Closing" shall have the meaning set forth in Section 2.3(a).
"Closing Date" shall have the meaning set forth in Section 2.3(a).
"Closing Purchase Price" shall have the meaning set forth in Section
2.2.
"Code" shall mean the Internal Revenue Code of 1986, as amended.
"Confidentiality Agreement" shall have the meaning set forth in
Section 5.2.
"Contract" shall mean any contract, agreement, Lease, license, sales
order, purchase order, instrument or other commitment or arrangement (oral or
written) that is binding on any Person or entity or any part of its property
under applicable Law.
"Controlled Foreign Subsidiaries" shall mean the Subsidiaries of DPC
set forth on Schedule 1.1(a).
"Controlled Foreign Subsidiary Shares" shall have the meaning set
forth in the recitals.
"Copyrights" means all copyrights, and all applications,
registrations, and renewals in connection therewith.
"Xxx-2 Patents" shall mean the Patents set forth in Schedule 1.1(b).
"Current Assets" shall mean all current assets of the Transferred
Business Companies (and all Additional Transferred Assets to the extent current
assets), determined in accordance with GAAP applied on a consistent basis with
the Audited Financial Statements, other than (i) Cash, (ii) accounts receivable
of a Transferred Business Company, owed to it by DuPont or any of its
Subsidiaries (other than Subsidiaries which are Transferred Business Companies),
(iii) any Excluded
6
Assets, (iv) the Endo Note, (v) any Assets relating to Taxes and (vi) any Assets
to be provided under the Related Agreements.
"DCI" shall have the meaning set forth in the recitals.
"DCI Shares" shall have the meaning set forth in the recitals.
"DEMI" shall have the meaning set forth in the recitals.
"Distributee" shall mean a Transferred Employee who elects to
receive a distribution from the DuPont 401(k) Plan, as contemplated by Section
5.11(g).
"DOJ" shall have the meaning set forth in Section 3.4.
"DPC" shall have the meaning set forth in the recitals.
"DPC Action" shall have the meaning set forth in Section 5.10.
"DPC Books and Records" shall mean the books and records of the
Transferred Business, including all computerized books and records of the
Transferred Business, to the extent they primarily relate to the Transferred
Business or the Transferred Assets, including, but not limited to, all such
books and records primarily relating to Transferred Employees, the purchase of
materials, Taxes (insofar as such books and records are reasonably necessary for
the determination of Tax Items for any Post-Closing Tax Period), supplies and
services, the development, marketing, manufacture and sale of products by the
Transferred Business or dealings with suppliers and customers of the Transferred
Business and all files primarily relating to any Action included in the Assumed
Liabilities.
"DPC Financial Statements" shall have the meaning set forth in
Section 3.5(a).
"DPC Interests" shall have the meaning set forth in the recitals.
"DPI" shall have the meaning set forth in the recitals.
"DPL" shall have the meaning set forth in the recitals.
"DPL Shares" shall have the meaning set forth in the recitals.
"DPRL" shall have the meaning set forth in the recitals.
"DPRL Shares" shall have the meaning set forth in the recitals.
7
"Due Date" shall have the meaning set forth in Section 6.3(c).
"DuPont" shall have the meaning set forth in the recitals.
"DuPont Action" shall have the meaning set forth in Section 5.10.
"DuPont Books and Records" shall mean the books and records,
including all computerized books and records, of or owned by DuPont and its
Subsidiaries (including the Transferred Business Companies), other than the DPC
Books and Records.
"DuPont 401(k) Plan" shall mean the Savings & Investment Plan of
E.I. du Pont de Nemours and Company.
"DuPont Indemnified Parties" shall have the meaning set forth in
Section 8.4(b).
"DuPont Marks" shall have the meaning set forth in Section 5.7.
"DuPont Merck Agreement" shall have the meaning set forth in Section
5.20.
"DuPont Shared Know-how" means all trade secrets and confidential
business information, including confidential ideas, research and development,
know-how, discoveries, improvements, formulas, manufacturing and production
processes and techniques, technical data, designs, drawings, and specifications
owned by DuPont or the Retained Subsidiaries at the Closing and used by the
Transferred Business Companies in the conduct of the Transferred Business as of
the Closing; PROVIDED that, for the avoidance of doubt, DuPont Shared Know-how
shall not include any (x) Patents or (y) applied for or registered Trademarks or
Copyrights.
"DuPont UK Plan" shall mean the DuPont Pharmaceutical (U.K.) Limited
Pensions Fund.
"EC Merger Regulations" shall mean Counsel regulation (EEC) No.
4064/89 of December 21, 1989 on the Control of Concentrations Between
Undertakings, OJ (1989) L 395/1 and the regulations and decisions of the
Councilor Commission of the European Community or other organs of the European
Union or European Community implementing such regulations.
"Encumbrance" shall mean any lien, encumbrance, security interest,
charge, mortgage, deed of trust, deed to secure debt, option, pledge or
restriction on
8
transfer of title or voting of any nature whatsoever, other than in the case of
securities, the restrictions imposed by federal, state and foreign securities
laws.
"Endo Note" shall mean the Amended and Restated Promissory Note,
dated as of August 26, 1997, between Endo Pharmaceuticals, Inc. and DPC, and all
other notes due to DPC of Endo Pharmaceuticals, Inc.
"Environment" shall mean any surface water, groundwater, drinking
water supply, land surface or subsurface strata, or ambient air.
"Environmental Claim" means any claim, action, cause of action,
investigation, demand, order, directive or written notice by or on behalf of,
any Governmental Authority or Person, including any Transferred Employee or
former employee, alleging potential liability (including, without limitation,
potential liability for investigatory costs, cleanup costs, governmental
response costs, natural resources damages, property damages, personal injuries,
medical monitoring or penalties) arising out of, based on or resulting from: (i)
the presence, Release or threatened Release of any Hazardous Substance at any
location; (ii) exposure to any Hazardous Substance; or (iii) requirements or
violation of any Environmental Laws or Environmental Permit.
"Environmental Laws" shall mean all Laws relating to pollution or
protection of human health or the Environment, including, without limitation,
the Comprehensive Environmental Response, Compensation, and Liability Act, the
Resource Conservation and Recovery Act, the Clean Air Act, the Clean Water Act,
the Occupational Safety and Health Act, the Toxic Substances Control Act, any
amendments thereto and any rules and regulations promulgated pursuant to or
implementing the foregoing, similar state Laws and other Laws relating to any of
(i) Releases, threatened Releases or the presence of Hazardous Substances or the
manufacture, processing, distribution, use, treatment, storage, transport or
handling of Hazardous Substances, including the disposal of radioactive
materials, (ii) noise or odors, (iii) pollution or protection of the air,
surface water, groundwater, drinking water, land surface or subsurface strata,
or (iv) exposure to Hazardous Substances and employee health and safety.
"Environmental Permit" shall mean any permit, license, approval or
other authorization under any applicable Law or of any Governmental Authority
relating to Environmental Laws.
"Equipment" shall mean all equipment, fixtures, physical facilities,
machinery, inventory, spare parts, supplies, tools and other tangible personal
property.
9
"ERISA" shall have the meaning set forth in Section 3.11(a).
"ERISA Affiliate" shall have the meaning set forth in Section
3.11(a).
"Estimated Closing Adjustment" shall have the meaning set forth in
Section 2.4(a).
"Estimated Closing Balance Sheet" shall have the meaning set forth
in Section 2.4(a).
"Estimated Net Assets" shall have the meaning set forth in Section
2.4(a).
"Exchange Act" shall mean the Securities Exchange Act of 1934, as
amended.
"Excluded Assets" shall mean (i) all Cash and notes receivable
(whether current or non-current), including, without limitation, amounts
outstanding under the Master Note Agreements, but excluding the Endo Note, (ii)
the Cozaar/Hyzaar/Fortzaar patent estate set forth on Schedule 1.1(c) hereto as
amended pursuant to Section 5.20(a), and all associated royalty, profit sharing
and review and approval and other rights, (iii) the Xxx-2 Patents and all
associated royalty, profit sharing and review and approval and other rights,
(iv) all rights (other than rights in related Intellectual Property owned by, or
to the extent licensed to, pursuant to a written license agreement, a
Transferred Business Company) to the compounds and information in DuPont's
Chemical and Biological Clearinghouse other than those compounds, and
information in the possession of a Transferred Business Company relating to
those compounds, set forth on Schedule 1.1(d) hereto, (v) all equity financial
instruments held by DPC set forth on Schedule 1.1(e) hereto, (vi) all rights of
the Sellers under this Agreement and any documents delivered or received in
connection herewith, (vii) all rights under the agreements set forth on Schedule
5.20(a)(i)(A) and the Patents and Trademarks set forth on Schedule
5.20(a)(i)(B), (viii) any rights to be licensed to DuPont pursuant to Section
5.8 (subject to the terms of the license agreements to be entered into in
connection therewith), (ix) the DuPont Marks and (x) the Real Property on
Schedule 1.1(f).
"FAS" shall mean the referenced Financial Accounting Standard
published by the Financial Accounting Standards Board.
"FDA" shall mean the United States Food and Drug Administration.
"Final Closing Adjustment" shall have the meaning set forth in
Section 2.4(e).
10
"Final Closing Balance Sheet" shall mean (i) the Preliminary Closing
Balance Sheet if deemed final pursuant to Section 2.4(c), (ii) any balance sheet
deemed by mutual agreement of Buyer and DuPont to be the Final Closing Balance
Sheet or (iii) the balance sheet determined by the Independent Accounting Firm
to be the Final Closing Balance Sheet in accordance with Section 2.4(d).
"Final Net Assets" shall mean (i) the Preliminary Net Assets if
deemed final pursuant to Section 2.4(c), (ii) the Net Assets deemed by mutual
agreement of Buyer and DuPont to be the Final Net Assets or (iii) the Net Assets
determined by the Independent Accounting Firm to be the Final Net Assets in
accordance with Section 2.4(d).
"Final Determination" means the final resolution of any Tax (or
other Tax matter) for a taxable period that, under applicable law, is not
subject to further appeal, review or modification through proceedings or
otherwise, including (i) by the expiration of a statute of limitations or a
period for the filing of claims for refunds, amending Tax Returns, appealing
from adverse determinations, or recovering any refund (including by offset),
(ii) by a decision, judgment, decree, or other order by a court of competent
jurisdiction, which has become final and unappealable, (iii) by a closing
agreement or an accepted offer in compromise under Section 7121 or 7122 of the
Code, or comparable agreements under laws of other jurisdictions, (iv) by
execution of an Internal Revenue Service Form 870 or 870AD, or by a comparable
form under the laws of other jurisdictions (excluding, however, with respect to
a particular Tax Item for a particular taxable period any such form that
reserves (whether by its terms or by operation of law) the right of the taxpayer
to file a claim for refund and/or the right of the Tax Authority to assert a
further deficiency with respect to such Tax Item for such period), or (v) by any
allowance of a refund or credit, but only after the expiration of all periods
during which such refund or credit may be recovered (including by way of
offset).
"Foreign Buyer Subs" shall have the meaning set forth in the
recitals.
"Foreign Tax Threshold Amount" shall have the meaning set forth in
Section 6.1(a).
"Former DPC Assets" means all Assets formerly owned by any of the
Transferred Business Companies or formerly used in the operation or conduct of
the Transferred Business, other than the Transferred Assets and the Assets
currently used in the Retained Business.
"FTC" shall have the meaning set forth in Section 3.4.
11
"GAAP" shall mean United States generally accepted accounting
principles as in effect on the date or for the period with respect to which such
principles are applied (it being understood that all concepts of materiality
shall be measured by reference to the Transferred Business Companies and not to
DuPont and its Affiliates).
"Good Manufacturing Practices" shall mean current good manufacturing
practices, as set forth in 21 C.F.R. Parts 210 and 211.
"Governmental Antitrust Entity" shall mean any Governmental
Authority with regulatory jurisdiction over enforcement of any applicable
Antitrust Laws.
"Governmental Authority" shall mean any nation or government, any
state, municipality or other political subdivision thereof and any entity, body,
agency, commission or court, whether domestic, foreign or multinational,
exercising executive, legislative, judicial, regulatory or administrative
functions of or pertaining to government and any executive official thereof.
"Governmental Filings" shall have the meaning set forth in Section
3.4.
"Hazardous Substance" shall mean any substance, whether solid,
liquid or gaseous, which is listed, defined or regulated as a "hazardous
substance", "hazardous waste", "oil", "pollutant", "toxic substance", "hazardous
material waste", or "contaminant" or is otherwise classified as hazardous or
toxic, in or pursuant to any Environmental Laws; or which is or contains any
asbestos, polychlorinated biphenyls, urea formaldehyde foam insulation,
explosive, nuclear, or radioactive material, or motor fuel or other petroleum
hydrocarbons, or pesticides, insecticides, fungicides, or rodenticides, or
biohazardous materials or waste.
"HSR Act" shall mean the Xxxx-Xxxxx-Xxxxxx Antitrust Improvements
Act of 1976, as amended.
"Indebtedness" of any Person shall mean, (a) all obligations of such
Person for borrowed money, including with respect to deposits or advances of any
kind, (b) all obligations of such Person evidenced by bonds, debentures, notes
or similar instruments, (c) all obligations of such Person upon which interest
charges are customarily paid, (d) all obligations of such Person under
conditional sale or other title retention agreements relating to property or
Assets purchased by such Person, (e) all obligations of such Person issued or
assumed as the deferred purchase price of property or services, (f) obligations
of such Person under letters of credit, (g) all
12
Indebtedness of others secured by (or for which the holder of such Indebtedness
has an existing right, contingent or otherwise, to be secured by) any mortgage,
lien, pledge, or other Encumbrance on property owned or acquired by such Person,
whether or not the obligations secured thereby have been assumed, (h) all
guarantees by such Person of Indebtedness of others, (i) all capital lease
obligations of such Person, and (j) all securities or other similar instruments
convertible or exchangeable into any of the foregoing.
"Indemnified Party" shall have the meaning set forth in Section
8.4(e).
"Indemnifying Party" shall have the meaning set forth in Section
8.4(e).
"Indemnitee" shall mean any party who is entitled to receive payment
from an Indemnifying Party pursuant to Section 8.4 or Section 8.5.
"Independent Accounting Firm" shall be an accounting firm selected
in the manner set forth in Section 2.4(d).
"Information" shall have the meaning set forth in Section 5.12.
"Intellectual Property" means (i) all Patents, (ii) all Trademarks,
(iii) all Copyrights, (iv) all trade secrets and confidential business
information, whether patentable or unpatentable, including confidential ideas,
research and development, know-how, discoveries, improvements, formulas,
manufacturing and production processes and techniques, technical data, designs,
drawings, and specifications and all customer and supplier lists and (v) all
Software.
"IP Disclosure" shall have the meaning set forth in Section 3.14(b).
"IRS" shall mean the United States Internal Revenue Service or any
successor agency.
"ISRA" shall have the meaning set forth in Section 5.3.
"Knowledge" shall mean, with respect to DuPont, the actual
knowledge, after reasonable inquiry, of any officer of DuPont or any of its
Subsidiaries (including the Transferred Business Companies) who has managerial
responsibility for any significant department or function of the Transferred
Business or any of the persons listed on Schedule 1.1(g) hereto.
"Law" shall mean any law, statute, ordinance, rule, regulation,
order, writ, judgment, Code, injunction or decree of any Governmental Authority.
13
"Leased Real Property" means the real property leased or subleased
by one of the Transferred Business Companies pursuant to a Lease, together with,
to the extent also leased or owned by one of the Transferred Business Companies,
all buildings and other structures, facilities or improvements currently or
hereafter located thereon, all fixtures of one of the Transferred Business
Companies attached or appurtenant thereto and all easements, licenses, rights
and appurtenances relating to the foregoing.
"Leases" shall mean all leases, subleases, licenses, concession
agreements, use and occupancy agreements or similar arrangements, pursuant to
which any Transferred Business Company has a leasehold or similar interest in
Assets.
"Lemelson Agreement" shall have the meaning set forth in Section
5.8(f).
"Liabilities" shall mean any and all Indebtedness, liabilities and
obligations, whether accrued, fixed or contingent, mature or inchoate, known or
unknown, reflected on a balance sheet or otherwise, including, but not limited
to, those arising under any Law or any judgment of any court of any kind or any
award of any arbitrator of any kind, and those arising under any Contract,
commitment or undertaking.
"Listed Agreements" shall have the meaning set forth in Section
5.11(e).
"LNA" shall have the meaning set forth in Section 5.3(a).
"Losartan Manufacturing Agreements" shall have the meaning set forth
in Section 5.23.
"Losses" shall mean any and all damages, losses, deficiencies,
Liabilities, obligations, penalties, judgments, settlements, claims, payments,
fines, interest, costs and expenses (including, without limitation, the costs
and expenses of any and all Actions and demands, assessments, judgments,
settlements and compromises relating thereto and the costs and expenses of
attorneys', accountants', consultants' and other professionals' fees and
expenses incurred in the investigation or defense thereof or the enforcement of
rights hereunder), but excluding consequential damages, loss of profits and
punitive damages (other than such damages awarded to any third party against an
Indemnified Party). Notwithstanding the foregoing, (i) Losses shall expressly
include any diminution in the fair value of any Asset (other than goodwill) and
(ii) for purposes of Section 3.17, Losses in
14
respect of any breach thereof shall be limited to the cost of any excess
inventory to the extent such inventory constitutes a breach of such
representation.
"MAA" shall have the meaning set forth in Section 3.7(c)(ii).
"Master Note Agreements" shall mean (i) the Master Note Agreement,
dated as of August 14, 1998, between DuPont and DPC and (ii) the Master Note
Agreement, dated as of September 17, 1999, between DuPont and DCI. "Material
Adverse Effect" shall mean any actual or prospective change, event or effect
that, individually or in the aggregate with all other such adverse actual or
prospective changes, events and effects, (i) is materially adverse to the
business, prospects, Assets, results of operations or condition (financial or
otherwise) of the Transferred Business Companies (including the Additional
Transferred Assets), taken as a whole (after taking into account insurance
recoveries in respect thereof which remain with the Transferred Business
Companies after the Closing), or (ii) impairs, hinders or adversely affects in
any material respect the ability of DuPont and its Subsidiaries to consummate
the Sale or the other material transactions contemplated hereby; PROVIDED,
HOWEVER, that the foregoing definition shall, for purposes of Section
8.4(a)(iii), but not Section 7.2(a), exclude actual or prospective changes,
events or effects to the extent they result from the development of products and
compounds, or additional or new therapeutic applications and uses of existing
products and compounds, in each case by third parties; PROVIDED, FURTHER, that
the foregoing proviso shall not apply to the extent that any change, event or
effect is reflected in (1) the results of operations or financial condition of
the Transferred Business Companies prior to the Closing or (2) to the extent
related to currently marketed products, the business or assets of the
Transferred Business Companies prior to the Closing; PROVIDED, FURTHER, that any
actual or prospective effects, events, or changes to the extent relating to or
resulting from (a) any change or changes in general economic conditions
(including, without limitation, changes in financial or market conditions) or
any change or changes applying generally to the pharmaceuticals industry in the
geographical areas in which the Transferred Business Companies operate (and not
specifically to the Transferred Business Companies), (b) the announcement or
consummation of the transactions contemplated by this Agreement (PROVIDED that
the exception in this clause (b) shall not apply to the use of the term
"Material Adverse Effect" in Section 3.4), or (c) any change in accounting
requirements or principles or the interpretation thereof, shall be deemed not to
constitute a "Material Adverse Effect"; PROVIDED, FURTHER, that the term
"Material Adverse Effect" shall not include or take into account (x) any change,
effect or event relating to any of the Transferred Business Companies' compounds
which are not yet nominated for development or (y) any of the matters referred
to in the IP Disclosure. For purposes of this definition of Material Adverse
Effect, each Assumed Liability
15
shall be deemed to be a Liability of, and each Additional Transferred Asset
shall be deemed to be an Asset of, the Transferred Business Companies.
"Minimum Buyer Adjustment Amount" shall mean $20 million.
"Minimum DuPont Adjustment Amount" shall mean $50 million.
"NDA" shall mean a New Drug Application or Product License
Application for any product of the Transferred Business, as appropriate,
requesting permission to place a drug on the market in accordance with 21 C.F.R.
Part 314, and all supplements filed pursuant to the requirements of the FDA,
including all documents, data and other information concerning such product
which are necessary for FDA approval to market such product in the United
States.
"Net Assets" shall mean the Current Assets minus the Total
Liabilities, as of the close of business (New York time) on the Closing Date.
"Outside Date" shall have the meaning set forth in Section 8.1(b).
"Owned Real Property" means the real property owned by any of the
Transferred Business Companies, together with all buildings and other
structures, facilities or improvements currently or hereafter located thereon
(except to the extent set forth on Schedule 1.1(h)) and all fixtures attached or
appurtenant thereto and all easements, licenses, rights and appurtenances
relating to the foregoing.
"Patents" means all inventions (whether patentable or unpatentable
and whether or not reduced to practice), and all U.S. and foreign patents,
patent applications, and patent disclosures (and all rights related thereto,
including all reissues, divisions, continuations, continuations-in-part,
substitutions, extensions, or renewals of any of the foregoing).
"Payor" shall have the meaning set forth in Section 6.3(c).
"PBGC" shall have the meaning set forth in Section 3.11(c).
"Pending Transferred Employees" shall have the meaning set forth in
Section 5.1(b)(4).
"Permits" shall have the meaning set forth in Section 3.7(a).
"Permitted Encumbrances" shall mean:
16
(a) Encumbrances identified on Schedule 1.1(i) or specifically
identified on the DPC Financial Statements (including in the notes
thereto);
(b) all Encumbrances approved in writing by Buyer;
(c) easements, rights-of-way, servitudes, permits, licenses, surface
leases and other rights; conditions, covenants or other restrictions; and
easements for streets, alleys, highways, telephone lines, power lines and
railways, and all matters of record (other than liens securing
indebtedness for borrowed money), over or in respect of any Real Property,
which in the case of each of the foregoing does not and will not interfere
in any material respect with the operation or use of any of the affected
Real Property as the Transferred Business is currently conducted;
(d) Encumbrances for Taxes, assessments, or other governmental
charges not yet due or payable or that may be subsequently paid without
penalty or that are being contested in good faith by appropriate
proceedings;
(e) any materialman's, mechanics', repairman's, employees',
contractors', operators', landlord's or other similar liens arising in the
ordinary course of business;
(f) all Encumbrances, Contracts, agreements, instruments,
obligations, defects and irregularities affecting or encumbering the
Assets that individually or in the aggregate are not such as to materially
and adversely (i) impair the marketability or market value of any material
Asset not constituting Real Property in the Transferred Business as
currently conducted or (ii) interfere with the operation or use of any
material Asset in the Transferred Business as currently conducted; and
(g) liens that have been placed by any developer, landlord or other
third party on property over which any Transferred Business Company has
easement rights or on any Leased Real Property and subordination or
similar agreements relating thereto.
"Person" shall mean any individual, corporation, limited liability
company, partnership, trust or other entity.
"Pharma Belgium" shall have the meaning set forth in the recitals.
"Pharma Brazil" shall have the meaning set forth in the recitals.
"Pharma Canada" shall have the meaning set forth in the recitals.
17
"Pharma France" shall have the meaning set forth in the recitals.
"Pharma Germany" shall have the meaning set forth in the recitals.
"Pharma Japan" shall have the meaning set forth in the recitals.
"Pharma Spain" shall have the meaning set forth in the recitals.
"Pharma UK" shall have the meaning set forth in the recitals.
"Pharmaceutical Field of Use" shall mean all commercial
applications, including associated discovery, research, development, and
commercialization activities, of new drug products or diagnostic products or
over-the-counter drug products (including any biological products) intended for
use in the cure, mitigation, treatment or prevention or IN VIVO diagnosis of
disease or injury in humans, or intended to affect the structure or any function
of the body of humans or components thereof, which if commercialized would have
to be approved for marketing by appropriate regulatory agencies. Notwithstanding
the foregoing, such Pharmaceutical Field of Use shall not include products
intended for use as functional foods, nutraceuticals, supplements (including
vitamin or mineral supplements), animal drugs, biomaterials (whether or not
intended for use in medical devices), or any product produced in a plant.
"Post-Closing Tax Period" shall have the meaning set forth in
Section 6.1(b).
"Post-Retirement Period" shall have the meaning set forth in Section
5.11(n).
"Pre-Adjusted Closing Purchase Price" shall have the meaning set
forth in Section 2.2.
"Pre-Closing Tax Period" shall have the meaning set forth in Section
6.1(a).
"PR Tax Grant" shall mean the Grant of Industrial Tax Exemption
granted by the Puerto Rico Department of State-Office of Industrial Tax
Exemption to DuPont Pharma Ltd., Case No. 99-135-I-33, granted as of December
30, 1999 as amended effective December 30, 1999.
"Preliminary Closing Balance Sheet" shall have the meaning set forth
in Section 2.4(b).
18
"Preliminary Net Assets" shall have the meaning set forth in Section
2.4(b).
"Preparer" shall have the meaning set forth in Section 6.3(c).
"Privilege" shall have the meaning set forth in Section 5.16(a).
"Privileged Information" shall have the meaning set forth in Section
5.16(a).
"PTO" shall have the meaning set forth in Section 5.11(f).
"Purchase Price" shall have the meaning set forth in Section 2.2.
"Purchase Price Allocation Schedule" shall have the meaning set
forth in Section 2.5.
"Real Property" means, collectively, the Leased Real Property and
the Owned Real Property.
"Recipient" shall have the meaning set forth in Section 6.4(a).
"Reference Net Assets" shall mean a net asset of $195 million.
"Related Agreements" shall mean the (i) Administrative Services
Agreement in the form to be agreed upon prior to the Closing by the parties in
good faith with terms consistent with those attached as Exhibit A hereto, (ii)
License and Supply Agreement in the form attached as Exhibit B hereto, (iii)
Agency Agreement in the form attached as Exhibit C hereto, (iv) Drum Storage
Agreement in the form attached as Exhibit D hereto, (v) Lease Agreements for the
Leased Real Property set forth in Schedule 1.1(j) in the form attached as
Exhibit E hereto and (vi) Site Services Agreements for the Real Property set
forth in Schedule 1.1(k) in the form to be agreed upon prior to the Closing by
the parties in good faith with terms consistent with those attached as Exhibit F
hereto.
"Release" means any release, spill, emission, discharge, leaking,
pumping, injection, deposit, disposal, dispersal, leaching or migration into the
indoor or outdoor Environment or into or out of any property, including the
movement of Hazardous Substances through or in the air, soil, surface water or
groundwater.
"Representative" shall mean, with respect to any Person, each of
such Person's directors, officers, employees, representatives, attorneys,
accountants, advisors and agents.
19
"Required Antitrust Approvals" shall mean any required filings,
consents and approvals pursuant to (i) the HSR Act, (ii) the EC Merger
Regulations and (iii) all other antitrust approvals required in order to
consummate the Sale.
"Required Filings" shall mean any required filings pursuant to (i)
the HSR Act, (ii) the EC Merger Regulations and (iii) all other foreign or
domestic filings required in order to consummate the Sale.
"Retained Business" shall mean the businesses in which, and the
activities in which, DuPont and its Subsidiaries have been formerly or are
currently engaged, but excluding the Transferred Business.
"Retained Employees" shall mean all current and former officers,
directors and employees of DuPont and its Affiliates, other than the Transferred
Employees.
"Retained Environmental Assets" shall have the meaning set forth in
Section 8.5(a)(ii).
"Retained Liabilities" shall mean, except in each case as otherwise
expressly provided in Article VI, (a) any and all Liabilities, whether arising
before or after the Closing Date, of DuPont, its Subsidiaries (including without
limitation the Transferred Business Companies) or any of their predecessor
companies or businesses, or any of their Affiliates, Subsidiaries or divisions,
to the extent the same relates to, results from or arises out of the present,
past or future operations or conduct of the Retained Business or the use or
ownership of the Excluded Assets and (b) any Liabilities for Losses allocated to
DuPont or a Retained Subsidiary, determined pursuant to Section 5.19 or 8.5
hereof.
"Retained Subsidiary" shall mean any Subsidiary of DuPont, other
than the Transferred Business Companies.
"Retention Plan Liabilities" shall mean any Liabilities arising
under (i) the Strategic Performance Incentive Plan, (ii) the 25% bonus increment
to the 2001 Variable Compensation Plan and (iii) the increment to the Sales
Incentive Compensation Plan announced to DPC employees on February 7, 2001.
"Sale" shall have the meaning set forth in Section 2.2 hereof.
"Sale Process" shall mean all matters relating to DuPont's sale of
the Transferred Business and all activities by or for DuPont in connection
therewith, including the process undertaken by DuPont with respect to soliciting
proposals from
20
third parties and the consideration of, and actions taken in connection with,
possible alternatives to the transactions contemplated by this Agreement.
"SEC" shall mean the Securities and Exchange Commission.
"Securities Act" shall mean the Securities Act of 1933, as amended.
"Seller Environmental Liabilities" shall have the meaning set forth
in Section 8.5(b).
"Sellers" shall mean DuPont, DPI, DEMI and DDI.
"Shared Contracts" shall mean the Contracts listed on Schedule
1.1(l).
"Shared Contractual Liabilities" shall mean Liabilities in respect
of Shared Contracts.
"Software" shall mean all computer software, including all software
implementation of algorithms, models and methodologies, whether in object code
or source code, databases and compilations, and documentation and user manuals
relating to the foregoing, to the extent owned by or licensed to a Transferred
Business Company.
"Straddle Period" shall have the meaning set forth in Section
6.2(b).
"Subsidiary" of a Person shall mean a corporation, partnership,
joint venture, association, limited liability company or other entity of which
such Person owns, directly or indirectly, 50% or more of the outstanding voting
stock or other ownership interests.
"Substituted Assumptions" shall have the meaning set forth in
Section 5.11(j).
"Tax Asset" shall mean any Tax Item that could reduce a Tax,
including a net operating loss, net capital loss, investment tax credit, foreign
tax credit, or any other Tax credit or deduction.
"Tax Audit" shall have the meaning set forth in Section 6.4(a)
hereof.
"Tax Authority" shall mean a Governmental Authority or any
subdivision, agency, commission or authority thereof, or any quasi-governmental
or private body having jurisdiction over the assessment, determination,
collection or imposition of any Tax (including, without limitation, the IRS).
21
"Taxes" shall mean (x) any charges, fees, levies, imposts, duties,
or other assessments of a similar nature, including income, alternative or
add-on minimum, gross receipts, profits, lease, service, service use, wage, wage
withholding, employment, workers compensation, business occupation, occupation,
premiums, environmental, estimated, excise, employment, sales, use, transfer,
license, payroll, franchise, severance, stamp, occupation, windfall profits,
withholding, social security, unemployment, disability, ad valorem, estimated,
highway use, commercial rent, capital stock, paid up capital, recording,
registration, property, real property gains, real estate, value added, business
license, custom duties, or other tax or governmental fee of any kind whatsoever,
imposed or required to be withheld by any Tax Authority including any interest,
additions to tax, or penalties applicable or related thereto, (y) Liability for
the payment of any amounts of the type described in clause (x) as a result of
being a member of an affiliated, consolidated, combined, unitary or aggregate
group and (z) Liability for the payment of any amounts as a result of being
party to any Tax Sharing Agreement or as a result of any express or implied
obligation to indemnify any other Person with respect to the payment of any
amounts of the type described in clause (x) or (y).
"Tax Item" shall mean any item of income, gain, loss, deduction or
credit, or other attribute that may have the effect of increasing or decreasing
any Tax.
"Tax Return" shall mean any return, report, certificate, form or
similar statement or document (including any related or supporting information
or schedule attached thereto and any information return, amended tax return,
claim for refund or declaration of estimated tax) required or permitted to be
supplied to, or filed with, a Tax Authority in connection with the
determination, assessment or collection of any Tax or the administration of any
Laws relating to any Tax.
"Tax Sharing Agreement" means any existing agreement or arrangement
(whether or not written) binding any of the Transferred Business Companies that
provide for the allocation, apportionment, sharing or assignment of any Tax
liability or benefit, or the transfer or assignment of income, revenues,
receipts, or gains for the principal purpose of determining any Person's Tax
liability (including any advance pricing agreement, closing agreement or other
agreement relating to Taxes with any Taxing Authority).
"Third Party Claim" shall mean any Action brought, asserted or
commenced by any Person, other than by a DuPont Indemnified Party or a Buyer
Indemnified Party, against any DuPont Indemnified Party or Buyer Indemnified
Party.
22
"Total Liabilities" shall mean all Liabilities of the Transferred
Business Companies (and all Assumed Liabilities), determined in accordance with
GAAP applied on a basis consistent with the Audited Financial Statements, other
than (i) accounts payable of a Transferred Business Company, owed by it to
DuPont or any of its Subsidiaries (other than Subsidiaries which are Transferred
Business Companies), (ii) any Retained Liabilities, (iii) any reserve related to
the litigation described in Schedule 1.1(m), (iv) any Liabilities relating to
Taxes, (v) any non-current employee related Liabilities, any Retention Plan
Liabilities and any Liabilities under the Listed Agreements and (vi) any
accruals for Liabilities under the Related Agreements.
"Trademarks" means all registered and unregistered service marks,
trademarks, trade names, brand names, certification marks, corporate names,
trade dress, Internet domain names, identifying symbols, logos, emblems, signs
or insignia, including all goodwill associated therewith, and all applications,
registrations, and renewals in connection therewith.
"Transfer Taxes" shall have the meaning set forth in Section 6.5.
"Transferred Assets" shall mean (i) any and all Assets of the
Transferred Business Companies, but excluding the Excluded Assets and the Assets
that the Related Agreements expressly contemplate being retained by DuPont and
the Retained Subsidiaries, (ii) the Transferred Equipment, (iii) all of DuPont's
rights under the Agreements set forth on Schedule 5.20(a)(ii)(A), (iv) all of
DuPont's rights related to the Intellectual Property set forth on Schedule
5.20(a)(ii)(B), and (v) any rights to be licensed to Buyer pursuant to Section
5.8 (subject to the terms of the license agreements to be entered into in
connection therewith).
"Transferred Business" shall mean the business of researching,
developing, manufacturing, distributing, marketing and selling human
pharmaceutical and radiopharmaceutical products and related product lines as
presently conducted by DuPont and its Subsidiaries (including the Transferred
Business Companies), but excluding, in any event, (i) the business and
activities currently or formerly conducted by DuPont and its Subsidiaries to the
extent related to the Excluded Assets and (ii) the business, currently or
formerly conducted by DuPont and its Subsidiaries, of researching, developing,
distributing, marketing and selling human pharmaceutical and radiopharmaceutical
products that incorporate one or more of the Patents described in clause (ii),
(iii) or (vii) of the definition of Excluded Assets and any related products.
"Transferred Business Companies" shall mean DPC, DPL, DCI, DPRL and
their respective Subsidiaries.
23
"Transferred Business Plans" shall have the meaning set forth in
Section 3.11(a).
"Transferred Business Title IV Plan" shall have the same meaning as
set forth in Section 3.11(d).
"Transferred Contracts" shall have the meaning set forth in Section
3.18(b).
"Transferred Employees" means (x) those persons who are employed as
officers or employees of the Transferred Business Companies immediately prior to
or effective as of the Closing and (y) all former officers and employees of the
Transferred Business Companies; PROVIDED that, in the event any person shall
have been employed by any of the Transferred Business Companies, as well as in
the Retained Business, such person shall be considered a Transferred Employee if
(i) as of the Closing Date such person's primary employment shall be with a
Transferred Business Company or (ii) such person's employment with the
Transferred Business Company terminated later than such person's employment with
the Retained Business.
"Transferred Environmental Assets" shall have the meaning set forth
in Section 8.5(a)(i).
"Transferred Equipment" shall mean the Equipment set forth on
Schedule 1.1(n).
"Transferred Pension Plans" shall have the meaning set forth in
Section 3.11(s).
"Treasury Regulations" shall mean the final, temporary and proposed
regulations promulgated by the United States Treasury Department under the Code.
"Unaudited Interim Financial Statements" shall have the meaning set
forth in Section 5.24(b).
"Underfunding" shall have the meaning set forth in Section 5.11(j).
"WARN Act" shall have the meaning set forth in Section 5.18.
"Wholly-Owned Subsidiary" shall mean, with respect to any Person,
any Subsidiary of such Person if all of the common stock or other similar equity
ownership interests (but not including non-participating preferred stock) in
such Subsidiary (other than any director's qualifying shares or investments by
foreign
24
nationals mandated by applicable Law) is owned directly or indirectly by such
Person.
ARTICLE II
THE PURCHASE AND SALE
2.1 PURCHASE AND SALE.
(a) Upon the terms and subject to the conditions of this
Agreement, on the Closing Date:
(i) immediately prior to any of the transactions
described in clauses (ii) through (vi) of this Section 2.1(a), (A) DPC
shall sell, convey, assign, transfer and deliver to a Foreign Buyer Sub,
and Buyer shall cause such Foreign Buyer Sub to, purchase, acquire and
accept from DPC, all of the shares of capital stock of Pharma Belgium and
DPC shall immediately distribute the proceeds of such sale to DuPont and
DPI, (B) DPC shall sell, convey, assign, transfer and deliver to a Foreign
Buyer Sub, and Buyer shall cause such Foreign Buyer Sub to, purchase,
acquire and accept from DPC, all of the shares of capital stock of Pharma
UK and DPC shall immediately distribute the proceeds of such sale to
DuPont and DPI, (C) DPC (or DuPont if DPC has distributed Pharma Canada to
DuPont prior to the Closing) shall sell, convey, assign, transfer and
deliver to a Foreign Buyer Sub, and Buyer shall cause such Foreign Buyer
Sub to, purchase, acquire and accept from DPC (or DuPont if DPC has
distributed Pharma Canada to DuPont prior to the Closing), all of the
shares of capital stock of Pharma Canada and DPC shall immediately
distribute the proceeds of such sale to DuPont and DPI, (D) DPC shall
sell, convey, assign, transfer and deliver to a Foreign Buyer Sub, and
Buyer shall cause such Foreign Buyer Sub to, purchase, acquire and accept
from DPC, all of the shares of capital stock of Pharma France and DPC
shall immediately distribute the proceeds of such sale to DuPont and DPI,
(E) DPC shall sell, convey, assign, transfer and deliver to a Foreign
Buyer Sub, and Buyer shall cause such Foreign Buyer Sub to, purchase,
acquire and accept from DPC, all of the shares of capital stock of Pharma
Italy and DPC shall immediately distribute the proceeds of such sale to
DuPont and DPI, (F) DPC shall sell, convey, assign, transfer and deliver
to a Foreign Buyer Sub, and Buyer
25
shall cause such Foreign Buyer Sub to, purchase, acquire and accept from
DPC, all of the shares of capital stock of Pharma Germany and DPC shall
immediately distribute the proceeds of such sale to DuPont and DPI, (G)
DPC shall sell, convey, assign, transfer and deliver to a Foreign Buyer
Sub, and Buyer shall cause such Foreign Buyer Sub to, purchase, acquire
and accept from DPC, all of the shares of capital stock of Pharma Japan
and DPC shall immediately distribute the proceeds of such sale to DuPont
and DPI, (H) DPC shall sell, convey, assign, transfer and deliver to a
Foreign Buyer Sub, and Buyer shall cause such Foreign Buyer Sub to,
purchase, acquire and accept from DPC, all of the shares of capital stock
of Pharma Brazil and DPC shall immediately distribute the proceeds of such
sale to DuPont and DPI, and (I) DPC shall sell, convey, assign, transfer
and deliver to a Foreign Buyer Sub, and Buyer shall cause such Foreign
Buyer Sub to, purchase, acquire and accept from DPC, all of the shares of
capital stock of Pharma Spain and DPC shall immediately distribute the
proceeds of such sale to DuPont and DPI (excluding, in the case of each of
the foregoing clauses (A) through (I), any director's qualifying shares or
investments by foreign nationals mandated by applicable Law);
(ii) DuPont shall sell, convey, assign, transfer and
deliver to Buyer Sub 1, and Buyer shall cause Buyer Sub 1 to, purchase,
acquire and accept from DuPont, all of (A) the DPC Interests held by
DuPont, (B) the DCI Shares and (C) DuPont's right, title and interest in
and to the Transferred Equipment;
(iii) DPI shall sell, convey, assign, transfer and
deliver to Buyer Sub 2, and Buyer shall cause Buyer Sub 2 to, purchase,
acquire and accept from DPI, immediately following the transfer referred
to in clause (ii)(A) above, all of the DPC Interests held by DPI;
(iv) DPI shall sell, convey, assign, transfer and
deliver to Buyer Sub 1, and Buyer shall cause Buyer Sub 1 to, purchase,
acquire and accept from DPI, all of the DPRL Shares;
(v) DEMI and DDI shall sell, convey, assign, transfer
and deliver to Buyer Sub 1, and Buyer shall purchase, acquire and accept
from DEMI and DDI, all of the DPL Shares, in each case free and clear of
all Encumbrances (other than, in the case of the Transferred Equipment,
Permitted Encumbrances); and
26
(vi) Buyer Sub 1 shall assume the Assumed Liabilities
(other than Assumed Liabilities which are solely Liabilities of a
Transferred Business Company).
(b) Prior to the Closing, DuPont shall, and shall cause its
Subsidiaries to, remove all Excluded Assets from the Transferred Business
Companies, other than at DuPont's election, and subject to the provisions of
Section 2.4(f), all or a portion of the Cash of the Transferred Business
Companies (in which case any Cash remaining in the Transferred Business
Companies at the Closing shall not be treated as an Excluded Asset for purposes
of this Agreement). The Excluded Assets shall be excluded from the Transferred
Business Companies and shall not be included in deriving the Estimated Closing
Balance Sheet, the Preliminary Closing Balance Sheet or the Final Closing
Balance Sheet and shall not be sold, conveyed or delivered to Buyer or its
Subsidiaries.
2.2 PURCHASE PRICE. The aggregate cash purchase price to be paid by
Buyer, Buyer Sub 1, Buyer Sub 2 and the Foreign Buyer Subs for the sale of the
Controlled Foreign Subsidiary Shares, the DPC Interests, the DCI Shares, the
DPRL Shares, the DPL Shares and the Additional Transferred Assets (the "SALE")
shall consist of $7,800,000,000 in cash (the "PRE-ADJUSTED CLOSING PURCHASE
PRICE"), subject to adjustment pursuant to Section 2.4(a) (as so adjusted
pursuant to Section 2.4(a), the "CLOSING PURCHASE PRICE"), subject to further
adjustment pursuant to Sections 2.4(e) and (f) (as so further adjusted pursuant
to Sections 2.4(e) and (f), the "PURCHASE PRICE").
2.3 THE CLOSING.
(a) The closing of the Sale (the "CLOSING") shall, subject to
the satisfaction or waiver of the conditions set forth in Article VII, be held
at the offices of Cravath, Swaine & Xxxxx in New York, New York (or such other
place or places as the parties may mutually agree, including, without
limitation, with respect to sales of the Controlled Foreign Subsidiary Shares,
such places outside of the United States as the parties may mutually agree), as
soon as practicable after the date of this Agreement upon (A) the second
Business Day after all the conditions precedent set forth in Article VII are
satisfied or waived or (B) such other time as the parties may mutually agree;
PROVIDED that the Closing Date shall not be extended beyond the date on which
this Agreement terminates pursuant to Section 8.1(b) hereof. The date on which
the Closing actually occurs is hereinafter referred to as the "CLOSING DATE."
27
(b) On the Closing Date, DuPont shall deliver or cause to be
delivered to Buyer the following:
(A) Certificates representing the DCI Shares, the
DPRL Shares and the DPL Shares, each duly endorsed and in form for
transfer to Buyer Sub 1.
(B) Certificates representing the Controlled
Foreign Subsidiary Shares, each duly endorsed and in form for
transfer to the applicable Foreign Buyer Sub.
(C) A duly executed instrument of transfer of the
DPC Interests being assigned and transferred to Buyer Sub 1 and
Buyer Sub 2 in a form to be reasonably agreed upon by the parties.
(D) A duly executed xxxx of sale and assignment
and such other instruments or documents as may be reasonably
requested by Buyer to evidence its purchase of the Transferred
Equipment hereunder or otherwise necessary to provide for the
transactions contemplated hereby.
(E) The stock books, stock ledgers, minute books
and corporate seals of the Transferred Business Companies and the
Controlled Foreign Subsidiaries as of the Closing Date; PROVIDED
that any of the foregoing items shall be deemed to have been
delivered pursuant to this Section 2.3(b)(E) if such item has been
delivered to or is otherwise certified to Buyer to be located at any
of the Transferred Business Companies as of the Closing Date or any
of their respective offices.
(F) The Related Agreements, duly executed by
DuPont or its Subsidiaries (to the extent that each is a party
thereto), to the extent not executed and delivered to Buyer prior to
the Closing; a duly executed instrument of assumption of all
Retained Liabilities, to the extent such Retained Liabilities are
Liabilities of any Transferred Business Company on the Closing Date,
being assumed by DuPont in a form to be reasonably agreed upon by
the parties; and all other documents required to be delivered by
DuPont or its Subsidiaries on or prior to the Closing Date pursuant
to this Agreement or otherwise reasonably required by Buyer in
connection herewith.
28
(c) On the Closing Date, Buyer, Buyer Sub 1, Buyer Sub 2 and
the Foreign Buyer Subs shall deliver or cause to be delivered to DuPont or its
designee the following:
(A) the Closing Purchase Price in immediately
available funds by wire transfer to an account or accounts at such
bank or banks specified by DuPont at least two Business Days prior
to the Closing Date (such amount to be exclusive of any amounts
required to be paid at the Closing pursuant to the Related
Agreements).
(B) A duly executed instrument acknowledging
acceptance of the DPC Interests being transferred to Buyer Sub 1 and
Buyer Sub 2 and the admission of Buyer Sub 1 and Buyer Sub 2 to DPC
as partners in a form to be reasonably agreed upon by the parties.
(C) A duly executed instrument of assumption of
the Assumed Liabilities being assumed by Buyer Sub 1 in a form to be
reasonably agreed upon by the parties.
(D) The Related Agreements, duly executed by Buyer
(to the extent that it is a party thereto), to the extent not
executed and delivered to DuPont prior to the Closing; and all other
documents required to be delivered by Buyer on or prior to the
Closing Date pursuant to this Agreement or otherwise reasonably
required by DuPont in connection herewith.
2.4 PURCHASE PRICE ADJUSTMENT.
(a) No later than three (3) Business Days prior to the Closing
Date, DuPont shall deliver to Buyer an unaudited combined balance sheet of the
Transferred Business Companies, prepared by DuPont in accordance with GAAP
applied on a basis consistent with the Audited Financial Statements as of the
close of business (New York time) on the day specified in Schedule 3.5(a) (which
is based on the date on which the Closing occurs) (the "ESTIMATED CLOSING
BALANCE SHEET"), which shall be accompanied by (i) a calculation by DuPont of
Net Assets based on the Estimated Closing Balance Sheet and in accordance with
GAAP applied on a basis consistent with the Audited Financial Statements (the
"ESTIMATED NET ASSETS") and (ii) a certificate of the Chief Financial Officer of
DuPont stating that the Estimated Closing Balance Sheet and Estimated Net Assets
have been prepared in accordance with this Section 2.4(a). The Pre-Adjusted
Closing Purchase Price shall
29
be (i) increased, if the Estimated Net Assets exceed the Reference Net Assets,
by an amount equal to the amount of such excess, or (ii) decreased, if the
Reference Net Assets exceed the Estimated Net Assets, by an amount equal to the
amount of such excess (the "ESTIMATED CLOSING ADJUSTMENT"); PROVIDED, HOWEVER,
that if the Reference Net Assets exceed the Estimated Net Assets by an amount
that is greater than zero ($0) and less than the Minimum Buyer Adjustment
Amount, then the amount of the Estimated Closing Adjustment shall be zero ($0)
and the Estimated Net Assets shall be deemed to be equal to the Reference Net
Assets; PROVIDED, further that if the Estimated Net Assets exceed the Reference
Net Assets by an amount that is greater than zero ($0) and less than the Minimum
DuPont Adjustment Amount, then the amount of the Estimated Closing Adjustment
shall be zero ($0) and the Estimated Net Assets shall be deemed to be equal to
the Reference Net Assets. The Pre-Adjusted Closing Price, as so increased or
decreased, as the case may be, is hereinafter referred to as the Closing
Purchase Price.
(b) As promptly as practicable following the Closing Date but
in no event later than seventy-five days (75) thereafter, Buyer shall deliver to
DuPont an unaudited combined balance sheet of the Transferred Business
Companies, prepared by Buyer in accordance with GAAP applied on a basis
consistent with the Audited Financial Statements, as of the close of business
(New York time) on the Closing Date (the "PRELIMINARY CLOSING BALANCE SHEET"),
which shall be accompanied by (i) a calculation by Buyer of Net Assets based on
the Preliminary Closing Balance Sheet (the "PRELIMINARY NET ASSETS") and (ii) a
certificate of the Chief Financial Officer of Buyer stating that, in his view,
the Preliminary Closing Balance Sheet and Preliminary Net Assets have been
prepared in accordance with this Section 2.4(b).
(c) DuPont shall have thirty (30) days following delivery to
DuPont of the Preliminary Closing Balance Sheet and the calculation of
Preliminary Net Assets during which to review the Preliminary Closing Balance
Sheet and such calculations, and to notify Buyer if it believes that (i) the
Preliminary Closing Balance Sheet was not prepared in accordance with Section
2.4(b) or contains mathematical error or (ii) that the calculation of
Preliminary Net Assets was not in accordance with the definition of Net Assets
contained herein, not calculated in accordance with Section 2.4(b) or contains
mathematical error, and, in each case, specifying the reasons therefor in
reasonable detail (in which case such notification shall be accompanied by a
certificate of the Chief Financial Officer of DuPont stating that he concurs
with DuPont's position set forth in such notice). In connection with such
review, Buyer shall provide (or, in the case of access to PricewaterhouseCoopers
LLP and its work papers, schedules, memoranda and other documents, shall use its
reasonable best efforts to provide) DuPont and its Representatives reasonable
access, during normal business hours and upon reasonable notice, to all work
papers,
30
schedules, memoranda and other documents prepared by Buyer or its
Representatives in connection with its preparation of the Preliminary Closing
Balance Sheet and/or its calculation of Preliminary Net Assets (and shall be
entitled to copies thereof) and to finance personnel of Buyer and its
Subsidiaries and any other information which DuPont reasonably requests, and
Buyer shall, and shall cause its Subsidiaries to cooperate reasonably with
DuPont and its Representatives in connection therewith. If (A) DuPont fails to
notify Buyer of any such dispute within such 30-day period, or (B) the aggregate
amount of the items disputed by DuPont is such that, were DuPont's position
adopted, it would not result in an amount payable pursuant to Section 2.4(e)
that is at least $5 million greater or less than would be the case if the
Preliminary Closing Balance Sheet were deemed final, the Preliminary Closing
Balance Sheet and the calculation of Preliminary Net Assets shall be deemed
final. In the event that DuPont shall so notify Buyer of any dispute, DuPont and
Buyer shall cooperate in good faith to resolve such dispute as promptly as
possible, and upon such resolution, if any, any adjustments to the Preliminary
Closing Balance Sheet and Preliminary Net Assets shall be made in accordance
with the agreement of Buyer and DuPont.
(d) If Buyer and DuPont are unable to resolve any such dispute
within thirty (30) days (or such longer period as Buyer and DuPont shall
mutually agree in writing) of DuPont's delivery of such notice, such dispute
shall be resolved by the Independent Accounting Firm, and such determination
shall be final and binding on the parties; PROVIDED, HOWEVER, that (i) the
calculation of Final Net Assets shall be based on the Final Closing Balance
Sheet and the definitions contained herein and (ii) unless the Independent
Accounting Firm determines that the Preliminary Closing Balance Sheet was not
prepared in accordance with Section 2.4(b) or contains mathematical error, the
Preliminary Closing Balance Sheet shall be the Final Closing Balance Sheet.
DuPont and Buyer shall mutually select the Independent Accounting Firm, but if
DuPont and Buyer cannot mutually agree on the identity of the Independent
Accounting Firm, then DuPont and Buyer shall each submit to the other party's
independent auditor the name of a national accounting firm other than
PricewaterhouseCoopers LLP, and the Independent Accounting Firm shall be
selected by lot from these two firms by the independent auditors of the two
parties. (If no national accounting firm shall be willing to serve as the
Independent Accounting Firm, then a nationally recognized (in the United States)
expert in public accounting shall be selected to serve as such, such selection
to be according to the above procedures.) Any expenses relating to the
engagement of the Independent Accounting Firm in respect of its services
pursuant to this Section 2.4(d)) shall be shared equally by DuPont and Buyer.
The Independent Accounting Firm shall be instructed to use every reasonable
effort to perform its services within 30 days of submission of the Preliminary
Closing Balance Sheet to it and, in any case, as promptly as practicable after
such submission. The calculation of Final Net Assets shall then be prepared by
Buyer in accordance with the written determination of the
31
Independent Accounting Firm, and delivered to DuPont. DuPont and Buyer agree
that judgment may be entered upon the written determination of the Independent
Accounting Firm in any court having jurisdiction over the party against which
such determination is to be enforced.
(e) The Purchase Price shall, subject to any increase pursuant
to Section 2.4(f), be equal to the Closing Purchase Price, (i) plus, if the
Final Net Assets exceed the Estimated Net Assets, then the amount of such
excess, or (ii) minus, if the Estimated Net Assets exceed the Final Net Assets,
then the amount of such excess (either such excess amount, the "FINAL CLOSING
ADJUSTMENT"). Buyer or DuPont, as the case may be, shall, within ten (10)
Business Days after the final determination of the Final Closing Balance Sheet
pursuant to Sections 2.4(c) and (d) hereof, make payment to the other by wire
transfer in immediately available funds of the amount of the Final Closing
Adjustment as determined pursuant to the preceding sentence, together with
interest thereon from the Closing Date to the date of payment at a floating rate
equal to the U.S. dollar prime rate per annum, as quoted by X.X. Xxxxxx Xxxxx &
Co., from time to time during such period. Such interest shall be calculated
based on a year of 365 days and the number of days elapsed since the Closing
Date.
(f) The parties acknowledge that DuPont intends to cause all
Cash held by the Transferred Business Companies prior to the Closing to be
transferred to DuPont or one or more of the Retained Subsidiaries and that
DuPont shall use reasonable best efforts to effect such transfers, PROVIDED,
HOWEVER, that DuPont shall have no obligation to transfer Cash held by Pharma
Canada, but may transfer such Cash at its sole discretion. To the extent that
DuPont does not transfer some or all of the Cash of Pharma Canada prior to the
Closing, Buyer and DuPont agree that (i) Buyer will use reasonable best efforts
to effect the transfer of Cash from Pharma Canada to Buyer or any Affiliate of
Buyer at the lowest possible withholding tax cost to Buyer, and (ii) DuPont
shall reimburse Buyer or any Affiliate of Buyer for 50% of any Canada
withholding Taxes actually incurred by Buyer (calculated at the actual
applicable withholding tax rate, but not to exceed 5% for purposes of this
calculation) upon such transfer from Pharma Canada. In addition, to the extent
there is a legal impediment that prevents Cash held by Pharma Canada at the time
of the Closing from being distributed by Pharma Canada to Buyer or any Affiliate
of Buyer within 30 days of the Closing, DuPont shall reimburse Buyer for 50% of
the costs to Buyer of the delay in distributing such Cash (including without
limitation reasonable time value of money and cost of currency xxxxxx to the
extent applicable), calculated up to the earlier of the date on which the
impediment to distribution no longer exists or December 31, 2002, and Buyer
shall use reasonable best efforts to minimize the costs resulting from the delay
in distributing such Cash. Any payments by DuPont under the preceding two
sentences of this Section 2.4(f) shall be made within 10 days
32
of the receipt by DuPont of documentation from Buyer providing reasonable
evidence of the withholding taxes and or costs incurred by Buyer.
Notwithstanding any other provision of this Agreement, to the extent that any
Cash held by the Transferred Business Companies is not transferred to DuPont or
a Retained Subsidiary prior to the Closing, there shall be an upward adjustment
to the Closing Purchase Price in an amount equal to the amount of such
undistributed Cash. The amount of such adjustment shall be determined in
accordance with the Preliminary Closing Balance Sheet and, if disputed, the
Final Closing Balance Sheet, on the same time frame and in a manner analogous to
that applicable to the calculation of Preliminary Net Assets and Final Net
Assets, except that there shall be no minimum amount of such undistributed Cash
required as a precondition to making any such adjustment.
2.5 ALLOCATION OF PURCHASE PRICE. The Closing Purchase Price shall
be allocated among the DPC Interests, DCI Shares, DPRL Shares, the DPL Shares,
the Controlled Foreign Subsidiary Shares and the Transferred Equipment and the
Transferred Assets to the extent required by reason of Section 754, Section
338(g) and/or Section 338(h)(10) elections having been made as agreed by DuPont
and Buyer (the "PURCHASE PRICE ALLOCATION SCHEDULE"), in accordance with Section
1060 of the Internal Revenue Code and the Treasury Regulations promulgated
thereunder and in accordance with local law. The Purchase Price Allocation
Schedule shall be amended, as appropriate, as agreed by DuPont and Buyer from
time to time to take into account purchase price adjustments pursuant to Section
2.4 hereof, Section 8.4(d) hereof and otherwise. DuPont and Buyer hereby agree
that prior to Closing, they will agree to purchase price allocations to each of
the Controlled Foreign Subsidiaries, after taking into account additional due
diligence, Cash balances, estimated net income from April 30, 2001 through the
Closing, and other relevant factors, provided that such allocations shall be
within the ranges indicated on Schedule 2.5 hereto (unless DuPont and Buyer
shall mutually agree otherwise) and that such agreed upon allocations shall be
included in the Purchase Price Allocation Schedule. The parties shall (i) timely
file all Tax Returns (including Internal Revenue Service Form 8594 and any
supplemental filings to reflect any revisions to the Purchase Price Allocation
Schedule) required to be filed in connection with the Purchase Price Allocation
Schedule, as amended, (ii) be bound by the Purchase Price Allocation Schedule
and take no position inconsistent with the Purchase Price Allocation Schedule,
as amended, for all Tax purposes (including, without limitation, in any audit or
judicial or administrative proceeding or otherwise), and (iii) prepare and file
all Tax Returns and determine all Taxes in a manner consistent with the Purchase
Price Allocation Schedule, as amended. Each of the parties shall notify the
other if it receives notice that any Tax Authority proposes any allocation
different from that set forth on the Purchase Price Allocation Schedule, as
amended.
33
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF DUPONT
DuPont hereby represents and warrants to Buyer that, except as set
forth in the Schedules to this Agreement delivered by DuPont with reference to
the specific Section of this Agreement so qualified:
3.1 ORGANIZATION, ETC. Each of the Sellers and the Transferred
Business Companies is a corporation (or, in the case of DPC, a general
partnership) duly organized, validly existing and in good standing under the
laws of the jurisdiction of its organization (in the case of good standing to
the extent such concept is recognized in such jurisdiction). Each of the
Transferred Business Companies has all requisite power and authority to conduct
its business as it is now being conducted and to own, lease and operate its
property and assets. Each of the Transferred Business Companies is qualified or
licensed to do business in each jurisdiction in which ownership of property or
the conduct of its business requires such qualification or license, except where
the failure to be so qualified or licensed would not reasonably be expected to
have a Material Adverse Effect. True and complete copies of (a) the certificate
of incorporation and by-laws of each of the Sellers and the Transferred Business
Companies (other than DPC) and (b) the partnership agreement of DPC, each as
presently in effect, have been made available to Buyer.
3.2 AUTHORITY RELATIVE TO THIS AGREEMENT, ETC. Each of the Sellers
and DPC has all requisite corporate or partnership power and authority to
execute and deliver this Agreement and any other Related Agreements to which it
is a party and to consummate the transactions contemplated hereby and thereby.
The execution and delivery of this Agreement and the Related Agreements and the
consummation of the transactions contemplated hereby and thereby have been duly
authorized by the Board of Directors of each of the Sellers and DPC to the
extent party thereto. No other corporate or partnership proceedings on the part
of DuPont (and no action on the part of stockholders of DuPont) or any of its
Subsidiaries are necessary to authorize the execution, delivery and performance
in accordance with their respective terms of this Agreement, the Related
Agreements and the consummation of the transactions contemplated hereby and
thereby. This Agreement and the Related Agreements, and the consummation of the
transactions contemplated hereby and thereby, has been (or in the case of the
Related Agreements will be) duly and validly executed and delivered by each of
the Sellers and DPC to the extent party thereto and, assuming this Agreement and
such other agreements have been duly authorized, executed and delivered by
Buyer, Buyer Sub 1, Buyer Sub 2 or a Foreign Buyer Sub, as applicable, each of
this Agreement and such other agreements constitutes (or in the case of the
Related Agreements will constitute) a legal, valid and binding agreement
34
of the Sellers and DPC to the extent party thereto, enforceable against each
such company in accordance with its terms.
3.3 CAPITALIZATION. (a) All of the authorized partnership interests
of DPC are owned 50% by DuPont and 50% by DPI. All of the DPC Interests are duly
authorized and validly issued. The authorized capital stock of DCI consists of
2,000 shares of common stock, of which 1,000 shares of common stock are issued
and outstanding. The authorized capital stock of DPRL consists of 40,000,000
shares of common stock, of which 13,489,604 shares of common stock are issued
and outstanding. The authorized capital stock of DPL consists of 12,000 shares
of common stock, of which 12,000 shares of common stock are issued and
outstanding. Except as described in the prior four sentences, no partnership
interests, shares of capital stock or shares of preferred stock or other
securities of DPC, DCI, DPRL or DPL are issued and outstanding. All the issued
and outstanding DPC Interests, DCI Shares, DPRL Shares and DPL Shares are duly
authorized, validly issued, fully paid and non-assessable and free of any
Encumbrances in respect thereto. Schedule 3.3 sets forth the name of each
Transferred Business Company, its jurisdiction of organization, the amount of
its authorized capital stock (or partnership interests), the amount of its
outstanding capital stock (or partnership interests) and the record owners of
such outstanding stock (or partnership interests). There are no outstanding (i)
securities convertible into or exchangeable for the capital stock of, or equity
or partnership interests in, any of the Transferred Business Companies, (ii)
options, warrants or other rights to purchase or subscribe for capital stock of,
or equity or partnership interests in, any of the Transferred Business
Companies, (iii) bonds, debentures, notes or other indebtedness having the right
to vote on matters involving the Transferred Business Companies, or (iv)
Contracts or understandings of any kind, other than this Agreement, (A) relating
to the sale, issuance, transfer, repurchase, redemption, reacquisition or voting
of any capital stock of, or equity or partnership interests in, any of the
Transferred Business Companies, or of any such convertible or exchangeable
securities or any such options, warrants or rights, or (B) which provides the
economic equivalent of an equity ownership interest in a Transferred Business
Company pursuant to which, in any of the foregoing cases, any of the Transferred
Business Companies is subject or bound.
(b) Upon consummation of the Sale, Buyer Sub 1, Buyer Sub 2
and the Foreign Buyer Subs, as the case may be, will own all of the issued and
outstanding DPC Interests, DCI Shares, DPRL Shares, DPL Shares and Foreign
Controlled Subsidiary Shares, free of any Encumbrances, other than Encumbrances
created by Buyer, Buyer Sub 1, Buyer Sub 2 or any of the Foreign Buyer Subs.
(c) Except for (i) their Subsidiaries set forth on Schedule
3.3(c) and (ii) the Excluded Assets, the Transferred Business Companies do not
35
directly or indirectly own any capital stock of or other equity interests in any
corporation, partnership or other Person and none of the Transferred Business
Companies is a member of or participant in any partnership, joint venture or
similar Person. The Transferred Business Companies have good and valid title to
the capital stock of or other equity interests in the entities listed on
Schedule 3.3(c), in the amounts set forth on such Schedule, free and clear of
any Encumbrances.
3.4 CONSENTS AND APPROVALS; NO VIOLATIONS. Neither the execution,
delivery and performance of this Agreement by the Sellers and DPC nor the
execution, delivery and performance of the Related Agreements by the Sellers and
DPC party thereto, nor the consummation of the transactions contemplated hereby
and thereby by the Sellers and DPC, will (a) violate any provision of the
certificate of incorporation, by-laws or partnership agreement (or other
comparable governing documents) of the Sellers or any Transferred Business
Company, (b) require any consent, waiver, approval, license, authorization or
permit of, or filing with or notification to (collectively, the "GOVERNMENTAL
FILINGS"), any Governmental Authority except for (i) filings with the Federal
Trade Commission (the "FTC") and with the Antitrust Division of the United
States Department of Justice (the "DOJ") pursuant to the HSR Act, and the rules
and regulations promulgated thereunder, (ii) requirements of the EC Merger
Regulations or any other foreign Antitrust Laws and Laws regulating exchange or
currency controls and (iii) Governmental Filings that are not material, (c)
conflict with or give rise to any Encumbrance or material preferential purchase
rights, material rights of first refusal or similar material rights of any third
party or result in a violation or breach of, or constitute (with or without
notice or lapse of time or both) a default (or give rise to any right of
termination, cancellation or acceleration or any obligation of any of the
Sellers or any Transferred Business Company) or a loss of any material benefit
to which any of the Sellers or any Transferred Business Company is entitled
under, any of the terms, conditions or provisions of any Indebtedness,
government registration, Contract, Plan, permit or other instrument or
obligation, in each case which is material, to which any of the Sellers or any
Transferred Business Company is a party or by which any of the Sellers or any
Transferred Business Company or any of its respective material properties or
material Assets may be bound, or (d) assuming the making or obtaining of the
Governmental Filings referred to in clause (b)(i) and (b)(ii) above, conflict
with, give rise to a loss of benefit under or violate any Law applicable to any
of the Sellers or any Transferred Business Company or by which any of their
respective properties or Assets may be bound, except for such conflicts or
violations which would not reasonably be expected to have a Material Adverse
Effect.
3.5 FINANCIAL STATEMENTS. (a) The DPC selected pro forma balance
sheet items at December 31, 2000 (the "BALANCE SHEET") and at March 31, 2001,
the DPC pro forma income statements and the DPC selected pro forma cash
36
flow items for the fiscal years ended December 31, 1999 and 2000 and for the
three month periods ended March 31, 2000 and 2001, all as set forth in Schedule
3.5 (collectively, the "DPC FINANCIAL STATEMENTS"), have been prepared from the
books and records of the Transferred Business Companies (including the
Additional Transferred Assets and Assumed Liabilities). The DPC selected pro
forma balance sheet items included in the DPC Financial Statements fairly
present in all material respects the combined financial position of the
Transferred Business Companies (including the Additional Transferred Assets and
Assumed Liabilities) as of their respective dates, and the other related
statements included in the DPC Financial Statements fairly present in all
material respects the combined results of operations (in the case of the pro
forma statements of income) and cash flows (in the case of the pro forma
selected cash flow items) of the Transferred Business Companies (including the
Additional Transferred Assets and Assumed Liabilities) for the respective
periods presented therein, all in conformity with the basis of presentation
stated in the DPC Financial Statements, applied on a consistent basis during the
periods involved. The adjustments as shown under the caption "Reconciliations"
in Schedule 3.5 fairly present in all material respects the items described
therein.
(b) The Audited Financial Statements and Unaudited Interim
Financial Statements, when delivered to Buyer pursuant to Section 5.24 of this
Agreement, will fairly present in all material respects the financial position,
results of operations and cash flows of the Transferred Business Companies
(including the Additional Transferred Assets and the Assumed Liabilities) as of
the dates and for the periods presented therein, all in conformity with GAAP,
applied on a consistent basis during the periods involved, except for such
exceptions with respect to the Unaudited Interim Financial Statements as are
permitted under the requirements of Regulation S-X under the Exchange Act, and
shall conform to the requirements of Regulation S-X under the Exchange Act.
(c) The financial position, results of operations and cash
flows of the Transferred Business as presented in the Audited Financial
Statements, including the notes thereto, as of December 31, 2000 and for the
fiscal years ended December 31, 1999 and 2000 and in the Unaudited Interim
Financial Statements, including the notes thereto, as of March 31, 2001 and for
the three month period ended March 31, 2001, in each case, shall not reflect an
adverse change, in any material respect, from the financial position, results of
operations and cash flows presented in the DPC Financial Statements as of such
respective dates for such respective periods.
3.6 ABSENCE OF CERTAIN CHANGES. Since December 31, 2000, the
Transferred Business (including the Transferred Business Companies) has not (a)
suffered any actual or prospective change, event or effect to its prospects,
Assets,
37
business, operations or position (financial or otherwise) which, individually or
in the aggregate when taken together with all other actual and prospective
adverse changes, events and effects, since such date, has had or would
reasonably be expected to have a Material Adverse Effect (in the case of the
Transferred Business' financial position and results of operations and cash
flows, as compared to its financial position and results of operations as
presented in the DPC Financial Statements), (b) as of the date of this
Agreement, except to the extent expressly contemplated by this Agreement or
consented to in writing by Buyer, conducted its business in any material respect
other than in the ordinary and usual course consistent with past practice, or
(c):
(i) incurred any long-term Indebtedness or issued any
debt securities or assumed, guaranteed or endorsed the obligations of any
other Person, except in the ordinary course of business consistent with
past practice and except for obligations of another Transferred Business
Company;
(ii) created or otherwise incurred any Encumbrance on
any material Asset, other than Permitted Encumbrances;
(iii) made any material loan or advance to or any
capital contributions to or investment in any Person other than loans,
advances or capital contributions to or investments in any of its
Wholly-Owned Subsidiaries;
(iv) suffered any damage, destruction or other casualty
loss (after taking into account any insurance recoveries to the extent
such recoveries remain with the Transferred Business Companies) affecting
its business or Assets which is material to the Transferred Business
Companies and the Transferred Equipment taken as a whole;
(v) except (A) to the extent expressly contemplated by
this Agreement or consented to in writing by Buyer or (B) in the ordinary
course of business consistent with past practice, or entered into any
transaction or commitment, or any Contract relating to its respective
Assets or business (including the acquisition or disposition of any
Assets) or relinquished any Contract or other right, in either case,
material to the Transferred Business Companies, taken as a whole, other
than this Agreement and the Related Agreements;
38
(vi) changed any method of accounting, or accounting
practice of any Transferred Business Company, except for any such change
required (A) by reason of a concurrent change in Law, SEC guidelines or
GAAP or (B) by reason of a change in DuPont's method of accounting or
accounting practices that, due to Law, SEC guidelines or requirements or
GAAP, requires a change in the accounting practices of a Transferred
Business Company;
(vii) (A) granted any severance or termination pay to
(1) any of its respective employees, other than ordinary course grants in
amounts consistent with past practice or (2) any of its respective
directors or officers, (B) increased benefits payable under any existing
severance or termination pay policies or employment agreements, (C)
entered into any material employment, consulting, deferred compensation or
other similar agreement (or adopted any amendment to any such existing
agreement) with any of its respective directors or officers, (D)
established, adopted or amended (except as required by applicable Law) any
collective bargaining, bonus, profit sharing, thrift, pension, retirement,
change-in-control, deferred compensation, compensation, stock option,
restricted stock or other benefit plan or arrangement covering any of its
respective directors, officers or employees, (E) materially increased
compensation, bonus or other benefits payable to any of its respective
directors or officers or (F) except in the ordinary course consistent with
past practice, increased the compensation, bonus or other benefits payable
to any of its respective employees (other than directors or officers),
where such increases could, in the aggregate, be material;
(viii) failed to pay any creditor of the Transferred
Business any material amount when due or defaulted on any material
obligation relating to the conduct or operation of the Transferred
Business;
(ix) taken, or omitted to take, any action that if taken
or omitted to be taken on or after the date of this Agreement would
violate Sections 5.1(b) (1), (2), (7), (8), (10), (12), (13) or (14); or
(x) committed to do any of the foregoing.
39
3.7 COMPLIANCE WITH LAW, PERMITS.
(a) The Transferred Business is not being conducted in
violation of any applicable Law, except such violations which individually or in
the aggregate would not reasonably be expected to have a Material Adverse
Effect. The Transferred Business Companies have all governmental permits,
licenses, certificates, qualifications, registrations, approvals for their
products, other approvals and other similar authorizations necessary for the
conduct of their businesses as presently conducted and the ownership or current
use of the Transferred Assets (the "PERMITS") and are in compliance with the
terms of the Permits, except where the failure to have such a Permit or for any
non-compliance which would not reasonably be expected to have a Material Adverse
Effect.
(b) The Transferred Business Companies hold all Permits
necessary as such activities are currently conducted to develop, manufacture,
distribute and sell the product known as Sustiva(TM) and are in compliance in
all material respects with the terms of such Permits. The NDA relating to such
product has been approved by, and none of DuPont or any of its Subsidiaries has
received any notice in writing which has, or reasonably should have, led DuPont
or any such Subsidiary to believe that the NDA relating to such product is not
currently in good standing in all material respects with the FDA. To DuPont's
Knowledge, no condition or state of facts exists that could reasonably be
expected to give rise to a violation of, or a material liability or default
under, any of the foregoing.
(c) (i) The Transferred Business, as conducted in the United
States, is conducted in compliance in all material respects with all applicable
Laws in connection with the preparation and submission to the FDA of each of the
NDAs relating to the material products of the Transferred Business, and each of
the NDAs relating to the material products of the Transferred Business has been
approved by, and none of DuPont or any of its Subsidiaries has received any
notice in writing which has, or reasonably should have, led DuPont or any such
Subsidiary to believe that any of the NDAs relating to the material products of
the Transferred Business are not currently in good standing with the FDA. The
Transferred Business Companies (or their designated agents) have filed, or
caused to be filed, with the FDA all required notices, supplemental applications
and annual or other reports, including adverse experience reports, with respect
to each NDA relating to each material product of the Transferred Business
required to be filed by the NDA holder except when the failure to file such
notices, applications and reports would not have a material adverse effect with
respect to the continued good standing of any such product with the FDA. With
respect to the material products of the Transferred Business for which an NDA
has been approved by the FDA, the applicant and all Persons performing
operations covered by the application acted in material
40
compliance with 21 U.S.C. ss.ss.355 or 357, 21 C.F.R. Parts 314 or 430 et seq.,
respectively, and all terms and conditions of such application.
(ii) The Transferred Business, as conducted outside the
United States, is conducted in compliance in all material respects with all
applicable Laws in connection with the preparation and submission to each
applicable Governmental Authority of each marketing authorization application or
its equivalent ("MAA"), amendment or variation or supplement to an MAA,
re-registration, safety report or necessary response relating to each material
product of the Transferred Business currently manufactured, marketed, promoted
or sold outside the United States, and, except for such failures as would not
have a material adverse effect on the continued good standing with the
applicable Governmental Authority of any such product, (A) each of the XXXx
relating to each such product of the Transferred Business has been approved by,
and (B) none of DuPont or any of its Subsidiaries has received any notice in
writing which has, or reasonably should have, led DuPont or any such Subsidiary
to believe that any of the XXXx relating to such product of the Transferred
Business are not currently in good standing with, each applicable Governmental
Authority. The Transferred Business Companies (or their designated agents) have
filed with each applicable Governmental Authority all required notices,
supplemental applications and annual or other reports, including adverse
experience reports, with respect to each MAA required to be filed by the holder
of the MAA, relating to each such product of the Transferred Business except
when the failure to file such notices, applications and reports would not have a
material adverse effect on the continued good standing of such product with the
regulatory jurisdiction which issued the MAA. With respect to such material
products of the Transferred Business for which an MAA has been approved by the
applicable Governmental Authority, the applicant and all Persons performing
operations covered by the application acted in material compliance with
applicable Law and all terms and conditions of such application.
(iii) None of DuPont or any of its Affiliates have
received any notice since January 1, 1999, that any Governmental Authority
(including the FDA) has commenced, or, to their Knowledge, threatened to
initiate any action to withdraw any approval for a material product or to limit
the ability of the Transferred Business to manufacture (or to have manufactured
for it by a third party) any material product or to request the recall of any
material product of the Transferred Business, or commenced or, to their
Knowledge, threatened to initiate any action to enjoin production of such
products at any facility.
(iv) Except as would not reasonably be expected to have
a Material Adverse Effect, all manufacturing operations conducted by the
Transferred Business Companies (or by third parties on behalf of the Transferred
41
Business Companies) relating to the manufacturing of the products of the
Transferred Business are being conducted in compliance with Good Manufacturing
Practices, with appropriate industry standards in the country in which such
manufacturing is being conducted and with appropriate industry standards in each
country in which the Transferred Business Companies intend to market, promote or
sell such products.
(v) DuPont has made available to Buyer copies of (A) all
reports of inspection observations, (B) all establishment inspection reports and
(C) all warning letters as well as any other documents received by DuPont or any
of its Subsidiaries since January 1, 1999 from the FDA or any other Governmental
Authority relating to the products of the Transferred Business and/or arising
out of the conduct of the Transferred Business that in the case of clauses (A),
(B) and (C) (1) are in the possession of DuPont or any of its Subsidiaries
(including any of the Transferred Business Companies) and (2) assert a material
violation or material non-compliance with any applicable laws or regulatory
requirements (including those of the FDA).
3.8 NO UNDISCLOSED LIABILITIES. Except as and to the extent
reflected in the Balance Sheet, none of the Transferred Business Companies had
at December 31, 2000 any Liabilities of a type required by GAAP to be reflected
on a combined balance sheet of the Transferred Business Companies or in the
notes thereto (it being deemed for the purpose of this Section 3.8 that each
Assumed Liability is a Liability of (and incurred by) a Transferred Business
Company). Since December 31, 2000, none of the Transferred Business Companies
has incurred any Liabilities required by GAAP to be reflected on a combined
balance sheet of the Transferred Business Companies or in the notes thereto
except for such Liabilities which were incurred by a Transferred Business
Company since December 31, 2000, in the ordinary course of business consistent
with past practice or as expressly permitted by this Agreement. The Assumed
Liabilities do not include any Liabilities that would, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect.
3.9 LITIGATION. There is no action, suit or proceeding pending, or,
to the Knowledge of DuPont, action, suit or proceeding threatened, against a
Transferred Business Company (or which would reasonably be expected to result in
a Liability that would be an Assumed Liability), before any Governmental
Authority or arbitration tribunal which individually or in the aggregate would
reasonably be expected to have a Material Adverse Effect. Schedule 3.9 lists as
of the date of this Agreement all actions, suits or proceedings pending, or to
the Knowledge of DuPont, threatened, which involve a claim for damages or other
monetary relief against a Transferred Business Company (or which specifically
relate to, or involve, a Transferred Business Company or Transferred Asset other
than actions, suits or
42
proceedings pending against Buyer or its Affiliates) or which would reasonably
be expected to result in a Liability that would be an Assumed Liability in any
instance in excess of $5 million (or if no damages or other monetary relief are
specified, would reasonably be expected to result in damages or other monetary
relief of in excess of such amount), which seek material injunctive relief or
which would reasonably be expected to (x) give rise to any legal restraint on or
prohibition against the Sale or the other material transactions contemplated by
this Agreement or (y) limit in any material respect the ability of Buyer to
exercise full rights of ownership and control of the Transferred Business
Companies or any of the Additional Transferred Assets after the Closing. As of
the date of this Agreement, none of DuPont or any of its Subsidiaries is subject
to any material outstanding injunction, writ, judgment, order or decree of any
Governmental Authority or arbitration tribunal to the extent related to the
Transferred Business. As of the date of this Agreement, none of DuPont or its
Subsidiaries has received any written notice from any Governmental Authority
that the Transferred Business is subject to any material investigation, is in
default under any material Law or is in breach of any material Permit.
3.10 TAXES.
(a) Each of the Transferred Business Companies has (i) timely
filed (or had timely filed on its behalf) with the appropriate Tax Authorities
all material Tax Returns required to be filed by or on behalf of it, and each
such Tax Return was complete and accurate in all material respects, and (ii)
timely paid (or had paid on its behalf) all material Taxes due and owing,
regardless of whether required to be shown or reported on a Tax Return,
including Taxes required to be withheld by it;
(b) there is no Tax Audit pending against or with respect to
any of the Transferred Business Companies or with respect to any Transferred
Equipment in respect of any material Tax and no written or, to DuPont's
Knowledge, unwritten notice of such a Tax Audit with respect to any material Tax
has been received by DuPont, any Affiliate of DuPont or any Transferred Business
Company;
(c) no deficiency for a material Tax has been asserted in
writing or otherwise, to DuPont's Knowledge, against any of the Transferred
Business Companies or with respect to any Transferred Equipment, except for
asserted deficiencies that either (i) have been resolved and paid in full or
(ii) are being contested in good faith;
(d) there are no material liens for Taxes upon the Assets or
property of any of the Transferred Business Companies or the Transferred
Equipment, except for Permitted Encumbrances;
43
(e) DPC has been taxed as a partnership under the provisions
of Subchapter K of the Code and the Treasury Regulations promulgated thereunder
for all taxable periods beginning on or after the date of its formation and
ending on or prior to the date of this Agreement;
(f) no material issues relating to Taxes relating to a
Transferred Business Company or the Transferred Equipment have been raised in
writing or otherwise, to DuPont's Knowledge, by the relevant Taxing Authority
during any completed or presently pending Tax Audit that can reasonably be
expected to recur in a later taxable period;
(g) none of the Transferred Business Companies is party to or
bound by, and the Transferred Equipment is not subject to, any Tax Sharing
Agreement;
(h) there is no agreement or other document extending, or
having the effect of extending, the period of assessment or collection of any
material Taxes, and no power of attorney with respect to any material Taxes has
been executed or filed with any Taxing Authority, by or on behalf of any
Transferred Business Company or in respect of the Transferred Equipment;
(i) none of the Transferred Business Companies shall be
required to include in a taxable period ending after the Closing Date taxable
income attributable to income that economically accrued in a prior taxable
period but was not recognized in any prior taxable period as a result of the
installment method of accounting, the long-term contract method of accounting,
the cash method of accounting of Section 481 of the Code or comparable
provisions of state, local or foreign Tax law;
(j) the Transferred Business Companies have complied in all
material respects with all applicable laws, rules and regulations relating to
the payment and withholding of Taxes (including, without limitation, withholding
of Taxes pursuant to Sections 1441, 1442, 3121 and 3402 of the Code or similar
provisions under any state, local or foreign laws) and have, within the time and
manner prescribed by law, withheld from and paid over to the proper governmental
authorities all amounts required to be so withheld and paid over under
applicable laws;
(k) neither DCI nor DPRL is a real property holding company
within the meaning of Section 897 of the Code. DuPont is not a "foreign person"
within the meaning of Section 1445 of the Code; and
44
(l) DCI and DPRL are members of a consolidated group, as
defined in Section 1504(a) of the Code, of which DuPont is the common parent.
3.11 EMPLOYEE BENEFIT PLANS; ERISA.
(a) Schedule 3.11(a) contains a true and complete list of each
deferred compensation plan and each incentive compensation, equity compensation
plan, bonus, severance, material "welfare" plan, fund or program (within the
meaning of section 3(1) of the Employee Retirement Income Security Act of 1974,
as amended ("ERISA")); "pension" plan, fund or program (within the meaning of
section 3(2) of ERISA); each material employment, change-in-control, termination
or severance agreement; and each other material employee benefit plan, fund,
program, agreement or arrangement, in each case, that is sponsored, maintained
or contributed to or required to be contributed to by any of the Transferred
Business Companies or by any trade or business, whether or not incorporated,
that together with any Transferred Business Company would be deemed a "single
employer" within the meaning of section 4001(b) of ERISA (an "ERISA AFFILIATE"),
or to which any of the Transferred Business Companies or an ERISA Affiliate is
party, whether written or oral, for the benefit of any United States and foreign
employee or former employee of any Transferred Business Company (the
"TRANSFERRED BUSINESS PLANS").
(b) With respect to each Transferred Business Plan, DuPont or
DPC has made available to Buyer true and complete copies of each such
Transferred Business Plan and any amendments thereto (or if such Transferred
Business Plan is not written, a description thereof), any related trust, deed or
rule or other funding vehicle, any reports or summaries required under ERISA,
the Code or applicable Law and the most recent determination letter received
from the IRS with respect to each Transferred Business Plan intended to qualify
under Section 401 of the Code, Form 5500 and, if applicable, attached Schedule B
(including related actuarial valuation report) with respect to the last three
(3) years and any other report reflecting the current funding status of each
such Transferred Business Plan.
(c) No liability under Title IV or Section 302 of ERISA, or
any comparable provision and/or applicable Law, has been incurred by any of the
Transferred Business Companies or any ERISA Affiliate that has not been
satisfied in full, and no condition exists that could present a material risk to
any of the Transferred Business Companies or any ERISA Affiliate of incurring
any such liability, other than liability for premiums due the Pension Benefit
Guaranty Corporation (the "PBGC") (which premiums have been paid when due).
(d) No Transferred Business Plan which is subject to Title IV
of ERISA ("TRANSFERRED BUSINESS TITLE IV PLAN") is, or within the five (5) year
period
45
preceding the date of their Agreement was, a "multiemployer pension plan," as
defined in Section 3(37) of ERISA, nor is any Transferred Business Title IV Plan
a plan described in Section 4063(a) of ERISA.
(e) Each Transferred Business Plan has been operated and
administered in all material respects in accordance with its terms and
applicable law, including but not limited to ERISA and the Code, and with
respect to each Transferred Business Plan, all contributions, premiums and
reserves required as of the Closing Date have been paid by, or in the case of
reserves, have been properly reflected on the books of, the appropriate
Transferred Business Company.
(f) Each Transferred Business Plan intended to be "qualified"
within the meaning of Section 401(a) of the Code, or to have tax-favored status
under applicable Law, is so qualified, or tax-favored, and the trusts maintained
thereunder are exempt from taxation under Section 501(a) of the Code or
applicable Law.
(g) With respect to each Transferred Business Plan that is
subject to Title IV of ERISA or to the minimum funding requirements of Section
412 of the Code or Part 3 of Title I of ERISA, each of the following is true:
(i) there is no event or condition existing (other than the transactions
contemplated by this Agreement) that could be deemed to be a "reportable event"
within the meaning of Section 4043 of ERISA with respect to which the notice
requirement has not been waived, and no condition exists that could subject any
of the Transferred Business Companies to a fine under Section 4071 of ERISA;
(ii) no amendment has occurred that has required or could require any of the
Transferred Business Companies to provide security to such Transferred Business
Plan under Section 401(a)(29) of the Code or Section 307 of ERISA; (iii) no
documentation or other information has been or is currently required to be
provided to the PBGC pursuant to Section 4011 of ERISA; (iv) no transaction has
occurred and no condition exists with respect to such Transferred Business Plan
that has subjected or shall likely subject any of the Transferred Business
Companies to liability under Section 4069 of ERISA; (v) no event has occurred
and no condition exists that could subject any of the Transferred Business
Companies or any ERISA Affiliate to any material Tax under Chapter 43 of the
Code or to a material fine under Section 502(c) of ERISA; and (vi) none of the
Transferred Business Companies or any ERISA Affiliate has engaged in a
non-exempt prohibited transaction, as such term is defined in Section 4975 of
the Code or Section 406 of ERISA.
(h) No Transferred Business Plan provides medical, surgical,
hospitalization, death or similar benefits (whether or not insured) for
employees or former employees of any Transferred Business Company for periods
extending beyond their retirement or other termination of service, other than
(i) coverage
46
mandated by applicable Law, (ii) death benefits under any "pension plan," or
(iii) benefits the full cost of which is borne by the current or former employee
(or his beneficiary). Schedule 3.11(h) discloses, as of December 31, 2000, the
amount of unfunded liabilities for retiree medical, dental and life insurance
benefits (and any other post-retirement benefits other than pensions) arising
under such plan, broken down with respect to current employees and former
employees of the Transferred Business Companies, as of December 31, 2000, in
accordance with FAS 106, and no amendment to such plan since such date has
increased such liabilities. The valuation in Schedule 3.11(h) discloses whether
it takes into account contributions of the current employees and former
employees of the Transferred Business Companies and all assumptions used in
calculating such valuation. In addition, Schedule 3.11(h) discloses the number
of Transferred Employees who are currently eligible or may become eligible to
receive such post-retirement benefits within three (3) years of the date of this
Agreement.
(i) The consummation of the transactions contemplated by this
Agreement shall not, either alone or in combination with another event, (i)
entitle any current or former employee or officer of any of the Transferred
Business Companies or any ERISA Affiliate to severance pay, unemployment
compensation or any other payment, except as expressly provided in this
Agreement, or (ii) accelerate the time of payment or vesting, or increase the
amount, of compensation due any such employee or officer.
(j) As of the date of this Agreement, to the Knowledge of
DuPont, there are (i) no pending or threatened claims, or facts that could
reasonably be expected to give rise to such claims, by or on behalf of any
Transferred Business Plan, by any employee or beneficiary covered under any such
Transferred Business Plan, or otherwise involving any such Transferred Business
Plan (other than routine claims for benefits) or (ii) no matters pending (other
than routine qualification determination filings) with respect to any of the
Transferred Business Plans before any Governmental Authority, which claims or
pending matters could give rise to Losses that in the aggregate would exceed
$2,000,000.
(k) As of the date of this Agreement, there has been no
amendment to, written interpretation or announcement (whether or not written) by
DPC or any of its Affiliates relating to, or change in employee participation or
coverage under, any Transferred Business Plan which would increase materially
the expense of maintaining such Transferred Business Plan above the level of the
expense incurred in respect thereof for the 12 months ended as of the date of
the DPC Financial Statements.
47
(l) To the Knowledge of DuPont, there is no leased employee,
as such term is defined in Section 414(n) of the Code, who must be taken into
account for the requirements of Section 414(n)(3) of the Code who has not been
so taken into account. To the Knowledge of DuPont, each person providing
services to any of the Transferred Business Companies as an independent
contractor has been properly classified as such.
(m) There is no voluntary employees' beneficiary association,
within the meaning of Sections 501(c)(9) and 505, or rabbi trust, within the
meaning of IRS Rev. Proc. 92-64 (1992), maintained with respect to any
Transferred Business Plan.
(n) No Transferred Business Plan is a multiple employer
welfare arrangement within the meaning of Section 3(40) of ERISA.
(o) Each of the Transferred Business Companies is in
compliance with all applicable Law respecting employment and employment
practices, terms and conditions of employment and wages and hours and
occupational safety and health, and is not engaged in any unfair labor practice
within the meaning of Section 8 of the National Labor Relations Act, or
applicable Law, and there is no action, suit or legal, administrative,
arbitration, grievance or other proceeding pending or, to the Knowledge of
DuPont, threatened, or, to the Knowledge of DuPont, any investigation pending or
threatened against any of the Transferred Business Companies relating to any
thereof, and, to the Knowledge of DuPont, no basis exists for any such action,
suit or legal, administrative, arbitration, grievance or other proceeding or
governmental investigation.
(p) None of the Transferred Business Companies is party to any
collective bargaining, union or labor agreement. There is no labor strike,
dispute, slowdown or stoppage actually pending or, to the Knowledge of DuPont,
threatened against any of the Transferred Business Companies, and no Transferred
Employee is a member of or represented by any labor union and, to the Knowledge
of DuPont, there are no attempts of whatever kind and nature being made to
organize any such Transferred Employees. No certification or decertification is
pending or was filed within twelve (12) months preceding the date of this
Agreement respecting any Transferred Employee and, to the Knowledge of DuPont,
no certification or decertification petition is being or was circulated among
the Transferred Employees within the twelve (12) months preceding the date of
this Agreement. No agreement, arbitration or court decision, decree or order or
governmental order that is binding on any of the Transferred Business Companies
in any way limits or restricts any of the Transferred Business Companies from
relocating or closing any of its operations.
48
(q) None of the Transferred Business Companies has experienced
any organized work stoppage in the five (5) years preceding the date of this
Agreement. There are no charges, administrative proceedings or formal complaints
of discrimination (including but no limited to discrimination based upon sex,
age, marital status, race, national origin, sexual preference, handicap or
veteran status) pending or, to the Knowledge of DuPont, threatened, or to the
Knowledge of DuPont, any investigation pending or threatened before the Equal
Employment Opportunity Commission or any Governmental Authority. There have been
no audits of the equal employment opportunity practices of any of the
Transferred Business Companies and, to the Knowledge of DuPont, no basis for any
such claim exists. With respect to the items set forth on Schedule 3.11(q), each
of the following is true: (i) as of the date of this Agreement, none of the
Transferred Business Companies is a defendant in any action filed, or to the
Knowledge of DuPont threatened to be filed, by a class under the Federal Rules
of Civil Procedure 23, or comparable state law, under any Federal, state or
local statute governing employment, and (ii) the aggregate amount of damages of
all the items set forth on Schedule 3.11(q) will not exceed $1,000,000
(excluding the matter identified on such schedule with an asterisk).
(r) (i) Other than the DuPont UK Plan, there are no defined
benefit pension plans, or such other plans required to be funded under
applicable Law, providing any benefit to any Transferred Employee in the United
Kingdom, Northern Ireland or the Republic of Ireland and pursuant to which any
of the Transferred Business Companies would have any liability. The DuPont UK
Plan is an exempt approved scheme and a contracted-out scheme, and DuPont is
named in a contracting-out certificate in relation to the DuPont UK Plan.
(ii) Other than the DuPont Pharmaceuticals Company
Pension and Retirement Plan (Puerto Rico), there are no defined benefit
pension plans, or such other plans required to be funded under applicable
Law, providing any benefit to any Transferred Employee in Puerto Rico and
pursuant to which any of the Transferred Business Companies could have any
liability.
(iii) Other than the DuPont Pharma, Inc.
Non-Contributory Pension Plan, there are no defined benefit pension plans,
or such other plans required to be funded under applicable Law, providing
any benefit to any Transferred Employee in Canada and pursuant to which
any of the Transferred Business Companies could have any liability. As of
December 31, 2000, the projected benefit obligation of the DuPont Pharma,
Inc. Non-Contributory Pension Plan on a FAS 87 basis did not exceed the
fair market value of such Plan's assets by an amount equal to $1,500,000
or more.
49
(iv) Other than the DuPont Pharmaceuticals Company
Pension and Retirement Plan, there are no defined benefit pension plans,
or such other plans required to be funded under ERISA and the Code,
providing any benefit to any Transferred Employee in the United States and
pursuant to which any of the Transferred Business Companies could have any
liability.
(v) Other than the Company Agreement G-14/88, there are
no defined benefit pension plans, or such other plans required to be
funded or a reserve to be established on the books of the plan sponsor
under applicable Law, providing any benefit to any Transferred Employee in
Germany and pursuant to which any of the Transferred Business Companies
could have any liability.
(vi) Other than the Pension Plan/Life Insurance (Fortis
AG) (the "BELGIAN PENSION PLAN"), there are no defined benefit pension
plans, or such other plans required to be funded or for which a reserve
must be established on the books of the plan sponsor under applicable Law,
providing any benefit to any Transferred Employee in Belgium and pursuant
to which any of the Transferred Business Companies could have any
liability. Liabilities under the Belgian Pension Plan, calculated on a
projected benefit obligation basis, do not exceed the fair market value of
the assets of such plan by an amount equal to $200,000 or more.
(vii) There is no defined benefit pension plan, or such
other plan required to be funded or for which a reserve must be
established on the books of the plan sponsor under applicable Law,
providing any benefit to any Transferred Employee in Brazil, Italy,
France, Spain, the Republic of Ireland or Japan and pursuant to which any
of the Transferred Business Companies could have any liability.
(s) With respect to the DuPont Pharmaceuticals Company Pension
and Retirement Plan and the DuPont Pharmaceuticals Company Pension and
Retirement Plan (Puerto Rico) (collectively, the "TRANSFERRED PENSION PLANS"),
Schedule 3.11(s) discloses the amount of unfunded liabilities pursuant to FAS
87, and the assumptions required thereunder, as of December 31, 2000. With
respect to any other Transferred Business Plan that is required to be funded
under applicable Law, or for which a reserve must be established on the books of
the plan sponsor of such plan under applicable Law, Schedule 3.11(s) discloses
the amount of unfunded liabilities pursuant to the greater of FAS 87, and the
assumptions required thereunder, or applicable Law, as of December 31, 2000.
With respect to each of the plans listed
50
in Section 5.11(i), Schedule 3.11(s) also separately discloses the amount of
unfunded liabilities pursuant to FAS 87, and the assumptions used thereunder, as
of December 31, 2000.
(t) The transactions contemplated by this Agreement shall not
result in the acquisition of assets from DuPont that have a total fair market
value equal to or more than one-third of the total fair market value of all
assets of DuPont, as a "corporation" (within the meaning of Section 1504 of the
Code) immediately prior to such "acquisition" (within the meaning of Section
280G of the Code and the regulations thereunder).
3.12 ENVIRONMENTAL MATTERS. To the Knowledge of DuPont, (a) the
Transferred Business Companies are in compliance with all applicable
Environmental Laws (which compliance includes, but is not limited to, the
possession by the Transferred Business Companies of all Environmental Permits,
and compliance with the terms and conditions thereof), except where failure to
be in compliance would not reasonably be expected to have a Material Adverse
Effect; (b) there is as of the date of this Agreement and, except as set forth
in Schedule 3.12, there will be as of the Closing, no Environmental Claim
pending or, to the Knowledge of DuPont, threatened against or affecting any
Transferred Business Company which would reasonably be expected to have a
Material Adverse Effect; (c) there have been no Releases of Hazardous Substances
on, at, in or underneath any of the Assets of the Transferred Business Companies
or, to the Knowledge of the Transferred Business Companies, on, at, in or
underneath any property formerly owned or operated by any Transferred Business
Company that would reasonably be expected to have a Material Adverse Effect; (d)
as of the date of this Agreement, there is no cleanup or remediation of
Hazardous Substances being conducted or planned at any of the Assets of the
Transferred Business Companies; and (e) the Transferred Business Companies have
delivered or otherwise made available for inspection to Buyer true, complete and
correct copies and results of any Phase I or Phase II Environmental Assessments
prepared within the past three years, and any other material reports, studies,
analyses, tests or monitoring possessed or initiated by the Transferred Business
Companies pertaining to Hazardous Substances in, on, beneath or adjacent to any
of the Assets of the Transferred Business Companies, or regarding the
Transferred Business Companies' compliance with applicable Environmental Laws.
Notwithstanding anything to the contrary herein, the parties hereby agree that
there is excluded from all other representations and warranties in this Article
III all matters with respect to compliance with, or Liabilities arising under,
Environmental Laws. The representations and warranties contained in this Section
3.12 shall be the exclusive representations and warranties with respect to such
matters.
51
3.13 REAL PROPERTY.
(a) Schedule 3.13(a) contains a complete and correct list of
all Owned Real Property. DPC or one of the other Transferred Business Companies
has (and upon the Closing will have) good and valid title in fee simple to the
Owned Real Property, free and clear of all Encumbrances other than Permitted
Encumbrances; PROVIDED, HOWEVER, that the use of the Real Property will be
limited to industrial use because of soil and groundwater contamination. To the
Knowledge of DuPont, no Person (other than the Transferred Business Companies)
has any right to use, occupy or lease the Owned Real Property.
(b) Schedule 3.13(b) contains a complete and correct list of
all Leased Real Property. True, correct and complete copies of all Leases
relating to the Leased Real Property have heretofore been delivered by DuPont to
Buyer. All such Leases are valid, binding and in full force and effect and are
enforceable by the lessee thereunder and grant such lessee the exclusive right
to use and occupy the premises. DPC or one of the other Transferred Business
Companies has quiet possession of the leasehold estate or other interest created
under such Leases, and no lessee under any material Lease relating to Leased
Real Property is in material default under any such Lease.
(c) The use and operation of the Real Property in the conduct
of the Transferred Business complies in all material respects with all material
instruments of record or material agreements affecting the Real Property.
(d) To the Knowledge of DuPont, (i) no certificate, permit or
license from any Governmental Authority having jurisdiction over any of the Real
Property or any agreement, easement or other right which is necessary to permit
the lawful use and operation of the buildings and improvements on any of the
Real Property or which is necessary to permit the lawful use and operation of
all driveways, roads and other means of egress and ingress to and from any of
the Real Property has not been obtained or is not in full force and effect, and
there is no pending threat of modification or cancellation of any of the same,
which would reasonably be expected to have a Material Adverse Effect, and (ii)
there is no written notice issued by any Governmental Authority of any violation
of any federal, state or municipal law, ordinance, order, regulation or
requirement that would reasonably be expected to have a Material Adverse Effect.
The Real Property shall be transferred to Buyer (by virtue of its acquisition of
the Transferred Business Companies) in its "AS IS" condition on the Closing
Date, subject to all latent and patent defects (whether physical, financial or
legal, but including only the title defects, if any, set forth on Schedule
1.1(i) hereto), based solely on Buyer's own inspection, analysis and evaluation
of the Real Property and not in reliance on any records or other
52
information obtained from DuPont or on DuPont's behalf, other than the title
reports referenced on Schedule 1.1(i) hereto. Each of Buyer, Buyer Sub 1 and
Buyer Sub 2 acknowledges that it is not relying on any statement or
representation that has been made or that in the future may be made by DuPont or
any of DuPont's employees, agents, attorneys or representatives concerning the
condition of the Real Property (whether relating to physical conditions,
operation, performance, legal matters or title matters (other than title matters
relating to any Real Property for which a title report has not been obtained as
set forth on Schedule 1.1(i) hereto)).
(e) None of the Sellers or any of the Transferred Business
Companies has received any written notice that (i) any condemnation proceeding
is pending or threatened with respect to any Real Property or (ii) any material
zoning, building or similar law, code, ordinance, order or regulation is or will
be violated by the continued maintenance, operation or use of any buildings or
other improvements on any Real Property or by the continued maintenance,
operation or use of the parking areas.
3.14 INTELLECTUAL PROPERTY. (a) Set forth in Schedule 3.14(a), for
all Intellectual Property that is owned (or in the case of clauses (v) and (vi)
licensed) by the Transferred Business Companies (other than the Excluded
Assets), is a complete and correct list (except for updates in dockets occurring
in the ordinary course of business or as corrected pursuant to Section 3.14(f))
of all United States and foreign: (i) issued and pending Patents; (ii) Trademark
registrations, and Trademark applications with their respective registration and
application numbers; (iii) tradenames; (iv) Copyright registrations and
Copyright applications with their respective registration and application
numbers; (v) material software used by the Transferred Business Companies (other
than commercially available software subject to "shrink-wrap," "click-through"
or other standard form license agreements); and (vi) material license agreements
relating to commercial products and compounds nominated for development pursuant
to which the Transferred Business Companies have rights to use Intellectual
Property of third parties (including DuPont and its other Subsidiaries) in the
Transferred Business.
(b) The Transferred Business Companies own or license from
third parties (including DuPont and its other Subsidiaries) or otherwise have
the right to use, as currently used, free and clear of all Encumbrances, all the
Intellectual Property currently used or necessary for the conduct of the
Transferred Business; and the consummation of the transactions contemplated
hereby will not impair any such rights in any material respect; PROVIDED that
the foregoing representations insofar as they relate to claims by or conflicts
with any third party (other than DuPont or any Subsidiary of DuPont) with
respect to such Intellectual Property are made to the Knowledge of DuPont
(except that, with respect to Sustiva, Coumadin, Sinemet,
53
Cardiolite, DPC 906, DPC A52350, DPC 368, DPC A69841/A53607/A69448, DPC 974, DPC
A37818, and DPC A37215 are also made to the knowledge, after reasonable inquiry,
of DPC's inside patent attorneys and the product manager for such compounds);
and PROVIDED, FURTHER, that the foregoing representations do not apply to
potential claims or conflicts by any third party (other than DuPont or any
Subsidiary of DuPont) previously disclosed in writing to Buyer's inside or
outside patent counsel by DuPont or any of its Subsidiaries (including the
Transferred Business Companies) (the "IP DISCLOSURE") and do not apply to
compounds not yet nominated for development or to any research tools used in
connection with such compounds not yet nominated for development.
(c) There are no material claims pending or, to the Knowledge
of DuPont, threatened, against DuPont or any of its Subsidiaries (including the
Transferred Business Companies) by any third party with respect to the
ownership, validity, enforceability or use (including claims of actual or
potential infringement, dilution or misappropriation) of any of the material
Intellectual Property used in or necessary to the conduct of the Transferred
Business related to (i) Sustiva, (ii) any such other Intellectual Property as of
the date of this Agreement, or (iii) any such other Intellectual Property as of
the Closing Date that, individually or in the aggregate with all other such
claims, would reasonably be expected to have a Material Adverse Effect.
(d) As of the date of this Agreement, there are no claims
pending or, to the Knowledge of DuPont, threatened, against any third party by
DuPont or any of its Subsidiaries (including the Transferred Business Companies)
regarding any actual or potential infringement, dilution, or misappropriation of
any Intellectual Property owned or used in the Transferred Business related to
(i) Sustiva, (ii) any such other Intellectual Property as of the date of this
Agreement, or (iii) any such other Intellectual Property as of the Closing Date
that, individually or in the aggregate with all other such claims, would
reasonably be expected to have a Material Adverse Effect.
(e) To the Knowledge of DuPont, the Transferred Business
Companies or their designated agents own or have the right to use all material
regulatory documents, including all material marketing applications, clinical
trials applications and other correspondence and reports made to Governmental
Authorities, necessary to market and sell the material products of the
Transferred Business Companies as currently marketed and sold, and the
consummation of the transactions contemplated hereby will not impair any such
rights in any material respect.
(f) (i) At Buyer's request and at Buyer's expense, DuPont will
take all reasonable steps to assist Buyer in the assignment and recordation
process
54
following the Closing to record ownership or to record a license for any pending
or issued Patents or applied for or registered Trademarks owned by a Transferred
Business Company to ensure that Buyer will have record ownership (or recording
of license agreements) of such Intellectual Property, and (ii) at DuPont's
expense, DuPont will take all reasonable steps prior to the Closing and shall
continue following the Closing with those efforts commenced prior to the Closing
to correct any title discrepancies with respect to the properties listed on
Schedule 3.14(a) and to record ownership or to record a license for any pending
or issued Patents or applied for or registered Trademarks owned by a Transferred
Business Company to ensure that the Transferred Business Companies will have
record ownership (or recording of license agreements) of such Intellectual
Property; PROVIDED that in any event Buyer must make any request under this
Section 3.14(f) within one year, and DuPont shall have no further obligations
under this Section 3.14(f) three (3) years, after the Closing.
3.15 ASSETS. DPC or one of the other Transferred Business Companies
owns, leases or has the legal right (including pursuant to the Related
Agreements) to use all material Assets (other than (i) Real Property, which is
the subject of Section 3.13, (ii) Intellectual Property, which is the subject of
3.14 and (iii) the Transferred Equipment) reflected on the Balance Sheet or,
except for Excluded Assets, thereafter acquired by the Transferred Business
except for those sold or otherwise disposed of since the date of the Balance
Sheet in the ordinary course of business consistent with past practice and not
in violation of this Agreement. DuPont owns, leases or has the legal right to
use all of the Transferred Equipment. DPC or one of the other Transferred
Business Companies has good and valid title to (or in the case of leased Assets,
valid leasehold interests in) all Transferred Assets free and clear of all
Encumbrances except Permitted Encumbrances (other than (i) Real Property, (ii)
Intellectual Property, or (iii) the Transferred Equipment). DuPont has good and
valid title to (or in the case of leased Assets, valid leasehold interests in)
the Transferred Equipment free and clear of all Encumbrances except Permitted
Encumbrances. Upon consummation of the Sale, Buyer will have acquired good and
valid title to the Transferred Equipment, free and clear of all Encumbrances,
other than Permitted Encumbrances. Except for the Excluded Assets, (i) the
Transferred Assets comprise all the Assets (other than Intellectual Property)
primarily employed or primarily used in or by DuPont and its Subsidiaries in the
conduct and operation of the Transferred Business and (ii) there are no Assets
(other than Intellectual Property, Assets being leased pursuant to a Lease or
services being provided under a Site Services Agreement, in each case that is a
Related Agreement) which are material to the conduct of the Transferred Business
as currently conducted other than the Transferred Assets.
55
3.16 BROKERS AND FINDERS. None of the Sellers or any Transferred
Business Company or any of their respective officers, directors or employees has
employed any broker or finder or incurred any Liability for any investment
banking fees, brokerage fees, commissions or finders' fees in connection with
the transactions contemplated by this Agreement, for which Buyer, Buyer Sub 1 or
Buyer Sub 2 has or could have any Liability.
3.17 INVENTORIES. The inventory of finished goods held in the trade
by the wholesale and warehousing customers of the Transferred Business Companies
does not constitute an amount of inventory exceeding in any material respect in
the case of each of (i) Sustiva(TM) 1.5 months, (ii) Coumadin(R) 3 months, (iii)
Cardiolite(R) 1.5 months and (iv) Sinemet(R) brand 10 months. The aggregate
amount of finished goods held in the trade by such wholesale and warehousing
customers shall be determined as of any date by reference to the most recent IMS
report provided by IMS on or prior to such date. As of the date of this
Agreement, the inventory of finished goods owned by the Transferred Business
Companies is not greater in any material respect than as set forth in the Xxxxx
00, 0000 XXX selected pro forma balance sheet items. Except for inventory with a
cost of less than $750,000 in the aggregate (for which a reserve has been
established), none of the finished goods inventory held by the Transferred
Business Companies has an expiration date within 12 months.
3.18 CONTRACTS.
(a) Except as set forth on Schedule 3.18, as of the date of
this Agreement, there is no Contract that constitutes a Transferred Asset or
under which an Assumed Liability arises, to which a Transferred Asset or Assumed
Liability is subject or to which a Transferred Business Company is a party or by
which its Assets are bound, that is:
(i) an employment agreement;
(ii) a collective bargaining agreement or other
agreement or arrangement with a labor union, labor organization, workers
council or similar body;
(iii) an agreement (A) which by its terms contains a
covenant that following the Closing would geographically limit in any
respect the ability or right of the Transferred Business Companies or
their Affiliates to compete or operate in any business or (B) which
otherwise prohibits the development, manufacture, marketing or
distribution or sale of the products and services of the
56
Transferred Business Companies or their Affiliates to any Person other
than the other party to any such agreement; PROVIDED that (x) any
development agreement with respect to a specified or a specified group of
compounds that contain restrictions with respect to the research,
development, manufacture, marketing, promotion or sale of the compounds
that are the primary subject of such agreement and (y) agreements of a
type described in clause (xiii) below (without regard to the dollar
limitation thereon) are excluded from the clause solely to the extent any
such agreement contains geographical exclusions with respect to the
exclusive territory or therapeutic categories that is the subject of such
agreement;
(iv) an agreement granting an Encumbrance (other than a
Permitted Encumbrance) on any material Transferred Asset or, taken in the
aggregate, a material portion of Transferred Assets (other than, in the
case of Contracts, any provision prohibiting, limiting or requiring
consent for the assignment thereof);
(v) a Contract with the Sellers or their Affiliates
(other than another Transferred Business Company) other than Contracts
that will be terminated at or prior to the Closing;
(vi) a Contract obligating any of the Transferred
Business Companies to make a future purchase of materials, supplies or
equipment that (A) has (I) annual payments by the Transferred Business
Companies in excess of $10,000,000 or an aggregate future Liability
pursuant to the terms of such Contract to any Person in excess of
$10,000,000 and (II) a term extending for more than one year from the date
of this Agreement or (B) is otherwise material with respect to Sustiva;
(vii) a Contract providing for indemnification by a
Transferred Business Company (or which would be an Assumed Liability) of
any Person with respect to material Liabilities relating to any current or
former business of the Transferred Business;
(viii) a license, sublicense, option or other Contract
affecting in whole or in part any of the Transferred Business Companies'
rights to any material Intellectual Property currently used in the conduct
of the Transferred Business (excluding any DuPont Shared Know-how);
57
(ix) a Contract pursuant to which any of the Transferred
Business Companies guarantees indebtedness, liabilities or obligations of
any Person, other than an inter-company arrangement that will terminate at
or prior to the Closing;
(x) a Contract under which any advance, loan or
extension of credit or any capital contribution to, or other investment
in, has been or is to be made in any Person in each case other than in the
ordinary course of business consistent with past practice;
(xi) a Contract (including a sales order) obligating any
of the Transferred Business Companies to deliver products or services
which has (I) annual payments in excess of $10,000,000 or an aggregate
future Liability pursuant to the terms of such Contract to any Person in
excess of $10,000,000 and (II) a term extending for more than one year
from the date of this Agreement;
(xii) a Contract for the sale of any material
Transferred Asset or material portion of Transferred Assets (other than
inventory sales in the ordinary course of business) that has not been
performed in all material respects as of the date of this Agreement or the
grant of any preferential rights to purchase any material Transferred
Asset;
(xiii) a Contract providing for the services of any
dealer, distributor, sales representative or similar representative
involving annual payments or receipts or annual sales volume in excess of
$10,000,000; or
(xiv) any other Contract that is material to the
Transferred Business taken as a whole and not entered into in the ordinary
course of the Transferred Business.
(b) Each Contract set forth or required to be set forth on
Schedule 3.18 or Schedule 3.20 (the "TRANSFERRED CONTRACTS") is legal, valid,
binding and in full force and effect and is enforceable by the Transferred
Business Companies in accordance with its terms except to the extent such
enforceability may be limited by the bankruptcy, insolvency, or the Chapter 11
or similar reorganization of the other party thereto. DuPont and its Affiliates
have performed in all material respects all obligations required to be performed
by them under the Transferred Contracts and no event has occurred that would
render them (with or without the lapse of time or the giving of notice, or both)
in breach in any material respect or default thereunder and, to DuPont's
Knowledge, no event has occurred that would render any other party to any such
Transferred Contract (with or without the lapse of time or the
58
giving of notice, or both) in breach in any material respect or default
thereunder as of the date of this Agreement or in a breach or default that would
reasonably be expected to have a Material Adverse Effect. None of DuPont nor any
of its Affiliates has received any written, or to DuPont's Knowledge, oral
notice of the intention of any party to terminate any such Transferred Contract
or that any party considers that DuPont or its Affiliates are in breach in any
material respect or default thereunder as of the date of this Agreement or in a
breach or default that would reasonably be expected to have a Material Adverse
Effect. Complete and correct copies of all of such Transferred Contracts,
together with all modifications and amendments thereto, have been made available
to Buyer.
(c) Except for the Transferred Business Plans, there is no
Contract to which a Transferred Business Company is a party or by which a
Transferred Asset is bound or an Assumed Liability arises that prior to Closing
requires any action or omission by DuPont or an Affiliate of DuPont that is not
in the ordinary and usual course of the Transferred Business consistent with
past practice or that would adversely impact in any material respect the ability
of DuPont or an Affiliate of DuPont prior to Closing to preserve intact its
business organizations and relationships with third parties and to keep
available the services of their present officers and employees to the extent
related to the Transferred Business.
3.19 SHARED SERVICES. Except as set forth in Schedule 3.19 and
except for the services to be provided under the Related Agreements and the
DuPont Marks (the use of which shall be phased out by the Transferred Business
Companies pursuant to Section 5.7), (a) DuPont and its Affiliates (other than
the Transferred Business Companies) do not provide any material support services
to the Transferred Business Companies and (b) DuPont and its Affiliates (other
than the Transferred Business Companies), on the one hand, and the Transferred
Business Companies, on the other hand, do not share any material Assets which
are used in, held for use in, or necessary for, the Transferred Business (other
than (i) Buyer Shared Know-how and DuPont Shared Know-how and (ii) Real Estate
and certain related services as expressly contemplated by the Leases and Site
Services Agreements).
3.20 AGREEMENTS RESTRICTING AFFILIATES. Except as set forth on
Schedule 3.20, there is no Contract that constitutes a Transferred Asset or
under which an Assumed Liability arises, or to which a Transferred Asset or
Assumed Liability is subject or bound, that would limit or restrict in any
manner whatsoever the conduct or operation of the business of Buyer and its
Affiliates (other than the
59
Transferred Business Companies) after the Closing (other than confidentiality
and non-disclosure agreements entered into in the ordinary course of business).
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF BUYER AND BUYER SUB
Buyer represents and warrants to the Sellers that, except as set
forth in the Schedules to this Agreement delivered by Buyer with reference to
the specific Section of this Agreement so qualified:
4.1 CORPORATE ORGANIZATION; ETC. Buyer is a corporation duly
organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation.
4.2 AUTHORITY RELATIVE TO THIS AGREEMENT, ETC. Buyer has all
requisite corporate authority and power to execute and deliver this Agreement
and the Related Agreements to which it is a party and to consummate the
transactions contemplated hereby and thereby. The execution and delivery of this
Agreement and the Related Agreements to which Buyer is a party and the
consummation of the transactions contemplated hereby and thereby have been duly
and validly authorized by the Board of Directors of Buyer. No other corporate
proceedings on the part of Buyer (and no action on part of any stockholders of
Buyer) or any Subsidiary thereof are necessary to authorize the execution,
delivery and performance of this Agreement and the Related Agreements to which
it is a party or the consummation of the transactions contemplated hereby and
thereby. This Agreement and the Related Agreements to which Buyer is a party
have been (or in the case of the Related Agreements, will be) duly and validly
executed and delivered by Buyer and, assuming this Agreement and such other
agreements have been duly authorized, executed and delivered by all of the other
parties hereto, each of this Agreement and such other agreements constitutes (or
in the case of the Related Agreements will constitute) a legal, valid and
binding agreement of Buyer, enforceable against Buyer in accordance with its
terms.
4.3 CONSENTS AND APPROVALS; NO VIOLATIONS. None of the execution,
delivery or performance of this Agreement or the Related Agreements to which
Buyer, Buyer Sub 1, Buyer Sub 2 or any of the Foreign Buyer Subs is a party nor
the consummation of the transactions contemplated hereby and thereby by Buyer,
Buyer Sub 1, Buyer Sub 2 and the Foreign Buyer Subs will (a) violate any
provision of the certificate of incorporation or bylaws of Buyer, Buyer Sub 1,
Buyer Sub 2 or any of
60
the Foreign Buyer Subs, (b) require any consent, waiver, approval, authorization
or permit of, or filing with or notification to, any Governmental Authority,
except for (i) filings with the FTC and the DOJ pursuant to the HSR Act, and the
rules and regulations promulgated thereunder, (ii) requirements of the EC Merger
Regulations or any other foreign Antitrust Laws and Laws regulating exchange or
currency controls and (iii) such consents, waivers, approvals, authorizations,
permits, filings or notifications which, if not obtained or made, would not, in
the aggregate, reasonably be expected to have a Buyer Material Adverse Effect,
(c) give rise to any material preferential purchase rights, material rights of
first refusal or similar material rights of any third party or result in a
violation or breach of, or constitute (with or without notice or lapse of time
or both) a default (or give rise to any right of termination, cancellation or
acceleration or any obligation to repay) or a loss of any benefit to which
Buyer, Buyer Sub 1, Buyer Sub 2 or any of the Foreign Buyer Subs is entitled
under, any of the terms, conditions or provisions of any Indebtedness, mortgage,
note, bond, Encumbrance, license, government registration, Contract, Lease,
franchise, permit, agreement or other instrument or obligation to which Buyer is
a party or by which Buyer or any of its properties or Assets may be bound,
except such violations, breaches and defaults which would not reasonably be
expected to have a Buyer Material Adverse Effect or (d) violate any Law
applicable to Buyer, Buyer Sub 1, Buyer Sub 2 or any of the Foreign Buyer Subs
or by which any of its properties or Assets may be bound, except such violations
which would not reasonably be expected to have a Buyer Material Adverse Effect.
4.4 BROKERS AND FINDERS. None of Buyer, Buyer Sub 1, Buyer Sub 2 or
any of the Foreign Buyer Subs or any of their officers, directors or employees
has employed any investment banker, broker or finder or incurred any Liability
for any investment banking fees, brokerage fees, commissions or finders' fees in
connection with the transactions contemplated by this Agreement for which DuPont
or any Retained Subsidiary or, in the event the Closing does not occur, any
Transferred Business Company, has or could have any Liability.
4.5 FINANCING. As of the date of this Agreement, Buyer, Buyer Sub 1,
Buyer Sub 2 and the Foreign Buyer Subs have access to, and as of the Closing
Buyer will have, sufficient funds necessary to (a) pay the Purchase Price, and
(b) pay all of their fees and expenses incurred in connection with the
transactions contemplated by this Agreement.
4.6 SECURITIES ACT. Buyer, Buyer Sub 1, Buyer Sub 2 and the Foreign
Buyer Subs are acquiring the DPC Interests, the DCI Shares, the DPRL Shares, the
DPL Shares and the Controlled Foreign Subsidiary Shares solely for the purpose
of investment and not with a view to, or for sale in connection with, any
distribution thereof in violation of the Securities Act or any applicable
foreign
61
securities laws. Buyer acknowledges that the DPC Interests, the DCI
Shares, the DPRL Shares, the DPL Shares and the Controlled Foreign Subsidiary
Shares being acquired by it and its Subsidiaries are not registered under the
Securities Act, any applicable state securities law or any applicable foreign
securities laws, and that such DPC Interests, DCI Shares, DPRL Shares, DPL
Shares and the Controlled Foreign Subsidiary Shares may not be transferred or
sold except pursuant to the registration provisions of the Securities Act or
such applicable securities laws or pursuant to an applicable exemption therefrom
and pursuant to state securities laws and regulations, as applicable.
ARTICLE V
COVENANTS
5.1 CONDUCT OF BUSINESS.
(a) During the period from the date of this Agreement to the
Closing Date, except (i) as expressly permitted by this Agreement, (ii) as
required by applicable Law or any Contract to which a Transferred Business
Company is a party or by which a Transferred Asset is bound or any Transferred
Business Plan, (iii) with the consent of Buyer or (iv) as set forth on Schedule
5.1, DuPont shall, and shall cause each Transferred Business Company and each of
its other Subsidiaries, to conduct its business (other than activities which are
not part of the Transferred Business) in all material respects in the ordinary
and usual course consistent with past practice and to use its commercially
reasonable efforts to preserve intact its business organizations and
relationships with third parties and to keep available the services of their
present officers and employees.
(b) Without limiting the generality of the foregoing (but
subject to clauses (i), (iii) and (iv) above), during the period from the date
of this Agreement to the Closing Date, DuPont shall cause each of the
Transferred Business Companies not to (and, solely to the extent such action
relates to the Additional Transferred Assets or gives rise to or increases an
Assumed Liability, DuPont shall not and shall cause each of its Subsidiaries not
to):
(1) adopt or propose any change in its respective
certificates of incorporation, bylaws or other constitutional documents,
except for changes which would not have an adverse impact on such company
or on Buyer;
62
(2) acquire, sell, transfer, lease or otherwise dispose
of any Assets of the Transferred Business outside of the ordinary course
of business consistent with past practice;
(3) make any change in any method of accounting, or
accounting practice of any Transferred Business Company, except for any
such change required (A) by reason of a concurrent change in Law, SEC
guideline or GAAP or (B) by reason of a change in DuPont's method of
accounting practices that due to Law, SEC guidelines or requirements or
GAAP requires a change in the accounting practices of a Transferred
Business Company;
(4) transfer any person providing services as an
employee, director, officer, independent contractor or consultant (i) from
DuPont to any of the Transferred Business Companies, or (ii) from any of
the Transferred Business Companies to DuPont, without the prior written
consent of Buyer, unless such transfer occurs pursuant to a transfer that
was pending as of date prior to the date hereof (the "PENDING TRANSFERRED
EMPLOYEES"). Schedule 5.1(b)(4) discloses the name of each Pending
Transferred Employee.
(5) other than in the ordinary course of business
consistent with past practice or as required by Law or contractual
obligations existing on the date of this Agreement, (i) grant any
severance or termination pay to (a) any of its employees, other than
ordinary course grants in amounts consistent with past practice or (b) any
of its directors or officers, (ii) increase benefits payable under any
existing severance or termination pay policies or employment agreements,
(iii) enter into any material employment, consulting, deferred
compensation or other similar agreement (or adopt any amendment to any
such existing agreement) with any of its directors or officers, (iv)
establish, adopt or amend (except as required by applicable Law) any
collective bargaining, bonus, profit sharing, thrift, pension, retirement,
change-in-control, deferred compensation, compensation, stock option,
restricted stock or other benefit plan or arrangement covering any of its
directors, officers or employees, or (v) materially increase compensation,
bonus or other benefits payable to any of its directors or officers;
(6) incur, except in the ordinary course of business
consistent with past practices, any Indebtedness or
63
Encumbrance on any Transferred Assets, except for Permitted Encumbrances;
(7) make any capital expenditure except as reflected in
the capital expenditure plan of the Transferred Business Companies (a copy
of which has been furnished to Buyer) and except for expenditures not in
excess of $10 million in the aggregate;
(8) settle or agree to settle any DPC Action (excluding
any Action related to Taxes) which settlements, in the aggregate, would be
in excess of $10 million or which would impose any injunctive, equitable
or other non-monetary relief or remedy which in any case impacts in any
material respect the Transferred Business or in any respect the business
of Buyer and its Affiliates, other than the Transferred Business
Companies;
(9) issue or sell any new debt securities, incur any
long-term Indebtedness or enter into any new credit facility;
(10) merge or consolidate with any other Person or
acquire any other Person or a business, division or product line of any
other Person (except as provided for in this Agreement);
(11) enter into, extend, renew or terminate (i) any
Contract of the type described in Section 3.18(a)(iii), (ii) any Contract
of the type described in Section 3.18(a)(vi)(B) (other than in the
ordinary course of business consistent with past practice), (iii) any
Contract of the type set forth in Schedule 5.20(a)(i)(A) or 5.20(a)(ii)(A)
or a DuPont Merck Agreement (except for the termination of the License and
Services Agreement, dated January 1, 1991, referred to in Schedule
5.20(b)), except to the extent that any such extension, renewal or
termination does not result in any additional liability to Buyer or any of
the Transferred Business Companies or (iv) any other Contract other than
in the ordinary course of business consistent with past practice;
(12) except as set forth in Section 5.1(c) and except
for Excluded Assets, declare, set aside or pay any dividend or make any
other distribution to its stockholders or other equity holders, redeem or
otherwise acquire any shares of its capital stock or other equity
interests or issue, sell or otherwise dispose of any capital stock or
other equity interests or any option, warrant or other similar
64
right or any securities convertible into or exchangeable for any such
securities above;
(13) except as set forth in Section 5.1(c) and except
for any Excluded Assets, pay, loan or advance any amount to, or sell,
transfer or lease any of its assets to, or enter into any Contract with,
or make any payments to or on behalf of DuPont or any of its Affiliates
(other than the Transferred Business Companies);
(14) settle or compromise any material Tax liability or
make or change any material Tax election; or
(15) agree or commit to do any of the foregoing.
(c) Notwithstanding any provision herein to the contrary,
prior to the Closing, each of the Transferred Business Companies will be
permitted to (A) declare and pay dividends and distributions of, or otherwise
transfer, to DuPont or any Subsidiary thereof (i) Cash, (ii) any Excluded
Assets, and (iii) any DuPont Books and Records.
(d) Between the date of this Agreement and the date of the
Closing, DuPont shall cause each of the Transferred Business Companies not to
sell, distribute or promote sales of its products in a manner that would
reasonably be expected to result in "trade loading" or otherwise in a material
increase in the inventory levels, taken in the aggregate, of products of the
Transferred Business held by distributors of such products. Any such conduct by
a Transferred Business Company shall be deemed to not be in all material
respects in the ordinary and usual course of business of the Transferred
Business or the Transferred Business Companies. DuPont and its Affiliates shall
use their reasonable best efforts after execution of this Agreement and prior to
the Closing to comply with the plan to reduce the amount of inventory of
finished goods of the Transferred Business Companies consistent with the
inventory levels set forth in Schedule 5.1(d).
5.2 ACCESS TO INFORMATION. From the date of this Agreement until the
Closing, DuPont will, and will cause its Subsidiaries to, give Buyer and its
Representatives reasonable access to the DPC Books and Records and to such
personnel, offices and other facilities and properties and Assets of the
Transferred Business Companies and to furnish such other information in respect
of the operation of the Transferred Business as Buyer may reasonably request;
PROVIDED, that all requests for access pursuant to this Section 5.2 shall be
made in writing and shall be directed to and coordinated with the Chief
Financial Officer of DPC or such person or
65
persons as he shall designate; PROVIDED, FURTHER, that any such access shall be
conducted at a reasonable time, upon reasonable advance notice to DuPont, and in
such a manner as not to interfere unreasonably with the operation of any
business conducted by any Transferred Business Companies. In addition, during
such period, DuPont and its Affiliates shall use their reasonable best efforts
to allow Buyer and its Representatives to communicate with, and to review all
work papers, schedules, memoranda and other documents prepared by,
PricewaterhouseCoopers LLP during the course of its audit or review of the DPC
Financial Statements, and such access shall be provided promptly after request
by Buyer and/or its Representatives; PROVIDED, that the foregoing shall be
subject to professional liability standards and PricewaterhouseCoopers LLP
policy, which may include, without limitation, the requirement that Buyer and
its Representatives sign an "indemnification letter" in the form generally used
by PricewaterhouseCoopers LLP prior to receiving access to any materials
prepared by PricewaterhouseCoopers LLP. All such information and access shall be
subject to the terms and conditions of the confidentiality agreement dated
January 30, 2001 between Buyer and DuPont (the "CONFIDENTIALITY AGREEMENT").
Notwithstanding anything to the contrary in this Agreement, neither DuPont nor
its Subsidiaries (including the Transferred Business Companies) shall be
required to disclose any information to Buyer or its Representatives if doing so
presents a significant risk of violating any Contract or Law to which DuPont or
any of its Subsidiaries is a party or to which it is subject or which it
believes in good faith presents a significant risk, based on an opinion of
counsel (which can be given by inside counsel), of resulting in a loss of the
ability to successfully assert a claim of Privilege; PROVIDED that the parties
hereto shall cooperate in seeking to find a way to allow disclosure of such
information without resulting in a loss of the ability to successfully assert a
claim of Privilege. Notwithstanding the foregoing, Sellers shall not be required
to provide any such information as and to the extent it relates to the Retained
Business, the Excluded Assets or the Retained Liabilities.
5.3 CONSENTS AND APPROVALS.
(a) DuPont and Buyer will cooperate, and will cause their
respective Affiliates to cooperate, with respect to the notices and filings to
be made in connection with the consents, approvals, waivers and authorizations
under Law required prior to or after the Closing in connection with the
transactions contemplated hereby. Any such notice prepared by any of the
Transferred Business Companies for the benefit of any employee shall be
reasonably satisfactory to Buyer. Subject to the provisions of Section 5.3(b),
each of the parties hereto shall use its reasonable best efforts to (i) cause
the Closing to occur on or prior to September 30, 2001 or as soon as possible
thereafter and obtain as promptly as practicable all material consents,
authorizations, approvals and waivers required in connection with the
consummation of the transactions contemplated by this Agreement under any Law,
including all state
66
property transfer laws and Environmental Laws, or any Contract, (ii) lift or
rescind any injunction or restraining order or other order adversely affecting
the ability of the parties hereto to consummate the transactions contemplated
hereby, (iii) effect all necessary notifications, or registrations and filings
including, but not limited to, the Required Filings and submissions of
information required by any Governmental Authority (including any such
notifications, registrations or filings required post-Closing), (iv) obtain as
promptly as practicable all material consents, authorizations, approvals and
waivers required in connection with all state property transfer laws, including
the receipt of a Letter of Non-Applicability ("LNA"), or its equivalent,
pursuant to the State of New Jersey's Industrial Site Recovery Act ("ISRA")
respecting all Transferred Assets at the Xxxxxxxx Works facility in Deepwater,
NJ, and (v) effect the transfer of all Environmental Permits, without material
changes to the operating conditions or discharge limitations contained therein,
required for the operations of the Transferred Business and all the Transferred
Environmental Assets. Sellers will timely notify Buyer and give Buyer the
opportunity to participate in all negotiations with the relevant Governmental
Authorities with respect to the terms and conditions of any Environmental
Permits to be transferred. Alternatively, and where not prohibited by Law or the
terms of any Environmental Permit, the parties may execute an agreement
providing that some or all of the operations of the Transferred Business and the
Transferred Environmental Assets will be conducted after Closing, subject to the
same material operating conditions and discharge limitations, pursuant to
existing Permits held by DuPont, DPC or DPI, as applicable. Subject to the
provisions of Section 5.3(b), the parties hereto further covenant and agree,
with respect to any threatened or pending preliminary or permanent injunction or
other order, decree, ruling, statute, rule, regulation or executive order that
would adversely affect the ability of the parties hereto to consummate the
transactions contemplated hereby, to respectively use their reasonable best
efforts to prevent the entry, enactment or promulgation thereof, as the case may
be.
(b) With respect to filings required under applicable
Antitrust Laws, each of the parties shall prepare and make, or cause to be made,
the Required Filings under the HSR Act within five (5) Business Days following
the execution of this Agreement and all other Required Filings under applicable
Antitrust Laws within twenty (20) Business Days following the execution of this
Agreement and thereafter use reasonable best efforts to certify as soon as
practicable its substantial compliance with any requests for additional
information or documentary materials in connection therewith. Buyer shall use
its reasonable best efforts to resolve such objections, if any, as may be
asserted with respect to the transactions contemplated hereby under any
Antitrust Laws by any Governmental Authorities with regulatory jurisdiction over
enforcement of any applicable Antitrust Laws (each, a "GOVERNMENTAL ANTITRUST
ENTITY") and shall take such action as may be required to (i) avoid the entry
of, or to effect the dissolution, modification or suspension of, any injunction,
temporary
67
restraining order or other order that has the effect of preventing or delaying
the consummation of any of such transactions by any domestic or foreign court or
similar tribunal in any suit brought by a Governmental Antitrust Authority or by
a private party challenging the transactions contemplated hereby as violative of
any Antitrust Laws, or (ii) to resolve any objections of any Government
Antitrust Entity in a manner and at a time that would allow the Closing to occur
prior to the Outside Date. Except as qualified by the following sentence,
neither the taking of any action that Buyer is required to take pursuant to this
Section 5.3(b) nor the entry by a court, in any suit brought by a private party
or Governmental Antitrust Entity challenging the transactions contemplated
hereby as violative of any Antitrust Laws, of an order or decree permitting the
transactions contemplated hereby but requiring that any assets or businesses be
divested or held separate by Buyer, or that would otherwise limit Buyer's
freedom of action with respect to, or its ability to retain, any assets or
businesses shall be deemed a failure to satisfy the conditions specified in
Section 7.2, and, notwithstanding such order or decree, Buyer shall still be
obligated to deliver the full amount of the Closing Purchase Price at the
Closing and the Final Closing Adjustment, if any, pursuant to Section 2.4.
Notwithstanding the foregoing provisions of this Section 5.3, under no
circumstances will Buyer be required to divest, hold separate or otherwise limit
Buyer's freedom of action with respect to, or its ability to retain, any of the
assets or businesses listed on Schedule 5.3(b) and any requirement to do so
would constitute a failure to satisfy the condition specified in Section 7.2(e).
In the event of any inconsistency or conflict between the provisions of this
Section 5.3(b) and any other provision of this Agreement, the provisions of this
Section 5.3(b) shall govern. No action taken pursuant to this Section 5.3(b),
whether or not Buyer is required to take such action, shall be a basis for
indemnification pursuant to Article VIII.
(c) Each party hereto shall promptly inform the other of any
written or substantive oral communication from any Governmental Antitrust Entity
regarding any of the transactions contemplated hereby. If any party hereto or
any Affiliate thereof receives a request for information or documentary material
from any such Governmental Antitrust Entity with respect to the transactions
contemplated hereby, then such party shall endeavor in good faith to make, or
cause to be made, as soon as reasonably practicable and after consultation with
the other party, an appropriate response in compliance with such request and to
provide the other party (and its counsel), upon request, advance drafts of all
presentations and filings in connection therewith. All substantive telephone
calls and meetings with a Governmental Antitrust Entity in connection with the
transactions contemplated hereby shall include Representatives of each of Buyer
and DuPont (except to the extent that the applicable Governmental Antitrust
Entity does not permit such inclusion).
68
5.4 FURTHER ASSURANCES. Subject to Section 5.3, each of the parties
hereto agrees to use its reasonable best efforts before and after the Closing
Date to take or cause to be taken all action, to do or cause to be done, and to
assist and cooperate with the other party hereto in doing, all things necessary,
proper or advisable under applicable Laws to consummate and make effective, in
the most expeditious manner practicable, the transactions contemplated by this
Agreement, including, but not limited to, (i) the satisfaction of the conditions
precedent to the obligations of any of the parties hereto; (ii) to the extent
consistent with the obligations of the parties set forth in Section 5.3, the
defending of any lawsuits or other legal proceedings, whether judicial or
administrative, challenging this Agreement or the performance of the obligations
hereunder; and (iii) the execution and delivery of such instruments, and the
taking of such other actions, as the other party hereto may reasonably require
in order to carry out the intent of this Agreement.
5.5 INTERCOMPANY ACCOUNTS AND ARRANGEMENTS. (a) Except as expressly
modified by a Related Agreement and except for the agreements set forth on
Schedule 5.5 hereto, all intercompany arrangements and agreements, whether
written or oral, providing goods, services or joint activities between DuPont or
any of the Retained Subsidiaries, on the one hand, and any of the Transferred
Business Companies, on the other hand, shall be terminated and of no further
force and effect after the Closing. Effective upon the Closing, all outstanding
intercompany accounts, whether payables or receivables, between DuPont or any of
the Retained Subsidiaries, on the one hand, and any of the Transferred Business
Companies, on the other hand, shall be cancelled and of no further force and
effect (it being understood that such cancellation shall not in any way affect
the Related Agreements or any amounts which may be payable pursuant to the
Related Agreements).
(b) Except to the extent provided to the contrary in Section
5.5(a), effective as of the Closing: (i) Buyer, on behalf of the Transferred
Business Companies, hereby releases DuPont and each of the Retained Subsidiaries
(and their respective officers, directors and employees, acting in their
capacity as such) from any Liability, obligation or responsibility to any of
them for any and all past actions or failures to take action prior to Closing,
including any actions which may be deemed to have been negligent or grossly
negligent, relating to or arising out of Contracts with DuPont or a Subsidiary
thereof or the operation or conduct of any businesses, Assets (including
activities performed thereat) or operations managed or operated by, or
operationally related to, directly or indirectly, to the Transferred Business or
the Retained Business, except for any Liability, obligation or responsibility
for any action or failure to take action in accordance with the provisions of
this Agreement or for any fraudulent act or willful or intentional misconduct in
the operation or conduct of Transferred Business prior to the Closing Date; and
(ii) DuPont, for itself and on behalf of its Subsidiaries other than the
69
Transferred Business Companies, hereby releases the Transferred Business
Companies (and their respective officers, directors and employees, acting in
their capacity as such) from any Liability, obligation or responsibility to any
of them for any and all past actions or failures to take action prior to
Closing, including any actions which may be deemed to have been negligent or
grossly negligent, relating to or arising out of Contracts with DuPont or a
Subsidiary thereof or the operation or conduct of any businesses, Assets
(including activities performed thereat) or operations managed or operated by,
or operationally related to, directly or indirectly, the Transferred Business or
the Retained Business, except for any Liability, obligation or responsibility
for any fraudulent act or willful or intentional misconduct in the operation or
conduct of the Transferred Business or the Retained Business prior to the
Closing Date.
(c) Nothing set forth in this Section 5.5 shall limit or
otherwise affect any party's rights or obligations pursuant to, or contemplated
by, this Agreement and the Related Agreements, including any obligations
relating to indemnification and the assumption of Liabilities.
5.6 PROVISION OF CORPORATE RECORDS. As soon as practicable after the
Closing Date, DuPont shall use its commercially reasonable efforts to deliver or
cause to be delivered to Buyer all DPC Books and Records then in the possession
of DuPont or any Retained Subsidiary, and Buyer shall use its commercially
reasonable efforts to deliver or cause to be delivered to DuPont all DuPont
Books and Records then in the possession of any Transferred Business Company.
The foregoing shall be limited by the following specific provisions:
(i) To the extent any document (including computer tape) can
be subdivided without unreasonable effort into two portions, one of which
constitutes a DPC Book and Record and the other of which constitutes a
DuPont Book and Record, such document (including computer tape) shall be
so sub-divided, and the original of the portion such document (including
computer tape) which constitutes a DPC Book and Record shall be provided
to Buyer (with a copy thereof provided to DuPont) and the original of the
portion such document (including computer tape) which constitutes a DuPont
Book and Record shall be provided to DuPont (with a copy thereof provided
to Buyer).
(ii) Neither party shall be required to conduct any
company-wide search or investigation of files.
70
(iii) "Commercially reasonable efforts" shall require, without
limitation, deliveries of any such specific and discrete books and records
requested in writing by either party.
(iv) Each party may retain copies of books and records
delivered to the other, subject to holding in confidence in accordance
with Section 5.15 hereof information contained in such books and records.
(v) Each party may refuse to furnish any Information if it
believes in good faith that doing so presents, based on an opinion of
counsel (which can be inside counsel), a significant risk of loss of the
ability to successfully assert a claim of Privilege; PROVIDED that the
parties hereto shall cooperate in seeking to find a way to allow
disclosure of such information without resulting in a loss of the ability
to successfully assert a claim of privilege.
(vi) Neither party shall be required to deliver to the other
books and records or portions thereof which are subject to confidentiality
agreements which would by their terms prohibit such delivery; PROVIDED,
HOWEVER, if requested by the other party, such party shall use its
commercially reasonable efforts to seek a waiver of such confidentiality
restriction.
(vii) DuPont may redact any Information covered by this
Section 5.6 as and to the extent such Information relates to the Retained
Business, the Excluded Assets or the Retained Liabilities.
(viii) Buyer may redact any Information covered by this
Section 5.6 as and to the extent such Information relates to Buyer's
business, assets or liabilities other than the Transferred Business
Companies, the Transferred Assets and the Assumed Liabilities.
5.7 NAMES. Buyer agrees that it shall, and shall cause the
Transferred Business Companies to, as soon as reasonably practicable after the
Closing Date and in any event within (x) 180 days (in the case of clause (a)(i)
below) and (y) one business day (in the case of clause (a)(ii) and (b) below)
following the Closing Date, (a) cease to (i) make any use of the name "DuPont,"
and any Trademarks related thereto or containing or comprising the foregoing,
including any name or xxxx confusingly similar thereto or dilutive thereof (the
"DUPONT MARKS"), and (ii)
71
hold itself out as having any affiliation with DuPont or any of its
Subsidiaries, and (b) in the case of any Transferred Business Company whose name
includes any XxXxxx Xxxx to change its corporate name to a name that does not
include any XxXxxx Xxxx and to make any necessary legal filings with the
appropriate Governmental Authority to effectuate such change. In furtherance
thereof, as promptly as reasonably practicable but in no event later than 180
days following the Closing Date, Buyer shall, and shall cause its Subsidiaries
to, remove, strike over or otherwise obliterate all DuPont Marks from (or
otherwise not use) all materials owned by any of the Transferred Business
Companies, including, without limitation, any vehicles, business cards,
schedules, stationery, packaging materials, displays, signs, promotional
materials, manuals, forms, computer software and other materials or media
including any Internet usage or domain names that include the DuPont Marks;
PROVIDED that Buyer and the Transferred Business Companies may during such
180-day period continue to use any material containing a XxXxxx Xxxx to the
extent that it is not reasonably practicable to remove or cover up such XxXxxx
Xxxx. Notwithstanding the above, Buyer and the Transferred Business Companies
shall have a right to sell off existing inventory of products manufactured or
packaged by or for any of the Transferred Business Companies, which products
bear any DuPont Marks, for a period of one year; PROVIDED, HOWEVER, that Buyer
and the Transferred Business Companies may use the DuPont Marks solely in
package inserts that have been packaged with products as of the Closing Date and
only until the applicable expiration date of each such respective product. Any
use of the DuPont Marks by Buyer pursuant to this Section 5.7 shall be in
reasonable conformity with the practices of DuPont as of the Closing Date and
shall be in a manner that is not intended to or is not reasonably likely to harm
or disparage DuPont or the reputation or goodwill of the DuPont Marks.
Notwithstanding the foregoing, nothing in this Section 5.7 shall be construed to
require, or to permit, Buyer to take, or fail to take, any action which is in
violation of the rules and regulations of the Food and Drug Administration.
5.8 INTELLECTUAL PROPERTY.
(a) Upon the Closing, DuPont and the Retained Subsidiaries
shall receive from Buyer a grant of a world-wide, irrevocable immunity from suit
by Buyer and the Transferred Business Companies for the continued use after the
Closing Date of the Buyer Shared Know-how outside of the Pharmaceutical Field of
Use; PROVIDED, HOWEVER, that such immunity shall be limited to use by DuPont or
any of the Retained Subsidiaries of any such Buyer Shared Know-how for internal
research and development outside the Pharmaceutical Field of Use; and PROVIDED,
FURTHER, that such immunity shall extend only to Buyer Shared Know-how in such
use by DuPont or any of the Retained Subsidiaries as of the Closing Date; and
PROVIDED, FURTHER, that neither DuPont nor the Retained Subsidiaries shall have
the right to transfer or grant such immunity to a third party other than a third
party purchaser of
72
substantially all the business and Assets to which such immunities pertain. In
the event that a third party acquires (by operation of law or otherwise) all or
substantially all of the businesses or assets of Buyer to which such immunities
pertain, or acquires (by operation of law or otherwise) a 50% or greater voting
equity interest in Buyer, Buyer shall require such acquiring party to maintain
the immunities set forth in this Section 5.8(a).
(b) Upon the Closing, Buyer shall receive from DuPont a grant
of a world-wide, irrevocable immunity from suit by DuPont and the Retained
Subsidiaries for the continued use after the Closing Date of the DuPont Shared
Know-how inside of the Pharmaceutical Field of Use; PROVIDED, HOWEVER, that such
immunity shall be limited to use by Buyer or any of its Subsidiaries of any such
DuPont Shared Know-how for internal research and development inside of the
Pharmaceutical Field of Use; and PROVIDED, FURTHER, that such immunity shall
extend only to such DuPont Shared Know-how in such use by the Transferred
Business Companies as of the Closing Date; and PROVIDED, FURTHER, that Buyer
shall not have the right to transfer or grant such immunity to a third party
other than a third party purchaser of substantially all the business and Assets
to which such immunities pertain. In the event that a third party acquires (by
operation of law or otherwise) all or substantially all of the businesses or
assets of DuPont to which such immunities pertain, or acquires (by operation of
law or otherwise) a 50% or greater voting equity interest in DuPont, DuPont
shall require such acquiring party to maintain the immunities set forth in this
Section 5.8(b).
(c) Upon the Closing, Buyer shall receive from DuPont, in a
separate patent license agreement to be agreed upon by DuPont and Buyer, a grant
of a world-wide, royalty-free, exclusive, fully paid-up, freely sublicenseable,
perpetual license inside of the Pharmaceutical Field of Use (except that such
license shall be non-exclusive with respect to "biological products" as set
forth and conditioned within the definition of Pharmaceutical Field of Use) to
the rights related to:
(i) the Bile Acid Sequesterant Technology Patents, as
set forth on Schedule 5.8(c)(i) hereto, subject to any license previously
granted by DuPont or the Transferred Business Companies, provided that any
such license granted after the date of this Agreement shall not be beyond
the scope permitted under this paragraph (c); and
(ii) the rights related to the Roxifiban Process
Patents, as set forth on Schedule 5.8(c)(ii) hereto.
(d) Upon the Closing, Buyer shall receive from DuPont, in a
separate patent license agreement to be agreed upon by DuPont and Buyer, a grant
of
73
a world-wide, royalty-free, non-exclusive, fully paid-up, non-sublicenseable
(except to Affiliates, collaborators, or any other Person assisting Buyer in
research and development efforts or contract manufacturing), perpetual license
inside of the Pharmaceutical Field of Use to:
(i) the rights related to the Catalysts for Asymmetric
Addition Patents, as set forth on Schedule 5.8(d)(i) hereto.
(ii) the rights related to the Lux Patents, as set forth
on Schedule 5.8(d)(ii) hereto;
(iii) the rights related to the OncoMouse Patents, as
set forth on Schedule 5.8(d)(iii) hereto; and
(iv) the rights related to the Info Evolve and Pattern
Discovery Patents as set forth on Schedule 5.8(d)(iv) hereto.
(e) Upon the Closing, Buyer shall receive from DuPont, in a
separate patent license agreement to be agreed upon by DuPont and Buyer, a grant
of a world-wide, royalty-free, exclusive, fully paid-up, freely sublicenseable,
perpetual license inside of the Pharmaceutical Field of Use (except that such
license shall be non-exclusive with respect to "biological products" as set
forth and conditioned within the definition of Pharmaceutical Field of Use) to
the rights related to the Cre-Lox Patents, subject to the licenses previously
granted by either DuPont or the Transferred Business Companies. Notwithstanding
the preceding sentence, all rights and obligations of the Transferred Business
Companies under the Cre-Lox agreements listed on Schedule 5.8(e) hereto in force
as of the Closing Date shall inure to Buyer.
(f) Upon the Closing, Buyer shall receive from DuPont, in a
separate patent license agreement to be agreed upon by DuPont and Buyer, a grant
of a world-wide, royalty-free, non-exclusive, fully paid-up, non-sublicensable,
perpetual license inside of the Pharmaceutical Field of Use to DuPont's rights
under the PDG Participant License Agreement, dated January 1, 1999, between the
Lemelson Medical, Education and Research Foundation, Limited Partnership, and
DuPont (the "LEMELSON AGREEMENT"), to the extent that such grant by DuPont is
permitted under the Lemelson Agreement.
(g) Upon the Closing, DuPont shall receive from Buyer, in a
separate know-how license agreement to be agreed upon by DuPont and Buyer, a
grant of a world-wide, royalty-free, exclusive, fully paid-up, freely
sublicenseable,
74
perpetual license outside of the Pharmaceutical Field of Use (and a
non-exclusive license, otherwise on the same terms with respect to "biological
products") to the rights related to the Deletion Mutants in E COLI technology,
including, but not limited to, access to the samples of the Deletion Mutants
existing as of the Closing.
(h) Upon the Closing, DuPont shall receive from Buyer, in a
separate patent license agreement to be agreed upon by DuPont and Buyer, a grant
of a world-wide, royalty-free, non-exclusive, fully paid-up, non-sublicenseable
(except to Affiliates, collaborators or any other Person assisting DuPont in
research and development efforts or contract manufacturing), perpetual license
outside of the Pharmaceutical Field of Use (and a non-exclusive license,
otherwise on the same terms with respect to "biological products") to:
(i) the rights related to the Combichem Patents, as set
forth on Schedule 5.8(h)(i) hereto; and
(ii) the rights related to the Combichem Discovery
Engine, as set forth on Schedule 5.8(h)(ii) hereto subject to any
license agreement existing as of Closing that would prevent such rights
from being granted, or would cause Buyer to incur an additional
financial obligation,except in the latter case if DuPont agrees to
accept such obligation).
(i) At the request of DuPont made within three (3) years from
Closing, DuPont shall receive from Buyer in a separate patent license agreement
to be agreed upon by Buyer and DuPont following such request, a grant of a
world-wide, royalty-free, non-exclusive, fully paid-up, freely sublicenseable,
perpetual license outside the Pharmaceutical Field of Use, to the rights related
to any Patents pending or issued as of Closing and owned (and available for such
license at the time of such request) by the Transferred Business Companies for a
compound in DuPont's Chemical and Biological Clearing House as of the date of
this Agreement other than those set forth on Schedule 1.1(d) hereto or the use
of such a compound outside the Pharmaceutical Field of Use; PROVIDED that such
licenses shall not apply to any commercialized products or nominated compounds
of the Transferred Business Companies as of the Closing Date.
(j) At the request of Buyer made within three (3) years from
Closing, Buyer shall receive from DuPont in a separate patent license agreement
to be agreed upon by DuPont and Buyer following such request, a grant of a
world-wide, royalty-free, non-exclusive, fully paid-up, freely sublicensable,
perpetual license inside the Pharmaceutical Field of Use, to the rights related
to any Patents pending or issued as of the Closing and owned (and available for
such license at the time of such
75
request) by DuPont or the Retained Subsidiaries for a compound set forth on
Schedule 1.1(d) hereto and the compounds within the Transferred Business
Companies' Pharma DB Library as of the date of this Agreement or the use of such
a compound inside the Pharmaceutical Field of Use; PROVIDED that such licenses
shall not apply to any commercialized products or compounds nominated for
agricultural venture qualification or other comparable stages of development in
other fields of DuPont or the Retained Subsidiaries as of the Closing Date.
(k) For a period of three (3) years from the Closing Date,
Buyer shall have (i) full rights to access the compounds set forth on Schedule
1.1(d) from DuPont's Chemical and Biological Clearing House and (ii) the right
to access any compounds in DuPont's Chemical and Biological Clearing House,
other than those listed on Schedule 1.1(d), which compounds are within the
literal scope of pending or issued Patents owned by or licensed to the
Transferred Business Companies which Patents cover the nominated compounds
specifically identified on page 49 of the DuPont Pharmaceuticals Company
Confidential Offering Memorandum, dated February, 2001, previously distributed
to Buyer, to the extent such compounds remain available for such access. In each
case, such access shall be provided pursuant to a separate site services access
agreement to be entered into by Buyer and DuPont on the Closing Date, which
shall provide that DuPont shall provide services related to the storage and
retrieval of samples accessible pursuant to the foregoing sentence at Buyer's
expense at a price equal to DuPont's fully-allocated cost. In addition, prior to
three (3) years from the Closing Date, DuPont shall as promptly as reasonably
practicable deliver to Buyer, at Buyer's request and expense at a price equal to
DuPont's fully-allocated cost, all of the compounds remaining in DuPont's
possession set forth on Schedule 1.1(d) from DuPont's Chemical and Biological
Clearing House.
5.9 POST-CLOSING COOPERATION. DuPont and Buyer shall cooperate with
each other, and shall cause their respective Subsidiaries and Representatives to
cooperate with each other, for a period of 180 days after the Closing, to ensure
the orderly transition of each Transferred Business Company and all Transferred
Assets and Assumed Liabilities from DuPont to Buyer (including the transition of
any information technology systems) and to minimize any disruption to their
respective businesses that might result from the transactions contemplated
hereby. Notwithstanding the forgoing, at any time after the Closing, upon
reasonable written notice, DuPont and Buyer shall furnish or cause to be
furnished to the other party and its employees, counsel, auditors and
Representatives reasonable access, during normal business hours, to such
Information and assistance relating to the Transferred Business Companies,
Transferred Assets and Assumed Liabilities as is reasonably necessary for
financial reporting and accounting matters, the preparation and filing of any
Tax Returns or the defense of any Tax Audit or any other requirement under any
76
applicable Law or regulation; PROVIDED that the provisions of Article VI shall
govern with respect to all Tax-related matters to the extent any provision in
Article VI is in conflict with this Section 5.9; PROVIDED, FURTHER, that
notwithstanding anything to the contrary in this Agreement, neither DuPont nor
the Retained Subsidiaries, on the one hand, and neither Buyer nor its
Subsidiaries, on the other hand, shall be required to disclose any information
to the other or its Representatives if doing so presents a significant risk of
violating any Law or Contract to which DuPont or any of the Retained
Subsidiaries, on the one hand, or Buyer or any its Subsidiaries, on the other
hand, is a party or to which it is subject or which it believes in good faith
presents a significant risk of, based on an opinion of counsel (which can be
inside counsel), resulting in a loss of the ability to successfully assert a
claim of Privilege; PROVIDED that the parties hereto shall cooperate in seeking
to find a way to allow disclosure of such information without resulting in a
loss of the ability to successfully assert a claim of Privilege. DuPont shall
not be required to provide any such information as and to the extent it relates
to the Retained Business, the Excluded Assets or the Retained Liabilities.
Neither party shall be required by this Section 5.9 to take any action that
would unreasonably interfere with the conduct of its business or unreasonably
disrupt its normal operations (or, in the case of Buyer, the business or
operations of any Transferred Business Company).
5.10 PENDING LITIGATION. Following the Closing Date, (a) Buyer shall
have exclusive authority and control over the investigation, prosecution,
defense and appeal of all then pending Actions relating to or arising in
connection with the Transferred Business Companies, the Transferred Assets or
the Assumed Liabilities, including Actions with respect to the matters set forth
on Schedule 5.10(a) (each, a "DPC ACTION"), and may settle or compromise, or
consent to the entry of any judgment with respect to any such Action, without
the consent of DuPont except to the extent such settlement or compromise
involves an order, injunction or other equitable relief adversely affecting
DuPont or its Subsidiaries, and (b) DuPont shall have exclusive authority and
control over the investigation, prosecution, defense and appeal of all then
pending Actions relating to or arising in connection with the Retained Business,
the Excluded Assets or the Retained Liabilities, including Actions with respect
to the matters set forth on Schedule 5.10(b) (each, a "DUPONT ACTION"), and may
settle or compromise, or consent to the entry of any judgment with respect to,
any such Action without the consent of Buyer except to the extent such
settlement or compromise involves an order, injunction or other equitable relief
adversely affecting Buyer or its Subsidiaries; PROVIDED, that if (i) both DuPont
(or a Retained Subsidiary) and a Transferred Business Company are named as
parties to any DPC Action or DuPont Action, or (ii) such Action involves a claim
for which indemnification would be provided pursuant to Article VIII, DuPont,
any of the Retained Subsidiaries, Buyer, the Transferred Business Companies and
any of their Subsidiaries must comply with the provisions of Section 8.4 hereof
instead of this
77
Section 5.10. Buyer shall, and shall cause each of its Subsidiaries to, use its
reasonable best efforts to have DuPont and any DuPont Indemnified Parties
removed as parties to any DPC Action in which they are named parties as soon as
is reasonably practicable, and DuPont shall, and shall cause the Retained
Subsidiaries to, use its reasonable best efforts to have DPC and any Buyer
Indemnified Parties removed as parties to any DuPont Action in which they are
named parties as soon as is reasonably practicable.
5.11 EMPLOYEE MATTERS.
(a) CONTINUATION OF EMPLOYMENT. Effective as of the Closing
Date, Buyer shall cause each Transferred Business Company to continue the
employment with such Transferred Business Company of all employees of the
applicable Transferred Business Company. Notwithstanding the foregoing, except
as may be required by applicable Law or employment agreement, if Buyer
terminates, or causes the applicable Transferred Business Company to terminate,
the employment of any Transferred Employee at any time on or after the Closing
Date, Buyer shall be responsible for the costs and consequences of any such
termination and shall indemnify and hold harmless the DuPont Indemnified Parties
against any Losses arising in connection therewith.
(b) COMPENSATION AND BENEFITS. For a period of at least three
(3) years following the Closing Date, Buyer shall or shall cause, as applicable,
a Transferred Business Company or a Subsidiary of Buyer to offer compensation
(including base salary or wage rate, variable compensation and long-term
compensation) and benefits (including severance benefits) to the Transferred
Employees substantially similar, in the aggregate, to those provided to such
Transferred Employees in the year prior to the Closing Date; PROVIDED that any
employee benefits provided to such Transferred Employees may be provided under
existing or newly established employee benefit plans which may, in either case,
be employee benefit plans of Buyer, a Subsidiary of Buyer, or a Transferred
Business Company (any such employee benefit plan in which Transferred Employees
participate, the "APPLICABLE BUYER PLAN") and which may be modified at any time.
(c) CERTAIN LIABILITIES. As of the Closing Date, with respect
to all employee Liabilities or obligations not otherwise provided for in this
Agreement, including, without limitation, any such Liability or obligation
relating to or arising under any employee benefit or compensation plan,
agreement, arrangement, or program (excluding any stock option or other stock
based incentive plan, but including any stock based incentive awards which, by
their terms, are payable only in cash), as well as accrued wages and workers'
compensation, holiday, vacation and sick day benefits, (i) DuPont or an
appropriate Subsidiary of DuPont shall assume and
78
be solely responsible for all Liabilities and obligations whatsoever with
respect to Retained Employees and (ii) Buyer or an appropriate Transferred
Business Company shall assume and be solely responsible for all Liabilities and
obligations whatsoever with respect to Transferred Employees.
(d) PARTICIPATION AND SERVICE CREDIT.
(i) On and after the Closing Date, Buyer and the
Transferred Business Companies shall give Transferred Employees service credit
for purposes of eligibility, vesting, determination of the level of benefits and
benefit accrual under any Applicable Buyer Plan, except to the extent that such
recognition would result in a duplication of benefits, for service prior to the
Closing Date, to the extent such service was recognized under the corresponding
employee benefit plans of the Transferred Business Company immediately prior to
the Closing Date.
(ii) Buyer shall cause any pre-existing conditions,
restrictions or waiting periods under Applicable Buyer Plans to be waived to the
extent necessary to provide immediate coverage to each Transferred Employee who
was an eligible participant in the comparable Transferred Business Plan as of
the Closing Date. Any Applicable Buyer Plan which is a medical plan shall apply
any amounts paid under the medical plan of the applicable Transferred Business
Company by a Transferred Employee as deductibles and co-payments during the year
in which the Closing Date falls toward deductible and out-of-pocket limits of
the Applicable Buyer Plan which is a medical plan for the plan year in which the
Closing Date occurs.
(e) CERTAIN PLANS AND AGREEMENTS. Buyer agrees to honor, and
to cause the Transferred Business Companies to honor, the severance agreements
and plans set forth on Schedule 5.11(e) hereto (the "LISTED AGREEMENTS"). DuPont
has previously provided to Buyer accurate annual base salaries and annual target
incentives, as of the date of this Agreement, of each individual who is a party
to a Listed Agreement. Buyer acknowledges that the Closing constitutes a "Change
in Control" for all purposes pursuant to the Listed Agreements. The Listed
Agreements shall not include any "supplemental agreement" listed on Schedule
3.11(i).
(f) PAID TIME OFF. As of the Closing Date, Buyer shall (i)
cause the Transferred Business Companies to continue to provide the paid time
off entitlements set forth on Schedule 5.11(f) ("PTO") to the Transferred
Employees that are substantially equivalent to the PTO entitlements of the
Transferred Employees under the PTO policy of the applicable Transferred
Business Company immediately prior to the Closing Date and (ii) assume all
obligations to Transferred Employees with respect to accrued PTO.
79
(g) DUPONT'S 401(k) PLAN. As soon as practicable following the
Closing Date, each Transferred Employee who is a participant in the DuPont
401(k) Plan shall have the right to elect to receive a distribution of all or a
portion of such employee's account balance in the DuPont 401(k) Plan (subject
to, and in accordance with, the provisions of the DuPont 401(k) Plan and
applicable Law). Buyer shall take any and all necessary action to cause the
trustee of a defined contribution plan of Buyer or one of its Subsidiaries, if
requested to do so by a Distributee, to accept the direct "roll over" of all or
a portion of any such distribution (including notes associated with the
outstanding balance of any loans of a Distributee under the DuPont 401(k) Plan)
from the DuPont 401(k) Plan.
(h) CARIBE DC PLAN. Unless otherwise agreed to by Buyer and
DuPont, effective as of the Closing Date, Buyer shall establish or designate a
defined contribution plan and trust intended to qualify under applicable law
(together, the "BUYER CARIBE DC PLAN") to accept a transfer from the trustee of
the Caribe DC Plan in respect of account balances of Transferred Employees under
the Caribe DC Plan. DuPont shall, upon receipt of satisfactory written evidence
of the adoption of the Buyer Caribe Plan and its compliance with all applicable
laws, direct the trustee of the Caribe DC Plan to transfer, to the trustee of
the Buyer Caribe DC Plan, as of the Closing Date, in cash and/or notes
associated with the outstanding balance of any loans to Transferred Employees,
the cash value of the account balances under the Caribe DC Plan in respect of
Transferred Employees. Upon such transfer, the Buyer Caribe DC Plan shall assume
all liabilities for accrued benefits under the Caribe DC Plan in respect of
Transferred Employees and the Caribe DC Plan shall be relieved of all such
liabilities. The parties shall cooperate in the filing of the documents required
by the transfer of assets and liabilities described herein.
(i) NON-QUALIFIED PLANS. Following the Closing Date, Buyer
shall cause DPC to continue to maintain its Pension Restoration Plan, Retirement
Restoration Plan and Supplemental Retirement Income Plan with respect to
Transferred Employees. Buyer and DPC shall assume and be solely responsible for
the liabilities and obligations relating to the Transferred Employees who
participate in the DuPont 401(k) Restoration Plan.
(j) TRANSFERRED PENSION PLANS. With respect to each of the
Transferred Pension Plans, as of the Closing Date, DuPont shall have, or shall
have caused its Subsidiaries to have, conducted: (i) a fair market valuation of
the assets of each Transferred Pension Plan, and (ii) a valuation of the
aggregate liabilities of each Transferred Pension Plan in accordance with FAS 87
but using an 8.5% interest rate assumption and a 5.5% salary increase assumption
(collectively, the "SUBSTITUTED ASSUMPTIONS"). To the extent that the aggregate
liabilities of both Transferred Pension Plans on a projected benefit obligation
basis in accordance with FAS 87 and
80
the Substituted Assumptions exceed the aggregate fair market value of the assets
set aside in trust with respect to both Transferred Pension Plans (the
"UNDERFUNDING"), then as soon as practicable after the Closing Date, DuPont
shall make contributions to the respective Transferred Pension Plans equal to
the amount of such Underfunding in excess of $50 million.
(k) FOREIGN PENSION PLANS. (i) With respect to any pension
plan maintained or sponsored by DuPont or any Subsidiary of DuPont for the
benefit of foreign employees in which only Transferred Employees participate,
Buyer or an appropriate Transferred Business Company shall assume or retain sole
Liability for each such pension plan and no additional assets shall be
transferred by DuPont or any Subsidiary of DuPont to Buyer, DPC or such pension
plan with respect to any such pension plan.
(ii) (1) DEFINITIONS. For the purposes of this Section
5.11(k), the following definitions shall apply:
"ACTUARIAL ASSUMPTIONS" means the actuarial method and assumptions
set out in the letter from DuPont's Actuary to Buyer's Actuary a copy of which
is attached to Schedule 5.11(k) hereto (the "ACTUARY'S LETTER").
"BUYER'S ACTUARY" means an actuary determined by Buyer for the
purposes of this Section 5.11(k).
"CONSENTING MEMBER" means a Member:
(i) who begins to accrue retirement benefits under the
New Plan as of the Closing Date; and
(ii) from whom the DuPont UK Plan receives a signed
request for a transfer payment in respect of his past service rights
to be made to the New Plan no later than 30 days after the Closing
Date or such later date as may be agreed by DuPont and Buyer (such
agreement not to be unreasonably withheld or delayed) and who does
not, before the transfer payment is made, withdraws his request or
die or become entitled to the payment of immediate benefits under
the DuPont UK Plan.
"DUE PAYMENT DATE" means the day 10 Business Days after (i)
the agreement between DuPont's Actuary and Buyer's Actuary as to the UK Transfer
Amount or (ii), if a reference is made to an independent actuary under Section
5.11(k)(ii)(6), the date of his determination of the UK Transfer Amount.
81
"DUPONT'S ACTUARY" means an actuary determined by DuPont for
the purposes of this Section 5.11(k).
"MEMBER" means a person who is a Transferred Employee and an
active member of the DuPont UK Plan immediately prior to the Closing Date.
"NEW PLAN" means the pension scheme or schemes described in
Section 5.11(K)(ii)(2) and, where the context permits, including its trustees.
"UK TRANSFER AMOUNT" has the meaning set out in Sections
5.11(k)(ii)(4)(C) and (D).
(2) NEW PLAN. As soon as practicable after the
Closing Date, Buyer shall provide to DuPont particulars of an occupational
pension scheme that is established and administered in the United Kingdom
and is an exempt approved scheme within the meaning of Section 592 of the
Income and Corporation Taxes Act of 1988 (or designed so as to be capable
of such approval) and of the benefits to be provided to Consenting Members
under Section 5.11(k)(ii)(3)(A).
(3) PROVISION OF BENEFITS.
(A) Buyer shall offer each Member membership
of the New Plan with effect from the Closing Date and, subject to
the conditions set out in Section 5.11(k)(ii)(3)(B), in respect of
his pensionable service in the DuPont UK Plan, benefits which are
overall at least equal in value to those applying for and in respect
of him under the DuPont UK Plan immediately before the Closing Date,
valuing benefits under the New Plan and under the DuPont UK Plan for
this purpose on the basis of the Actuarial Assumptions.
(B) The conditions referred to in Section
5.11(k)(ii)(3)(A) are that the Member has become a Consenting Member
and that the New Plan has received the UK Transfer Amount.
(4) CALCULATION OF UK TRANSFER AMOUNT.
(A) Buyer shall provide to DuPont all such
documents and information in its possession or control that are
reasonably required for the calculation of the UK Transfer Amount
and undertakes to DuPont that all such documents and information
shall be true complete and accurate in all material respects.
82
(B) DuPont shall provide to Buyer all such
documents and information in its possession and/or control that are
reasonably required for the calculation of the UK Transfer Amount
and covenants that all such documents and information shall be true
complete and accurate in all material respects.
(C) The UK Transfer Amount shall be calculated
by DuPont's Actuary as being the value of the benefits prospectively
payable under the DuPont UK Plan as at the Closing Date to and in
respect of the Consenting Members and calculated on the basis of the
Actuarial Assumptions, and adjusted in accordance with the Actuary's
Letter.
(D) DuPont shall cause DuPont's Actuary to
calculate the unadjusted UK Transfer Amount as soon as practicable
after the Closing Date, but no later than 60 days after the Closing
Date, and DuPont shall notify Buyer of the result of that
calculation and provide such particulars of the calculation and the
data on which it is based as Buyer's Actuary reasonably requires to
enable Buyer's Actuary to check that the calculation is correct.
DuPont's Actuary must provide such further particulars or data that
Buyer's Actuary reasonably requests within 30 days of receipt of the
result of the calculation from DuPont's Actuary. Buyer's Actuary has
60 days from the date on which those particulars and data have been
supplied to him to raise any objection to the calculation. The
calculation shall be final and binding on DuPont and Buyer on the
later of the agreement between DuPont's Actuary and Buyer's Actuary
as to the UK Transfer Amount or, if a reference is made to an
independent actuary under Section 5.11(k)(ii)(6), the date of his
determination of the UK Transfer Amount.
(5) TRANSFER OF UK TRANSFER AMOUNT OF AVCS.
(A) DuPont shall, or cause its Subsidiary to,
use reasonable efforts to cause the DuPont UK Plan to transfer, on
the Due Payment Date, to the New Plan the UK Transfer Amount and the
assets representing, as at the date of transfer, the additional
voluntary contributions paid by the Consenting Members.
(B) DuPont and Buyer shall, or shall cause
their respective Subsidiaries to, use reasonable best efforts
83
to secure agreement between the DuPont UK Plan and the New Plan
respectively as to the particular assets to be transferred
representing the UK Transfer Amount. If Agreement is not reached by
the Due Payment Date, the transfer shall be in cash. Any listed
securities to be transferred shall be valued at the mid-market price
at the close of business on the relevant stock exchange on the day
before the date of transfer.
(C) DuPont and Buyer shall respectively seek
promptly from the Board of Inland Revenue approval to the transfer
of assets from the DuPont UK Plan to the New Plan in respect of the
Consenting Members.
(D) If the total amount that has been actually
transferred (if any) by the DuPont UK Plan to the New Plan on or
before the Due Payment Date in respect of the Consenting Members is
less than the UK Transfer Amount, DuPont shall, within 5 business
days after the Due Payment Date, pay to Buyer or as it may direct,
the amount of the underpayment (the "Shortfall"), together with
interest at 2% above the base rate from time to time of National
Westminster Bank plc calculated on the basis of a year of 360 days
for the actual number of days elapsed accrued from the Due Payment
Date up to and including the date of payment.
(E) Immediately following any payment pursuant
to Section 5.11(k)(ii)(5)(D), Buyer shall procure that an amount
equal to the payment is contributed to the New Plan.
(6) DISPUTES. Any dispute between DuPont and Buyer
or between DuPont's Actuary and Buyer's Actuary concerning any calculation
or valuation of benefits under this Section 5.11(k) shall, in the absence
of agreement between them within one month of the party concerned having
notified the other in writing of the dispute, be referred to an
independent actuary chosen by agreement between DuPont and Buyer or,
failing agreement, appointed by the President for the time being of the
Institute of Actuaries at the instance of either DuPont or Buyer. The
independent actuary shall be instructed by DuPont and Buyer not to make a
compromise determination but to adopt the submission of either DuPont (or
DuPont's Actuary) or of Buyer (or Buyer's Actuary). The independent
actuary shall determine the disputed matter as an expert and not as an
arbitrator, and his decision shall be final and binding.
84
The fees and expenses of the independent actuary and of such President
shall be borne equally between the parties, except that the independent
actuary shall have the power to determine, at the request of any party,
that the fees and expenses shall be borne exclusively by the other
parties or in such proportions as the actuary may determine and any such
determination shall be final and binding.
(7) INDEMNITIES. Dupont covenants with Buyer to
pay to Buyer on an after-Tax basis, so far as possible by way of reduction
in the consideration payable under this Agreement:
(A) an amount equal to any payment that any
Transferred Business Company is or becomes liable to make to the
DuPont UK Plan whether pursuant to section 75 of the UK Pensions Xxx
0000, or otherwise, and any Liability or Loss that any Transferred
Business Company incurs in relation to that payment;
(B) an amount equal to any Liability or Loss
that any Transferred Business Company incurs in relation to a claim
made against that Transferred Business Company in relation to the
exclusion prior to the Closing Date of an employee or former
employee from an occupational pension scheme.
(l) EMPLOYMENT RELATED LIABILITIES. DPC shall assume Liability
with respect to any and all Losses incurred or suffered as a result of any claim
by any Transferred Employee which arises under Law (including, without
limitation, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of
1991, the Age Discrimination in Employment Act of 1990, the Equal Pay Act, the
Americans with Disabilities Act of 1990, ERISA and all other statutes regulating
the terms and conditions of employment), under the common law or in equity
(including any claims for wrongful discharge or otherwise), or under any policy,
agreement, understanding or promise, written or oral, formal or informal,
between DuPont (but only with respect to the Listed Agreements) or DPC (or any
Subsidiary of DuPont (but only with respect to the Listed Agreements) or DPC)
and the Transferred Employee, whether arising out of actions, events or
omissions that occurred (or, in the case of omissions, failed to occur) prior
to, or after, the Closing Date. DuPont shall assume Liability with respect to
any Losses incurred or suffered as a result of any claim by any Retained
Employee which arises under Law (including, without limitation, Title VII of the
Civil Rights Act of 1964, the Civil Rights Act of 1991, the Age Discrimination
in Employment Act of 1990, the Equal Pay Act, the Americans with Disabilities
Act of 1990, ERISA and all other statutes regulating the terms and conditions of
employment), under the common law or in equity (including any claims
85
for wrongful discharge or otherwise), or under any policy, agreement,
understanding or promise, written or oral, formal or informal, between DuPont or
any of its Subsidiaries and the Retained Employee, whether arising out of
actions, events or omissions that occurred (or, in the case of omissions, failed
to occur) prior to, or after, the Closing Date.
(m) INDEMNIFICATION. All Liabilities retained, assumed or
indemnified by Buyer pursuant to this Section 5.11 shall in each case be deemed
to be Assumed Liabilities, and all liabilities retained, assumed or indemnified
by DuPont pursuant to this Section 5.11 shall in each case be deemed to be
Retained Liabilities, and, in each case, shall be subject to the indemnification
provisions set forth in Section 8.4 of this Agreement.
(n) POST-RETIREMENT COVERAGE.
(i) POST-RETIREMENT HEALTH COVERAGE. For a three (3)
year period commencing on the Closing Date (the "POST-RETIREMENT PERIOD"),
Buyer shall, or shall cause a Subsidiary of Buyer to, provide
post-retirement health coverage (excluding any post-retirement dental
coverage) to each Transferred Employee (and eligible dependents) upon the
termination of such Transferred Employee's employment; PROVIDED that such
Transferred Employee otherwise satisfies the applicable age and/or service
requirements. Such post-retirement health coverage shall be at least
substantially equivalent (in terms of the eligibility requirements, scope
of the post-retirement health coverage provided and the cost of such
coverage to the Transferred Employees) to either (A) that provided under
the applicable post-retirement health program in effect immediately prior
to the Closing Date, recognizing additional age and service credit accrued
with Buyer and/or a Subsidiary of Buyer after the Closing, or (B) that
provided to similarly situated employees of Buyer; PROVIDED, HOWEVER, that
if Buyer or a Subsidiary of Buyer shall elect to provide post-retirement
health coverage through an Applicable Buyer Plan pursuant to this Section
5.11(n)(i)(B), Buyer or such Subsidiary of Buyer shall, for the duration
of the Post-Retirement Period, waive any otherwise applicable company
cost-sharing and life-time maximum limitations with respect to such
post-retirement health coverage.
(ii) POST-RETIREMENT LIFE INSURANCE COVERAGE. For the
Post-Retirement Period, Buyer shall, or shall cause a Subsidiary of Buyer
to, provide post-retirement life insurance coverage to each Transferred
Employee upon the termination of such
86
Transferred Employee's employment; PROVIDED that such Transferred Employee
otherwise satisfies the applicable age and/or service requirements. Such
post-retirement life insurance coverage shall be at least substantially
equivalent (in terms of the eligibility requirements, amount of life
insurance coverage provided and the cost of such coverage to the
Transferred Employees) to either (A) that provided under the applicable
post-retirement life insurance program in effect immediately prior to the
Closing Date, or (B) that provided to similarly situated employees of
Buyer; PROVIDED, HOWEVER, that if Buyer or a Subsidiary of Buyer shall
elect to provide post-retirement life insurance coverage under an
Applicable Buyer Plan pursuant to this Section 5.11(n)(ii)(B) and if such
plan requires evidence of insurability in connection with the purchase of
supplemental life insurance coverage, then Buyer or such Subsidiary of
Buyer shall, for the duration of the Post-Retirement Period, cause such
Applicable Buyer Plan to provide post-retirement life insurance coverage
with terms and conditions that are substantially equivalent to the
post-retirement life insurance coverage provided under the applicable
post-retirement life insurance program in effect immediately prior to the
Closing Date with the exception of such requirement to provide evidence of
insurability.
(o) DUPONT ASSUMED LIABILITIES. Notwithstanding anything to
the contrary herein, as of the Closing Date, DuPont shall assume all Liabilities
with respect to (i) providing long-term disability benefits to those Transferred
Employees who were in receipt of, or were eligible to receive, long-term
disability benefits from a Transferred Business Company immediately prior to the
Closing Date, excluding however any disability benefits paid or payable to a
Transferred Employee under a Transferred Pension Plan, (ii) providing
post-retirement welfare benefits (if any) to Transferred Employees (and eligible
dependents) whose employment had terminated prior to the Closing Date and (iii)
claims incurred during a period of a Transferred Employee's employment with
DuPont or any of its Affiliates (other than the Transferred Business Companies)
arising solely from such employment relationship (except to the extent such
claims relate to Liabilities under any funded Transferred Business Plan).
(p) No later than forty-five (45) days after the date of this
Agreement, DuPont shall deliver to Buyer (i) a schedule setting forth the name,
current annual compensation rate (including bonus and commissions), title,
classification as executive officer, officer, director or senior manager,
department and current base salary rate of each Transferred Employee who is
employed by a Transferred Business Company as such date; (ii) a list of each
agreement between a Transferred Business Company and an independent contractor
which may not be
87
terminated without material penalty on less than six months notice; (iii) a list
of each material agreement between a Transferred Business Company and a
Transferred Employee (other than standard non-disclosure agreements entered into
in the ordinary course of business consistent with past practice) or independent
contractor relating to proprietary processes, formulae or information; and (iv)
a detailed schedule of the PTO entitlements of Transferred Employees as of the
date of this Agreement, or as of such other time agreed to by DuPont and Buyer.
(q) FUTA; FICA. Buyer and DuPont shall, to the extent
possible, (i) treat Buyer or a Subsidiary of Buyer as a "successor employer" and
the applicable Transferred Business Company as a "predecessor," within the
meaning of Sections 3121(a)(1) and 3306(b)(1) of the Code, with respect to
Transferred Employees to be employed by Buyer or a Subsidiary of Buyer for
purposes of Taxes imposed under the United States Federal Unemployment Tax Act
or the United States Federal Insurance Contributions Act, and (ii) cooperate
with each other to avoid the filing of more than one IRS Form W-2 with respect
to each such Transferred Employee for the calendar year in which the Closing
Date occurs.
(r) ACTIONS BY DUPONT. Any action required to be taken under
this Section 5.11 by DuPont may be taken by a Subsidiary of DuPont.
(s) MUTUAL COOPERATION. DuPont and Buyer shall (or shall cause
their respective Subsidiaries, third-party plan administrators and plan trustees
to) cooperate with each other prior to and following the Closing in effectuating
any communications, elections, access to populations, enrollments, payroll
transitions and such other actions as may be necessary or reasonable with
respect to participants in any Transferred Business Plan and/or employment,
consulting or such other agreement in connection with the actions contemplated
under Section 5.11 of this Agreement.
(t) AGREEMENT TO PROVIDE TRANSITIONAL SERVICES. As soon as
practicable following the date of this Agreement, Buyer and DuPont shall enter
into a benefit transitional services agreement pursuant to which DuPont shall
provide to Buyer or a Subsidiary of Buyer, in exchange for payment (not to
exceed the actual cost of such services) from Buyer or a Subsidiary of Buyer,
services relating to the administration of certain Transferred Business Plans
(for a period not exceeding nine months, or such shorter period as requested by
Buyer or a Subsidiary of Buyer, during which period DuPont also provides payroll
services), payroll services (for a period not exceeding nine months, or such
shorter period as requested by Buyer or a Subsidiary of Buyer) and such other
services reasonably requested by Buyer or a Subsidiary of Buyer.
88
5.12 POST-CLOSING ACCESS TO INFORMATION. From and after the Closing
Date, except as prohibited by applicable Law, DuPont and Buyer shall, subject to
compliance by the other and its Subsidiaries with the provisions of Section
5.15, afford to each other and to each other's Representatives reasonable access
and duplicating rights (with copying costs to be borne by the requesting party)
during normal business hours to all books and records, documents and other
information (collectively, "INFORMATION") within the knowledge, possession or
control of the other party or any DuPont Indemnified Party or Buyer Indemnified
Party solely to the extent relating to (a) in the case of Buyer, the Transferred
Business, Transferred Business Companies, Transferred Assets, Assumed
Liabilities or Transferred Employees and (b) in the case of DuPont, the Retained
Business, the Excluded Assets or the Retained Liabilities, insofar in each case
as such access is reasonably required by DuPont or Buyer or any of their
Subsidiaries or Affiliates and does not violate any applicable Law or any
confidentiality obligations applicable to DuPont or Buyer or any of their
Subsidiaries or Affiliates, as the case may be (and shall use reasonable efforts
to cause persons or firms possessing relevant Information to give similar
access), PROVIDED, HOWEVER, that no party shall be required to disclose any
Information if it believes in good faith that doing so presents a significant
risk, based on an opinion of counsel (which can be inside counsel) of resulting
in a loss of the ability to successfully assert a claim of Privilege; PROVIDED
that the parties hereto shall cooperate in seeking to find a way to allow
disclosure of such information without resulting in a loss of the ability to
successfully assert a claim of Privilege. Without limiting the generality of the
foregoing, Information may be requested under this Section 5.12 for audit and
accounting purposes and in connection with Actions, as well as for purposes of
fulfilling disclosure and reporting obligations. Notwithstanding the foregoing,
the provisions of this Section 5.12 shall not apply to Actions brought by one
party (or its Affiliates) to this Agreement against another party (or its
Affiliates) to this Agreement.
5.13 PRODUCTION OF WITNESSES AND INDIVIDUALS. From and after the
Closing Date, DuPont and Buyer shall use and shall cause their respective
Subsidiaries to use reasonable efforts to make available to each other, upon
written request, its officers, directors, employees and agents for fact finding,
consultation and interviews and as witnesses to the extent that any such person
may reasonably be required in connection with any Actions in which the
requesting party may from time to time be involved relating to the conduct of
the Transferred Business or the Retained Business. DuPont and Buyer agree to
reimburse each other for reasonable out-of-pocket expenses (other than officers'
or employees' salaries) incurred by the other in connection with providing
individuals and witnesses pursuant to this Section 5.13. Notwithstanding the
foregoing, the provisions of this Section 5.13 shall not apply to Actions
brought by one party (or its Affiliates) to this Agreement against another party
(or its Affiliates) to this Agreement.
89
5.14 RETENTION OF RECORDS. Except when a longer retention period is
otherwise required by Law or agreed to in writing, including as set forth in
Section 6.8, DuPont and the Transferred Business Companies and their
Subsidiaries shall retain, in accordance with their respective records control
schedule policy existing from time to time, all Information relating to the
Transferred Business and the Retained Business, respectively. The parties hereto
agree that upon written request from the other that certain Information relating
to the Transferred Business or the transactions contemplated hereby be retained
in connection with an Action, the parties shall use reasonable efforts to
preserve and not to destroy or dispose of such Information without the consent
of the requesting party.
5.15 CONFIDENTIALITY.
(a) For a period of ten years from the Closing Date, DuPont
and Buyer shall hold and shall respectively cause their respective Affiliates
(including the Transferred Business Companies) to hold, and shall each cause
their respective Representatives to hold, in strict confidence and not to
disclose or release without the prior written consent of the other party, any
and all Confidential Information (as defined herein); PROVIDED, that the parties
may disclose, or may permit disclosure of, Confidential Information (i) to their
respective Representatives who have a need to know such information and are
informed of their obligation to hold such information confidential to the same
extent as is applicable to the parties hereto and in respect of whose failure to
comply with such obligations, DuPont or Buyer, as the case may be, will be
responsible or (ii) if the parties hereto, their Affiliates or their
Representatives are compelled to disclose any such Confidential Information by
judicial or administrative process or, in the opinion of independent legal
counsel, by other requirements of Law. Notwithstanding the foregoing, in the
event that any demand or request for disclosure of Confidential Information is
made pursuant to clause (ii) above, DuPont or Buyer, as the case may be, shall
promptly notify the other of the existence of such request or demand and shall
provide the other a reasonable opportunity to seek an appropriate protective
order or other remedy, which both parties will cooperate in obtaining (each at
their own expense). In the event that such appropriate protective order or other
remedy is not obtained, the party who is required to disclose such Confidential
Information shall furnish, or cause to be furnished, only that portion of the
Confidential Information that is legally required to be disclosed. As used in
this Section 5.15, "CONFIDENTIAL INFORMATION" shall mean all proprietary
technical, economic, environmental, operational, financial and/or other business
Information or material of one party which, prior to or following the Closing
Date, has been disclosed by DuPont or its Affiliates, on the one hand, or Buyer
or its Affiliates (including the Transferred Business Companies), on the other
hand, in written, oral (including by recording), electronic, or visual form to,
or otherwise has come into the possession of, the other, in each case including
pursuant to the access
90
provisions of Section 5.9 or Section 5.12 hereof or any other provision of this
Agreement or any Related Agreement or, (A) in the case of DuPont and its
Affiliates and Representatives, as a result of DuPont's direct or indirect
ownership of the Transferred Assets and Transferred Business Companies prior to
the Closing or (B) in the case of Buyer and the Transferred Business Companies,
as a result of DuPont's direct or indirect ownership of the Transferred Business
Companies or as a result of relationships, agreements and course of conduct of
the Transferred Business Companies with DuPont and its other Subsidiaries prior
to Closing, including, but not limited to, (a) ideas and concepts for existing
products, processes and services; (b) specifications for products, Equipment and
processes; (c) manufacturing and performance specifications and procedures; (d)
engineering drawings and graphs; (e) technical, research and engineering data;
(f) formulations and material specifications; (g) laboratory studies and
benchmark tests; (h) service and operation manuals; (i) quality assurance
policies, procedures and specifications; (j) evaluation and/or validation
studies; (k) pending patent applications; (l) all other know-how, methodology,
procedures, techniques and trade secrets related to research, engineering,
development and manufacturing; and (m) business information, including marketing
and development plans, forecasts, research and development agreements, and
customer and vendor information (except to the extent that such Information can
be shown to have been (1) in the public domain through no fault of such party or
its Affiliates (including, in the case of DuPont, any of the Retained
Subsidiaries or, in the case of Buyer, any of its Subsidiaries (including the
Transferred Business Companies)) or (2) lawfully acquired from other sources by
the party (or its Affiliates (including the Transferred Business Companies)) to
which it was furnished; PROVIDED, however, in the case of (2) that such sources
did not provide such Information in breach of any confidentiality or other legal
obligations). Notwithstanding the first sentence of this Section 5.15(a), with
respect to any Confidential Information first disclosed after the Closing Date
to DuPont or its Affiliates or Representatives, on the one hand, or Buyer or its
Affiliates or Representatives (including the Transferred Business Companies), on
the other hand, by the other party or its Affiliates or Representatives, the
obligations of this subsection shall terminate ten years after the date of the
first such disclosure of such Information.
(b) Notwithstanding anything to the contrary set forth herein,
(i) DuPont and its Affiliates, on the one hand, and Buyer and its Affiliates
(including the Transferred Business Companies), on the other hand, shall be
deemed to have satisfied their obligations hereunder with respect to
Confidential Information if they exercise the same degree of care (but no less
than a reasonable degree of care) as they take to preserve confidentiality for
their own similar Information and (ii) confidentiality obligations provided for
in any agreement between DuPont or any of its Affiliates, or Buyer or any of its
Affiliates (including the Transferred Business
91
Companies), on the one hand, and any employee of DuPont or any of its Affiliates
(or, prior to the Closing Date, any Transferred Business Company), or Buyer or
any of its Affiliates (including after the Closing Date the Transferred Business
Companies), on the other hand shall remain in full force and effect.
Confidential Information of DuPont and its Affiliates, on the one hand, or the
Transferred Business Companies, on the other hand, in the possession of and used
by the other as of the Closing Date may continue to be used by DuPont or its
Affiliates, or Buyer or its Affiliates (including the Transferred Business
Companies), as the case may be, in the operation of their businesses, so long as
the Confidential Information is maintained in confidence and not disclosed in
violation of this Agreement. Such continued right to use may not be transferred
to any third party (other than an Affiliate of a party hereto) unless the third
party purchases all or substantially all of the business and Assets in one
transaction or in a series of related transactions for which or in which the
relevant Confidential Information is used or employed.
(c) Immediately prior to the Closing, DuPont will request that
all confidential material provided to prospective purchasers of the Transferred
Business in connection with Sale Process (other than Buyer and its Subsidiaries)
be returned to DuPont or a Transferred Business Company or be destroyed.
5.16 PRIVILEGED MATTERS.
(a) DuPont and Buyer agree that their respective rights and
obligations to maintain, preserve, assert or waive any or all privileges
belonging to either corporation with respect to the Transferred Business and the
Retained Business, including but not limited to the attorney-client and work
product privileges (collectively, "PRIVILEGES"), shall be governed by the
provisions of this Section 5.16. With respect to matters relating to the
Retained Business or to the Sale Process, DuPont shall have sole authority in
perpetuity to determine whether to assert or waive any or all Privileges, and
Buyer and its Affiliates (including the Transferred Business Companies) shall,
to their knowledge, take no action without the prior written consent of DuPont
that could result in any waiver of any Privilege that could be asserted by
DuPont under applicable Law and this Agreement. With respect to matters relating
to the Transferred Business (except as provided in the preceding sentence),
after the Closing, Buyer shall have sole authority in perpetuity to determine
whether to assert or waive any or all Privileges, and DuPont and its Affiliates
shall, to their knowledge, take no action after the Closing without the prior
written consent of Buyer that could result in any waiver of any Privilege that
could be asserted by Buyer under applicable Law and this Agreement. The rights
and obligations created by this Section 5.16 shall apply to all Information as
to which DuPont, Buyer, or the Transferred Business Companies would be entitled
to assert or has asserted a Privilege as provided above ("PRIVILEGED
INFORMATION"). Privileged Information of DuPont includes but is not
92
limited to (i) all Information regarding the Retained Business and all
Information of DuPont relating to the Sale Process, but which after the Closing
is in the possession of Buyer or any of its Subsidiaries (including the
Transferred Business Companies); (ii) all communications subject to a Privilege
occurring prior to the Closing between counsel for DuPont or any of the Retained
Subsidiaries (including in-house counsel and former in-house counsel who are
Transferred Employees) and any person who, at the time of the communication, was
an employee of DuPont or any of the Retained Subsidiaries, regardless of whether
such employee is or becomes an employee of Buyer or any of its Subsidiaries
(including the Transferred Business Companies); and (iii) all Information
generated, received or arising after the Closing Date that refers or relates to
Privileged Information generated, received or arising prior to the Closing Date.
Privileged Information of Buyer includes but is not limited to (i) any and all
Information generated prior to the Closing regarding the Transferred Business
but which after the Closing is in the possession of DuPont or any of the
Retained Subsidiaries (excluding Information of DuPont or its Subsidiaries
relating to the Sale Process); (ii) all communications subject to a Privilege
occurring prior to the Closing (excluding communications relating to the Sale
Process generated by DuPont or its Representatives) between counsel for the
Transferred Business Companies (including in-house counsel and former in-house
counsel who were employees of DuPont or the Retained Subsidiaries) and any
person who, at the time of the communication, was an employee of any of the
Transferred Business Companies, regardless of whether such employee is or
becomes an employee of DuPont or any of the Retained Subsidiaries; and (iii) all
Information generated, received or arising after the Closing Date that refers or
relates to Privileged Information generated, received or arising prior to the
Closing Date.
(b) Upon receipt by DuPont or its Subsidiaries or Buyer or its
Subsidiaries (including the Transferred Business Companies), as the case may be,
of any subpoena, discovery or other request from any third party that actually
or arguably calls for the production or disclosure of Privileged Information of
the other or if DuPont or its Subsidiaries or Buyer or its Subsidiaries
(including the Transferred Business Companies), as the case may be, obtains
knowledge that any current or former employee of either DuPont or its
Subsidiaries or Buyer or its Subsidiaries (including the other Transferred
Business Companies), has received any subpoena, discovery or other request from
any third party that actually or arguably calls for the production or disclosure
of Privileged Information of the other, DuPont or Buyer, as the case may be,
shall promptly notify the other of the existence of the request and shall
provide the other a reasonable opportunity to review the Information and to
assert any rights it may have under this Section 5.16 or otherwise to prevent
the production or disclosure of Privileged Information. DuPont or its
Subsidiaries or Buyer or its Subsidiaries (including DPC and the other
Transferred Business Companies), as the case may be, will not produce or
disclose to any third party any of the
93
other's Information covered by a Privilege under this Section 5.16 unless (i)
the other has provided its express written consent to such production or
disclosure, or (ii) a court of competent jurisdiction has entered an order not
subject to interlocutory appeal or review finding that the Information is not
entitled to protection from disclosure under any applicable privilege, doctrine
or rule.
(c) DuPont's transfer of DPC Books and Records and other
Information to Buyer, DuPont's agreement to permit Buyer to obtain Information
existing prior to the Closing, Buyer's and DPC's transfer of DuPont Books and
Records and other Information and Buyer's agreement to permit DuPont to obtain
Information existing prior to the Closing are made in reliance on DuPont's,
Buyer's and DPC's respective agreements, as set forth in Section 5.15 and this
Section 5.16, to maintain the confidentiality of such Information and to take
the steps provided herein for the preservation of all Privileges that may belong
to or be asserted by DuPont or Buyer, as the case may be. The access to
Information being granted pursuant to Section 5.9 and Section 5.12 hereof, the
agreement to provide witnesses and individuals pursuant to Section 5.13 hereof
and the disclosure to Buyer and DuPont of Privileged Information relating to the
Transferred Business or Retained Business pursuant to this Agreement shall not
be asserted by DuPont or Buyer to constitute, or otherwise deemed, a waiver of
any Privilege that has been or may be asserted under this Section 5.16 or
otherwise. Nothing in this Agreement shall operate to reduce, minimize or
condition the rights granted to DuPont and Buyer in, or the obligations imposed
upon DuPont and Buyer by, this Section 5.16.
5.17 MAIL AND OTHER COMMUNICATIONS; ACCOUNTS.
(a) After the Closing Date, each of DuPont and its
Subsidiaries and Buyer and its Subsidiaries may receive mail, telegrams,
packages and other communications properly belonging to the other (or the
other's Subsidiaries). Accordingly, at all times after the Closing Date, each of
DuPont and Buyer authorizes the other and their respective Subsidiaries to
receive and open all mail, telegrams, packages and other communications received
by it and not unambiguously intended for the other party (or its Subsidiaries)
or any of the other party's (or its Subsidiaries') officers or directors, and to
retain the same to the extent that they relate to the business of the receiving
party or, to the extent that they do not relate to the business of the receiving
party, the receiving party shall promptly deliver such mail, telegrams, packages
or other communications (or, in case the same relate to both businesses, copies
thereof) to the other party. The provisions of this Section 5.17 are not
intended to, and shall not be deemed to, constitute an authorization by either
DuPont or Buyer to permit the other to accept service of process on its behalf
and neither party is or shall be deemed to be the agent of the other for service
of process purposes.
94
(b) All payments and reimbursements received by DuPont or its
Subsidiaries in connection with or arising out of the Transferred Business, the
Transferred Assets or the Assumed Liabilities after the Closing shall be held by
such Person in trust for the benefit of Buyer and, immediately upon receipt by
such Person of any such payment or reimbursement, such Person shall pay over to
Buyer the amount of such payment or reimbursement, without right of set off.
(c) All payments and reimbursements received by Buyer or its
Subsidiaries in connection with or arising out of the Excluded Assets, Retained
Liabilities or Retained Business, after the Closing shall be held by such Person
in trust for the benefit of DuPont and, immediately upon receipt by such Person
of any such payment or reimbursement such person shall pay over to DuPont the
amount of such payment or reimbursement without right of set off.
5.18 COMPLIANCE WITH WARN ACT AND SIMILAR STATUTES. Buyer agrees
that it shall, and shall cause its Subsidiaries to, comply with the Worker
Adjustment and Retraining Notification Act of 1988 (the "WARN ACT") and any
applicable state, local and foreign plant closing and layoff law as it relates
to any site of employment of the Transferred Business Companies. Buyer agrees
to, and shall cause its Subsidiaries to, indemnify, defend and hold harmless
DuPont and the Retained Subsidiaries from and against any and all Losses which
DuPont and the Retained Subsidiaries may incur in connection with any Action or
claim of violation brought against DuPont and any of the Retained Subsidiaries
under the WARN Act or any state, local and foreign plant closing and layoff law,
which relate, in whole or in part, to actions taken by Buyer or any of its
Subsidiaries following the Closing Date with regard to any site of employment of
the Transferred Business Companies or any of their respective operating units
within any site of employment of the Transferred Business.
5.19 SHARED CONTRACTS. Subject to Section 5.20 below: (a) With
respect to Shared Contractual Liabilities pursuant to, under or relating to a
given Shared Contract, such Shared Contractual Liabilities shall be allocated
between DuPont and Buyer as follows:
(i) If a Liability is incurred exclusively in respect of a
benefit received by DuPont or by DPC (or in the case of DuPont, the
Retained Subsidiaries, or in the case of DPC, the Transferred Business
Companies), the party receiving such benefit shall be responsible for such
Liability.
(ii) If a Liability cannot be so allocated under clause (i),
such Liability shall be allocated to DuPont or Buyer, as the
95
case may be, based on the relative proportions of total benefit received
(over the term of the Shared Contract, measured as of the date of the
allocation) by such party or such party's Subsidiary under the relevant
Shared Contract. Notwithstanding the foregoing, each of DuPont and Buyer
shall be responsible for any or all Liabilities arising from its (or its
Subsidiary's) breach of the relevant Shared Contract to which this Section
5.19 otherwise pertains.
(b) If DuPont or any Retained Subsidiary, on the one hand, or
Buyer or any of its Subsidiaries (including DPC), on the other hand, receives
any benefit or payment which under any Shared Contract was intended for the
other, DuPont and Buyer will use their respective reasonable best efforts to,
and to cause their respective Subsidiaries to, deliver such benefit or payment
to the other party.
5.20 CERTAIN MATTERS RELATING TO INTELLECTUAL PROPERTY AND
AGREEMENTS WITH MERCK & CO. INC.
(a) Prior to the Closing, (i) DPC shall assign to DuPont all
of its rights and obligations under the agreements listed in Schedule
5.20(a)(i)(A) and all of its rights in and to the Patents and Trademarks listed
in Schedule 5.20(a)(i)(B) and (ii) DuPont shall assign to DPC all of its rights
and obligations under the agreements listed in Schedule 5.20(a)(ii)(A) and all
of its rights in and to the Patents and Trademarks listed in Schedule
5.20(a)(ii)(B). In the event Schedules 1.1(c) and 5.20(a)(i)(B) for the
Cozaar/Hyzaar/Fortzaar patent estate are not complete or correct as of the date
of this Agreement, (x) DuPont may amend such schedules prior to the Closing and
such schedules shall be deemed amended for all purposes under this Agreement,
and (y) Buyer shall make any assignments necessary to effectuate DuPont's or the
Retained Subsidiaries' ownership of such Patents, it being understood that (i)
with respect to all Patents corresponding to the last four Patents listed in
Schedule 1.1(c), such Patents shall be added to the Schedules 1.1(c) and
5.20(a)(i)(B), (ii) with respect to Patents that relate solely to AII Blockers,
DuPont shall exercise its reasonable good faith judgment in making such
corrections, and (iii) with respect to Patents that relate to AII Blockers but
not solely, DuPont shall first obtain the consent of Buyer, not to be
unreasonably withheld or delayed; PROVIDED, HOWEVER, that no such Patents under
the foregoing (i), (ii), and (iii) shall include any of those listed on Schedule
3.14(a)(i).
(b) From and after the Closing, (i) Buyer shall cause each of
the Transferred Business Companies not to amend, extend or modify any agreement,
commitment or arrangement with Merck & Co., Inc. or any of its Affiliates listed
on Schedule 5.20(b) (each a "DUPONT MERCK AGREEMENT") which amendment, extension
or modification would have an adverse effect on DuPont or any of the Retained
96
Subsidiaries pursuant to the terms of any DuPont Merck Agreement or would result
in the termination of any such agreement or which would be the subject of a
guarantee or similar obligation of DuPont or any of the Retained Subsidiaries or
otherwise is binding on DuPont or any of the Retained Subsidiaries or any of
their respective properties or assets and (ii) Buyer shall cause each of the
Transferred Business Companies to comply with any and all obligations of such
Transferred Business Company under any of the DuPont Merck Agreements (including
DPC's acting as DuPont's agent pursuant to any such DuPont Merck Agreements)
where the failure of a Transferred Business Company to comply with any such
obligations is reasonably likely to give rise to a Liability of DuPont or any
Retained Subsidiary.
(c) From and after the Closing, (i) DuPont shall not, and
shall cause the Retained Subsidiaries not to, amend, extend or modify any DuPont
Merck Agreement, which amendment, extension or modification would have an
adverse effect on any of the Transferred Business Companies pursuant to the
terms of any DuPont Merck Agreement or would result in the termination of such
agreement or would be the subject of a guarantee or similar obligation of any
Transferred Business Company or any of the Transferred Business Companies
respective properties or assets and (ii) DuPont shall, and shall cause the
Retained Subsidiaries to, comply with any and all obligations of DuPont and such
Retained Subsidiaries under the DuPont Merck Agreements where the failure of
DuPont or such Retained Subsidiaries to comply with any such obligations is
reasonably likely to give rise to a Liability of a Transferred Business Company.
(d) DuPont shall not unreasonably withhold or delay its
consent to (i) the assignment by DPC of the Agency Agreement (including all its
rights and obligations thereunder) to a reputable third-party manufacturer
capable of performing DPC's obligations thereunder or (ii) to any other
reasonable arrangement with Merck & Co. Inc. in lieu thereof for the supply to
Merck & Co. Inc. of Losartan finished products; PROVIDED that, in either case,
Merck & Co. Inc. consents in writing to such assignment or alternative
arrangement. --------
5.21 SECTION 754 ELECTION. Buyer, Buyer Sub 1, Buyer Sub 2 and
DuPont shall cooperate and take any and all actions reasonably required to
ensure that a valid election under Section 754 of the Code is in effect with
respect to DPC for the taxable year that includes the Closing Date.
5.22 RESPONSIBILITY FOR SUBSIDIARIES. (a) All obligations owed to
Buyer Sub 1 or Buyer Sub 2, and all deliveries and notices required to be
provided to Buyer Sub 1 and Buyer Sub 2, pursuant to this Agreement shall be
deemed to have been satisfied and complied with if performed with respect to
Buyer, which shall be deemed to be authorized to take actions and receive
deliveries and notices on their
97
behalf. Buyer agrees, for the benefit of DuPont and its Affiliates, to cause
Buyer Sub 1 and Buyer Sub 2 to perform all of their respective obligations and
agreements pursuant to this Agreement and hereby fully guarantees to DuPont and
its Affiliates their performance hereunder.
(b) All obligations owed to any Subsidiaries of DuPont, and
all deliveries and notices required to be provided to any such Subsidiaries,
pursuant to this Agreement shall be deemed to have been satisfied and complied
with if performed with respect to DuPont, which shall be deemed to be authorized
to take actions and receive deliveries and notices on their behalf. DuPont
agrees, for the benefit of Buyer and its Affiliates, to cause its Subsidiaries
(including the Transferred Business Companies prior to the Closing) to perform
all of their respective obligations and agreements pursuant to this Agreement
and hereby fully guarantees to Buyer and its Affiliates their performance
hereunder.
5.23 MAINTENANCE OF PARTNERSHIP EXISTENCE. Buyer agrees that from
and after the Closing, Buyer shall not, and shall not permit any of its
Subsidiaries to, terminate or shorten the term of the Partnership Agreement
governing DPC or dissolve, cause or permit the dissolution of DPC, unless in
each case such action would not result in a modification or termination of DPC's
agency pursuant to (i) the Bulk Losartan Supply Agreement, dated as of March 31,
1993, between DuPont and Merck and Co. Inc. or (ii) the Losartan Finished
Product Supply Agreement, dated March 31, 1993, between DuPont and Merck & Co.,
Inc. (the "LOSARTAN MANUFACTURING AGREEMENTS"). In the event that Buyer or any
of its Affiliates sell any or all of the DPC Interests after the Closing, Buyer
shall cause the purchaser of such DPC Interests to agree to be bound by the
provisions of this Section 5.23. The foregoing covenant shall terminate
immediately following any termination of the Losartan Manufacturing Agreements.
5.24 DELIVERY OF FINANCIAL STATEMENTS.
(a) DuPont shall cause to be delivered to Buyer not later than
the earlier to occur of thirty (30) Business Days before the Closing Date and
September 1, 2001 (i) an audited combined balance sheet of the Transferred
Business Companies (including the Additional Transferred Assets and the Assumed
Liabilities) at December 31, 2000 and audited combined statements of income and
cash flows of the Transferred Business Companies for the year ended December 31,
2000 (the "AUDITED 2000 FINANCIAL STATEMENTS") and (ii) an audited combined
balance sheet of the Transferred Business Companies (including the Additional
Transferred Assets and the Assumed Liabilities) at December 31, 1999 and audited
combined statements of income and cash flows of the Transferred Business
Companies for the year ended December 31, 1999 (the "AUDITED 1999 FINANCIAL
STATEMENTS" and, taken together
98
with the Audited 2000 Financial Statements, the "AUDITED FINANCIAL STATEMENTS"),
in each case together with a report without qualification or exception of
PricewaterhouseCoopers LLP, DuPont's independent accountants, with respect
thereto. DuPont shall use its reasonable best efforts to cause
PricewaterhouseCoopers LLP to provide to Buyer any consent necessary for Buyer
to include such report in any filing made by Buyer under applicable securities
laws.
(b) For each fiscal quarter ending after December 31, 1999 and
before the Closing, DuPont shall deliver to Buyer, in each case of each fiscal
quarter ending on or prior to June 30, 2001, not later than August 15, 2001, and
for each fiscal quarter thereafter, within 45 days after the last day of such
fiscal quarter promptly after they are available, unaudited combined balance
sheets and unaudited combined statements of income of the Transferred Business
Companies as of the end of such fiscal quarter and for the period then ended
(each, an "UNAUDITED INTERIM FINANCIAL STATEMENT").
(c) The Audited Financial Statements and the Unaudited Interim
Financial Statements shall be prepared in accordance with GAAP and the
requirements of Regulation S-X of the Exchange Act.
5.25 CERTAIN REAL ESTATE MATTERS. Upon the request of Buyer, DuPont
and Buyer shall use their good faith efforts for a period commencing on the date
of this Agreement and expiring on the first (1st) anniversary of the date of
this Agreement, to negotiate a commercially reasonable purchase agreement with
respect to the purchase by Buyer of not less than fifteen (15) and no more than
forty (40) acres owned by DuPont or a Subsidiary of DuPont located adjacent to
the facility owned by DDI and located in Manati, Puerto Rico; PROVIDED, HOWEVER,
nothing contained herein shall be deemed to require DuPont or such Subsidiary to
consummate such purchase and sale or to incur any cost or expense in connection
therewith and the failure to so consummate such purchase and sale shall not
affect the rights and the obligations of the parties hereunder.
ARTICLE VI
TAX MATTERS
6.1 TAX INDEMNIFICATION.
(a) DUPONT'S INDEMNIFICATION OF BUYER. DuPont shall indemnify
Buyer and its Affiliates and hold them harmless from, against and in respect of,
without duplication, (i) any Taxes of the Transferred Business Companies
99
or in respect of the Transferred Equipment, for or relating to any taxable
period ending on or before the Closing Date and the portion of any Straddle
Period (as defined herein) ending on the Closing Date (computed in accordance
with Section 6.2 hereof) (each, a "PRE-CLOSING TAX PERIOD") (including any Taxes
arising as a result of the removal of the Excluded Assets from the Transferred
Business Companies) (ii) any Taxes with respect to the Transferred Equipment
attributable to any Pre-Closing Tax Period; and (iii) any Taxes (as a result of
Treasury Regulation 1.1502-6 or otherwise) of any entity (other than a
Transferred Business Company) with whom any Transferred Business Company has
ever been affiliated or with whom any Transferred Business Company joins or has
ever joined (or has ever been required to join) in filing prior to the Closing
Date, any consolidated combined or unitary Tax Return; PROVIDED that, for
purposes of this Section 6.1(a) DuPont shall be credited for any estimated or
other similar Tax payments made or accrued by DuPont, any of the Transferred
Business Companies, or any of their Subsidiaries on or before the Closing Date;
and PROVIDED FURTHER that, except as otherwise provided by Section 6.4(b)(i),
DuPont shall be liable for Taxes of a Controlled Foreign Subsidiary or DPL for a
Pre-Closing Tax Period only to the extent that the aggregate amount of such
Taxes exceeds $300,000 (the "FOREIGN TAX THRESHOLD AMOUNT"); (iv) any U.S.
federal, state and local Taxes resulting from the Section 338(g) and Section
338(h)(10) elections (or any comparable elections under state or local Tax law)
contemplated by Section 6.6(d) of this Agreement; (v) all liability for
reasonable legal fees and expenses for any item attributable to an item
described in this Section 6.1(a); (vi) any income, franchise or other similar
Taxes resulting from the allocation of income, gain, loss, deduction and credit
of DPC to its partners for any Pre-Closing Tax Period; and (vii) any Transfer
Taxes for which DuPont is responsible under Section 6.5 hereof. Notwithstanding
the foregoing, DuPont shall not indemnify and hold harmless Buyer and its
Affiliates from any liability for Taxes directly related to any action taken on
or after the Closing Date by Buyer or any of its Affiliates (other than any such
action expressly required or permitted by this Agreement or required by
applicable law) (a "BUYER TAX ACT").
(b) BUYER'S INDEMNIFICATION OF DUPONT. Buyer shall, and shall
cause the Transferred Business Companies to, indemnify DuPont and its Affiliates
and hold them harmless from, against and in respect of, without duplication, (i)
any Taxes of the Transferred Business Companies for any taxable period beginning
after the Closing Date and the portion of any Straddle Period beginning after
the Closing Date (computed in accordance with Section 6.2 hereof) (each, a
"POST-CLOSING TAX PERIOD"); (ii) any income, franchise or other similar Taxes
resulting from the allocation of income, gain, loss, deduction and credit of DPC
to its partners for any Post-Closing Tax Period; (iii) all liability for Taxes
directly related to a Buyer Tax Act; (iv) all liability for reasonable legal
fees and expenses for any item attributable to an item described in this Section
6.1(b); (v) any Taxes of Controlled
100
Foreign Subsidiaries for which DuPont is not liable pursuant to Section 6.1(a);
(vi) any Taxes with respect to the Transferred Equipment attributable to any
Post-Closing Tax Period; and (vii) any Transfer Taxes for which Buyer is
responsible under Section 6.5 hereof.
6.2 CLOSING OF CURRENT TAXABLE YEAR, ETC.
(a) CLOSING OF TAXABLE YEAR. To the extent required or
permitted by Law (including, without limitation, pursuant to Treasury
Regulations promulgated under Section 1502 of the Code), the parties shall elect
to close any taxable year of the Transferred Business Companies as of the close
of business on the Closing Date.
(b) STRADDLE PERIODS. In the case of any taxable period that
includes (but does not end on) the Closing Date (a "STRADDLE PERIOD"), the Taxes
of the Transferred Business Companies for the Pre-Closing Tax Period and
Post-Closing Tax Period shall be determined based on an interim closing of the
books as of the close of business on the Closing Date, notwithstanding the
foregoing, (i) exemptions, allowances, credits, deductions or other Tax Items
(such as real, personal and other property or similar Taxes) that must under
applicable Law be calculated on an annual basis (including, without limitation,
the annual limitation applicable to any Transferred Business Company pursuant to
Section 382 of the Code and the Treasury Regulations promulgated thereunder) and
(ii) all real, personal and other property or similar Taxes relating to the
Transferred Equipment shall be determined by reference to the relative number of
days in the pre-Closing and post-Closing portions of such Straddle Period.
(c) CLOSING OF THE PARTNERSHIP TAXABLE YEAR. Consistent with
Section 6.2(a) hereof, DuPont and Buyer acknowledge and agree that the
partnership taxable year of DPC shall terminate as of the close of business on
the Closing Date, in accordance with Treasury Regulation Sections 1.708-1(b)(3)
and 1.706-1(c), utilizing a "closing of the books" methodology.
6.3 TAX RETURNS.
(a) Except as provided in Section 6.5 hereof, DuPont shall
prepare, or cause to be prepared in accordance with applicable Law, and file or
cause to be filed, when due, all Tax Returns (other than Straddle Period Tax
Returns) with respect to Taxes for which DuPont is responsible as described in
Section 6.1(a) hereof, including, without limitation, income, franchise, or
other similar Tax Returns for any Transferred Business Company for any
Pre-Closing Tax Period. Buyer shall and shall cause the Transferred Business
Companies to cooperate with, and take any
101
action reasonably requested by, DuPont with respect to the preparation and
filing of such Tax Returns. The immediately preceding sentence shall, in no way,
be construed as limiting or otherwise modifying the rights and obligations of
the parties under Section 6.7 hereof.
(b) Except as provided in Section 6.5 hereof, Buyer shall
prepare, or cause to be prepared in accordance with applicable Law (in the case
of any Straddle Period Tax Return, consistent with past practice for such Tax
Return) and file or cause to be filed, when due, all Tax Returns with respect to
the Transferred Business Companies and the Transferred Equipment required to be
filed other than those described in Section 6.3(a) hereof.
(c) If either DuPont or Buyer is obligated under this
Agreement to bear the economic burden for any portion of the Tax payable in
connection with any Tax Return to be prepared and filed by the other (or an
Affiliate of the other), the party responsible for filing such return (the
"PREPARER") shall prepare and deliver to the other party (the "PAYOR") a copy of
such return and any schedules, work papers and other documentation that are
relevant to the preparation of the portion of such return for which the Payor is
or may be liable hereunder not later than thirty (30) days prior to the due date
for such Tax Return (including applicable extensions) (the "DUE DATE"). The
Preparer shall not file such Tax Return until the earlier of (i) the receipt of
written notice from the Payor indicating the Payor's consent thereto, or (ii)
one (1) day prior to the Due Date.
The Payor shall have the option of providing to the Preparer,
at any time at least ten (10) days prior to the Due Date, written instructions
as to how the Payor wants any, or all, of the Tax Items for which it may be
liable reflected on such Tax Return. The Preparer shall, in preparing such Tax
Return, cause the items for which the Payor is liable hereunder to be reflected
in accordance with the Payor's instructions on such Tax Return. In the absence
of having received instructions from Payor, such items shall be reported in any
manner determined by the Preparer.
6.4 CONTEST PROVISIONS.
(a) NOTIFICATION OF CONTESTS. DuPont and its Affiliates, on
the one hand, and Buyer and its Affiliates, on the other hand (the "RECIPIENT"),
shall notify the other party in writing within ten (10) Business Days of receipt
by the Recipient of written notice of any pending or threatened audits,
adjustments, assessments, examinations or proceedings (whether judicial or
administrative) (a "TAX Audit") which may affect the liability for Taxes of such
other party or may give rise to an indemnification payment under Section 6.1 by
such other party. For purposes of the preceding sentence, Buyer shall notify
DuPont of any notice received
102
by Buyer relating to a Tax Audit of a Controlled Foreign Subsidiary or DPL for
any Pre-Closing Tax Period. If the Recipient fails to give such notice to the
other party, or if such notice is not in sufficient detail to notify the other
party of the nature of the Tax Audit, the Recipient shall not be entitled to
indemnification for any Taxes arising in connection with such Tax Audit to the
extent such failure to give notice materially adversely affects the other
party's right to participate in and contest the Tax Audit.
(b) WHICH PARTY CONTROLS.
(i) DUPONT'S ITEMS. If such Tax Audit relates to any
Taxes for which DuPont is liable hereunder, DuPont shall at its expense
control the defense and settlement of such Tax Audit (including, without
limitation, selection of counsel, determining whether to pursue or forego
any and all administrative appeals, proceedings (whether judicial or
administrative), hearings and conferences with any Tax Authority with
respect thereto, and may, in its sole discretion, either pay the Tax
claimed and xxx for a refund where applicable Law permits such refund
suits or contest such Tax Audit in any permissible manner). In no case
shall Buyer, the Transferred Business Companies or any of their Affiliates
settle or otherwise compromise any Tax Audit referred to in the preceding
sentence without DuPont's prior written consent. In addition, if a Tax
Audit relates to a Tax of a Controlled Foreign Subsidiary for a
Pre-Closing Tax Period and the Foreign Tax Threshold Amount has not been
exceeded, DuPont shall have the right (but not the obligation) to control
the defense and settlement of such Tax Audit, provided that DuPont agrees
to be responsible for the Taxes assessed in such Tax Audit and any such
Taxes shall not be applied to the Foreign Tax Threshold Amount.
(ii) BUYER'S ITEMS. If such Tax Audit relates to any
Taxes for which Buyer is liable in full hereunder, Buyer shall at its
expense control the defense and settlement of such Tax Audit (including,
without limitation, selection of counsel, determining whether to pursue or
forego any and all administrative appeals, proceedings (whether judicial
or administrative), hearings and conferences with any Tax Authority with
respect thereto, and may, in its sole discretion, either pay the Tax
claimed and xxx for a refund where applicable Law permits such refund
suits or contest such Tax Audit in any permissible manner).
103
(iii) COMBINED AND MIXED ITEMS. If such Tax Audit
relates to Taxes for which both DuPont and Buyer are liable hereunder, to
the extent possible such Tax Items will be distinguished and each party
will control the defense and settlement of those Taxes for which it is so
liable.
If such Tax Audit relates to any Straddle Period and any
Tax Item cannot be identified as being a liability of only one party or
cannot be separated from a Tax Item for which the other party is liable,
the party which has the greater potential liability for those Tax Items
that cannot be so attributed or separated (or both) shall control the
defense and settlement of the Tax Audit, PROVIDED that, such party defends
the items as reported on the relevant Tax Return.
(iv) PARTICIPATION RIGHTS. Any party who is entitled to
participate but does not control a Tax Audit under this Section 6.4(b)
shall participate at its own expense in the defense of such Tax Audit and
employ counsel of its choice at its expense and the party controlling such
Tax Audit under this Section 6.4(b) shall in good faith keep such party
informed with respect to such Tax Audit and, upon the reasonable request
of such party, shall consult with such party from time to time regarding
the conduct of such Tax Audit.
6.5 TRANSFER TAXES. Notwithstanding any other provision of this
Agreement, one-half of all excise, sales, use, value added, transfer (including
real property transfer), stamp, documentary, filing, recordation and other
similar taxes arising directly or indirectly from the Closing ("TRANSFER
TAXES"), shall be paid to the appropriate Tax Authority by DuPont and one-half
of such Transfer Taxes shall be paid by Buyer. Notwithstanding Section 6.3
hereof, which shall not apply to Tax Returns relating to Transfer Taxes, any Tax
Returns that must be filed in connection with Transfer Taxes shall be prepared
and filed when due by the party primarily responsible for filing such Tax
Returns under the applicable Law imposing such Transfer Taxes; PROVIDED that
such Tax Returns shall be prepared and filed jointly by DuPont and Buyer if
either (i) no party to this Agreement is or (ii) both DuPont, on the one hand,
and Buyer, DPC or the Transferred Business Companies, on the other hand, are
primarily responsible for filing such Tax Returns under the applicable Law
imposing such Transfer Taxes.
104
6.6 CERTAIN POST-CLOSING SETTLEMENT PAYMENTS AND POST-CLOSING
ACTIONS.
(a) BUYER'S CLAIMING, RECEIVING OR USING OF REFUNDS AND
OVERPAYMENTS. If Buyer or any of its Affiliates (a) receives any refund of Tax,
or (B) utilizes the benefit of any overpayment of Taxes which, in each case (a)
and (B), (x) relates to Taxes paid or accrued by DuPont or any of its
Subsidiaries with respect to a Pre-Closing Tax Period, or portion thereof,
ending on or before the Closing Date, or (y) is the subject of indemnification
by DuPont pursuant to this Agreement, Buyer shall transfer, or cause to be
transferred, to DuPont, within ten (10) days of receipt, the entire amount of
the refund or overpayment (including interest), net of any Tax payable by Buyer
or any of its Affiliates with respect thereto (including with respect to any
interest on such refund or overpayment), received or utilized by Buyer or any of
its Affiliates. Buyer agrees to notify DuPont within ten (10) days after the
discovery of a right to claim any such refund or overpayment and the receipt of
any such refund or utilization of any such overpayment. Buyer agrees to claim
any such refund or to utilize any such overpayment as soon as possible and to
furnish to DuPont all information, records and assistance necessary to verify
the amount of the refund or overpayment. The amount of economic benefit of any
refunds, credits or offsets of Taxes of the Transferred Business Companies for
any Straddle Period shall be equitably apportioned between DuPont and Buyer on a
"closing of the books" basis, except with respect to items calculated on an
annual or per diem basis, in which case apportionment shall be on a pro rata
basis.
(b) DUPONT'S CLAIMING, RECEIVING OR USING OF REFUNDS AND
OVERPAYMENTS. If DuPont or any of its Affiliates (a) receives any refund of Tax,
or (B) utilizes the benefit of any overpayment of Taxes which, in each case (A)
and (B), (x) relates to Taxes paid by Buyer or any of its Subsidiaries with
respect to a taxable period, or portion thereof, beginning after the Closing
Date (including any refund of Tax in a Pre-Closing Tax Period by reason of a
carryback from a Post-Closing Tax Period) or (y) is the subject of
indemnification by Buyer pursuant to this Agreement, DuPont shall transfer, or
cause to be transferred, to Buyer, within ten (10) days of receipt, the entire
amount of the refund or overpayment (including interest), net of any Tax payable
by DuPont or any of its Affiliates with respect thereto (including with respect
to any interest on such refund or overpayment), received or utilized by DuPont
or any of its Affiliates. DuPont agrees to notify Buyer within ten (10) days
after the discovery of a right to claim any such refund or overpayment and the
receipt of any such refund or utilization of any such overpayment. DuPont agrees
to claim any such refund or to utilize any such overpayment as soon as possible
and to furnish to Buyer all information, records and assistance necessary to
verify the amount of the refund or overpayment.
105
(c) PRE-CLOSING TAX RETURNS. None of Buyer, the Transferred
Business Companies or any of their Affiliates shall amend any Tax Return
prepared and filed by DuPont pursuant to Section 6.3(a) hereof. DuPont agrees to
reasonably cooperate with Buyer to claim any refund arising from carrybacks from
a Post-Closing Tax Period to a Pre-Closing Tax Period as soon as possible.
(d) SECTION 338(g) AND (h)(10) ELECTIONS. DuPont and Buyer
agree to make Section 338(g) elections with respect to the Controlled Foreign
Subsidiaries and that no Section 338(g) election shall be made with respect to
DPL. DuPont and Buyer agree to make Section 338(h)(10) elections with respect to
DPRL and DCI.
(e) PR TAX GRANT. DuPont and Buyer acknowledge that Buyer may
seek an amendment to Buyer's existing grant with respect to Puerto Rico Taxes
and intends for the PR Tax Grant to terminate as to DuPont as of the Closing
Date, PROVIDED, HOWEVER, that DuPont and Buyer shall cooperate in good faith and
use their reasonable best efforts to obtain a letter agreement, amendment to the
PR Tax Grant, or similar agreement as expeditiously as possible (and to the
extent reasonably possible prior to August 15, 2001) from the necessary
Governmental Authorities (including, without limitation, the Puerto Rico
Department of State-Office of Industrial Tax Exemption, The Puerto Rico
Department of Treasury and the Puerto Rico Industrial Development Company),
permitting a termination as to DuPont or amendment of the PR Tax Grant as of the
Closing Date which provides in substance that, after the Closing, none of
DuPont, DPL or any DuPont Affiliate shall have any further obligations under the
PR Tax Grant and that there will be no loss of Tax benefits (including Tax
Assets) and no additional Taxes to DuPont or its Affiliates (including DPL) for
any Pre-Closing Tax Period by reason of the termination (the "PR Tax
Amendment"). Buyer and DuPont agree that to the extent that obtaining the PR Tax
Amendment results in incremental costs to Buyer that Buyer would not have
incurred except by reason of the PR Tax Amendment, DuPont shall indemnify Buyer
for 50% of such costs up to $15,000,000 and that DuPont shall bear all direct
costs of obtaining the PR Tax Amendment in excess of $15,000,000. For purposes
of the preceding sentence, costs taken into account are intended to include
costs of complying with the requirements imposed by the relevant Governmental
Authorities, but not incidental or similar costs including costs of negotiating
the PR Tax Amendment.
6.7 MUTUAL COOPERATION. DuPont and Buyer will cooperate with each
other in paying any Taxes, filing any Tax Return and conducting any Tax Audit
(including, without limitation, any judicial or administrative proceeding)
contemplated by this Agreement and, except as set forth to the contrary in this
Agreement, take such action as the other party may reasonably request including,
without
106
limitation, the following: (a) provide data for the preparation of any Tax
Return, including schedules, and make any elections that reasonably may be
required by the other party; (b) provide required documents and data and
cooperate in any Tax Audit or investigation of any Tax Return and execute
appropriate powers of attorney in favor of the other party and/or its agents;
(c) file protests or otherwise contest any proposed or asserted Tax
deficiencies, including filing petitions for redetermination or prosecuting
actions for refund in any court, and pursuing the appeal of any such actions;
(d) execute Tax Returns or other documents reasonably required by the other
party; (e) take any of the actions of the type described in Treasury Regulation
Section 1.1502-77(a), which describes the scope of the agency of the common
parent of a group of affiliated corporations; (f) provide complete access to,
and comply with reasonable requests for copies of, all Tax Returns, books and
records, data, documents, work papers, materials and other information relating
to the Taxes of the Transferred Business Companies for any taxable period; (g)
make reasonably available to each other, its officers, directors, employees and
agents for any fact finding, consultation and discussions related to the
preparation and filing of any Tax Return, the conduct of any Tax Audit
(including, without limitation, any judicial or administrative proceeding), and
any other matter with respect to Taxes; (h) execute such powers of attorney as
are reasonably requested and required by DuPont or any of DuPont's Affiliates or
Buyer or any of Buyer's Affiliates on behalf of, as the case may be, Buyer or
any of Buyer's Affiliates or DuPont or any of DuPont's Affiliates to enable the
requesting party to represent the other party in a Tax Audit involving a Tax for
which the requesting party is liable under applicable Law; and (i) provide data
requested related to the earnings and profits of DPL and information
specifically required under Section 1248 of the Code and Treasury Regulation
1.1248-7. DuPont and Buyer hereby agree to reimburse each other for reasonable
out-of-pocket expenses (excluding officers' or employees' salaries and general
corporate overhead and other similar expenses) incurred by the other in
connection with satisfying its obligations under this Section 6.8.
6.8 MAINTENANCE OF BOOKS AND RECORDS. Until the applicable statute
of limitation (including periods of waiver) has expired for any Tax Return filed
or required to be filed covering the periods up to and including the Closing
Date (including any Straddle Periods), Buyer and its Affiliates shall retain all
Tax work papers and related materials in its possession and under its control
that were used in the preparation of any such Tax Return. Buyer will notify
DuPont sixty (60) days prior to disposing of any Tax records relating to taxable
periods and will deliver to DuPont any such records requested by DuPont.
107
6.9 MISCELLANEOUS.
(a) TERMINATION OF EXISTING TAX SHARING AGREEMENTS. DuPont
hereby agrees and covenants that any Tax Sharing Agreement to which any of the
Transferred Business Companies is a party will cease to apply to the Transferred
Business Companies as of the Closing Date.
(B) SECTION 41 NOTIFICATION. Pursuant to Code Section
41(f)(3)(B), DuPont shall provide Buyer with the "qualified research
expenditures" (as DuPont has interpreted Code Section 41(b)) and the "gross
receipts" (as DuPont has interpreted Code Section 41(c)(6)) used by DuPont to
calculate the "fixed base percentage" as defined in Code Section 41(c)(3) of the
Business being acquired by Buyer.
(c) INTERPRETATION. To the extent that there is a conflict
between any provision of this Article VI and any other provision of this
Agreement that otherwise would be applicable with respect to any Taxes, Tax
Returns, Tax Audits, Tax indemnification claims or any other matter related to
Taxes, the provisions of this Article VI shall govern.
ARTICLE VII
CONDITIONS TO THE SALE
7.1 CONDITIONS TO THE OBLIGATIONS OF THE SELLERS TO EFFECT THE SALE.
The obligations of the Sellers to effect the Sale and the other transactions
contemplated hereby shall be subject to the fulfillment, or written waiver by
the Sellers, at or prior to the Closing of each of the following conditions:
(a) REPRESENTATIONS AND WARRANTIES. The representations and
warranties of Buyer contained in Sections 4.1 and 4.2 shall be true and correct
in all material respects as of the date of this Agreement and the Closing Date.
The representations and warranties of Buyer contained in Article IV hereof
(other than Sections 4.1 and 4.2) that are qualified by materiality or by Buyer
Material Adverse Effect shall be true and correct in all respects as of the date
of this Agreement and the Closing Date, and the representations and warranties
contained in Article IV hereof (other than Sections 4.1 and 4.2) that are not
qualified by materiality or by Buyer Material Adverse Effect shall be true and
correct in all material respects as of the date of this Agreement and the
Closing Date, except (i) to the extent such representations and warranties speak
as of an earlier date, in which case they shall be so true and correct as of
such date or (ii) in the case of the representations and warranties of
108
Buyer contained in Article IV hereof that are not qualified by Buyer Material
Adverse Effect (other than those in Sections 4.1 and 4.2) for any such failures
to be true and correct in all respects as would not, taken individually or in
the aggregate with any inaccuracies of the other representations and warranties
of Buyer contained in Article IV, have or reasonably be expected to have a Buyer
Material Adverse Effect.
(b) PERFORMANCE BY BUYER. Buyer shall have performed and
complied in all material respects with all agreements, obligations, covenants
and conditions required by this Agreement to be performed or complied with by
Buyer on or prior to the Closing.
(c) CERTIFICATES. Buyer shall have furnished DuPont with a
certificate signed by its Chief Financial Officer to the effect that the
conditions set forth in Sections 7.1(a) and 7.1(b) hereof have been satisfied.
(d) NO INJUNCTION OR PROCEEDING. No statute, rule, regulation,
executive order, decree, preliminary or permanent injunction or restraining
order shall have been enacted, entered, promulgated or enforced by any
Governmental Authority which prohibits or restricts the consummation of the
Sale.
(e) REQUIRED ANTITRUST APPROVALS. All required waiting periods
and approvals applicable to this Agreement and the transactions contemplated
hereby with respect to the Required Antitrust Approvals shall have expired or
been received or terminated, and all filings, approvals, waiting periods and
orders of Governmental Authorities under Antitrust Laws, the failure to obtain
which would expose DuPont or any of its Subsidiaries (or any officer, director
or employee of any of the foregoing) to criminal charges, shall have expired or
been received or terminated.
7.2 CONDITIONS TO THE OBLIGATIONS OF BUYER TO EFFECT THE SALE. The
obligation of Buyer to effect the Sale and the other transactions contemplated
hereby shall be subject to the fulfillment, or written waiver by Buyer, at or
prior to the Closing of each of the following conditions:
(a) REPRESENTATIONS AND WARRANTIES OF DUPONT. The
representations and warranties of DuPont contained in Sections 3.1, 3.2 and 3.3
shall be true and correct in all material respects as of the date of this
Agreement and as of the Closing Date. The representations and warranties of
DuPont contained in Article III hereof (other than Sections 3.1, 3.2 and 3.3)
that are qualified by materiality or by Material Adverse Effect shall be true
and correct in all respects as of the date of this Agreement and the Closing
Date, and the representations and warranties contained in Article III hereof
(other than Sections 3.1, 3.2 and 3.3) that are not qualified by
109
materiality or by Material Adverse Effect shall be true and correct in all
material respects as of the date of this Agreement and the Closing Date, except
(i) to the extent such representations and warranties speak as of an earlier
date, in which case they shall be so true and correct as of such date and (ii)
in the case of the representations and warranties of DuPont contained in Article
III hereof that are not qualified by Material Adverse Effect (other than
Sections 3.1, 3.2 and 3.3), for any such failures to be true and correct in all
material respects as would not, taken individually or in the aggregate with any
inaccuracies of the other representations and warranties of DuPont contained in
Article III, have or reasonably be expected to have a Material Adverse Effect.
(b) PERFORMANCE BY THE SELLERS. The Sellers shall have
performed and complied in all material respects with all agreements,
obligations, covenants and conditions required by this Agreement to be performed
or complied with by them on or prior to the Closing (other than those contained
in Section 5.25).
(c) CERTIFICATES. DuPont shall have furnished Buyer with such
certificate signed by its Chief Financial Officer to the effect that the
conditions set forth in Sections 7.2(a) and 7.2(b) hereof have been satisfied.
(d) NO INJUNCTION OR PROCEEDING. No statute, rule, regulation,
executive order, decree, preliminary or permanent injunction or restraining
order shall have been enacted, entered, promulgated or enforced by any
Governmental Authority which prohibits or restricts the consummation of the Sale
or which otherwise would reasonably be expected to have a Material Adverse
Effect or Buyer Business Material Adverse Effect, nor shall any proceeding by
any Governmental Authority seeking any of the foregoing be pending or
threatened.
(e) REQUIRED ANTITRUST APPROVALS. All required waiting periods
and approvals applicable to this Agreement and the transactions contemplated
hereby with respect to the Required Antitrust Approvals shall have expired or
been received or terminated and all filings, approvals, waiting periods and
orders of Governmental Authorities under Antitrust Laws, the failure to obtain
which would expose Buyer, the Transferred Business Companies or any of their
respective Subsidiaries (or any officer, director or employee of any of the
foregoing) to criminal charges or the failure of which to comply with would,
individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect or a Buyer Material Adverse Effect, shall have expired or been
received or terminated.
The conditions set forth in Sections 7.2(d) and 7.2(e) above shall be deemed
satisfied if the failure to satisfy such conditions results from Buyer's failure
to perform or comply with its obligations under Section 5.3(b). No action, suit
or proceeding
110
seeking to prohibit the Sale shall be taken into account in determining whether
the condition set forth in Section 7.2(a) has been satisfied.
ARTICLE VIII
TERMINATION AND ABANDONMENT; INDEMNIFICATION
8.1 TERMINATION. This Agreement may be terminated at any time prior
to the Closing:
(a) by mutual consent of DuPont and Buyer;
(b) by DuPont or Buyer if the Closing shall not have occurred
on or before December 31, 2001 (the "OUTSIDE DATE"), PROVIDED, HOWEVER, that the
terminating party shall have fulfilled its obligations contained in Section 5.3
prior to exercising its right to termination hereunder;
(c) by DuPont or Buyer if any Governmental Authority shall
have issued an order, decree or ruling or taken any other action restraining,
enjoining or otherwise prohibiting any material portion of the transactions
contemplated hereunder and such order, decree, ruling or other action shall have
become final and nonappealable; PROVIDED, HOWEVER, that the terminating party
shall have fulfilled its obligations contained in Section 5.3 prior to
exercising its right to termination hereunder;
(d) by Buyer upon written notice to DuPont if any of the
conditions to the Closing set forth in Section 7.2 shall have become incapable
of fulfillment by the Outside Date and shall not have been waived in writing by
Buyer; or
(e) by DuPont upon written notice to Buyer if any of the
conditions to the Closing set forth in Section 7.1 shall have become incapable
of fulfillment by the Outside Date and shall not have been waived in writing by
DuPont.
8.2 PROCEDURE AND EFFECT OF TERMINATION. In the event of termination
of this Agreement pursuant to Section 8.1 hereof, written notice thereof shall
forthwith be given to the other party, and, except as set forth below, this
Agreement shall terminate and be void and have no effect and the transactions
contemplated hereby shall be abandoned; PROVIDED that if such termination shall
result from the failure of a party to perform a covenant, obligation or
agreement in this Agreement or from the breach by Buyer or DuPont of any
representation or warranty contained herein, such party shall be fully liable
for any and all damages incurred or suffered by
111
the other party as a result of such failure or breach. If this Agreement is
terminated as provided herein:
(a) each party hereto will redeliver, and will cause its
agents (including, without limitation, attorneys and accountants) to redeliver,
all documents, work papers and other material of each party hereto relating to
the transactions contemplated hereby, whether obtained before or after the
execution hereof;
(b) all Information received by Buyer with respect to the
business, operations, Assets or financial condition of DuPont or its
Subsidiaries shall remain subject to the Confidentiality Agreement;
(c) DuPont agrees that all confidential information received
by DuPont or its Affiliates or their Representatives with respect to Buyer or
this Agreement or the transactions contemplated hereby shall be kept
confidential (subject to the proviso in Section 5.15(a)) notwithstanding the
termination of this Agreement; and
(d) notwithstanding the termination hereof, the following
Sections of this Agreement shall remain in full force and effect: (i) Sections
3.16 and 4.4 relating to brokers, (ii) the penultimate sentence of Section 5.2
relating to confidentiality matters, (iii) Section 9.13 relating to certain
expenses and (iv) Sections 8.1 and 8.2.
8.3 SURVIVAL OF REPRESENTATIONS, WARRANTIES AND COVENANTS. The
representations and warranties contained herein shall survive the Closing and
shall thereupon terminate 18 months from the Closing, except that (i) the
representations contained in Sections 3.1, 3.2, 3.3, 4.1 and 4.2 shall survive
indefinitely, (ii) the representations contained in Section 3.10 shall survive
until the expiration of the applicable statute of limitations with respect to
the matter at issue, and (iii) the representations contained in Section 3.12
shall survive until the third anniversary of the Closing. All covenants and
agreements contained herein which by their terms contemplate actions following
the Closing shall survive the Closing and remain in full force and effect in
accordance with their terms. All other covenants and agreements contained herein
shall not survive the Closing and shall thereupon terminate, except that claims
for indemnification in respect of any breach thereof shall survive until the
second anniversary of the Closing.
8.4 INDEMNIFICATION. (a) DuPont shall indemnify and hold harmless
Buyer and its Subsidiaries and each of their Affiliates and each of Buyer's, its
Subsidiaries', and its Affiliates' respective officers, directors, employees,
and agents (collectively, the "BUYER INDEMNIFIED PARTIES") from and against any
Losses
112
(other than indemnification related to Taxes which shall be covered exclusively
by Article VI) arising from or in connection with (i) the failure of the Sellers
to duly perform or observe any term, provision, covenant or agreement to be
performed or observed by the Sellers pursuant to this Agreement the remedy for
which survives the Closing, (ii) any of the Retained Liabilities and any
Liabilities arising out of the Retained Business whether arising prior to or
after the Closing, and (iii) any breach, or failure to be true, as of the date
of this Agreement or as of the Closing, of any representation of DuPont set
forth in Article III of this Agreement (other than Section 3.10); PROVIDED,
HOWEVER, that no indemnification shall be available with respect to any breach
or failure to be true of Section 3.12 for any matter as to which Buyer is
required to indemnify the DuPont Indemnified Parties under Section 8.5 and (iv)
any claim, action, proceeding, suit or litigation commenced by Merck & Co. Inc.
or any of its Affiliates with respect to the execution, delivery or performance
of this Agreement and/or the execution, delivery or performance of a Related
Agreement in accordance with its respective terms.
(b) Buyer shall indemnify and hold harmless DuPont and its
Subsidiaries and each of their Affiliates and each of DuPont's, its
Subsidiaries' and its Affiliates' respective officers, directors, employees, and
agents (collectively, the "DUPONT INDEMNIFIED PARTIES") from and against any
Losses arising from or in connection with (i) the failure of Buyer to duly
perform or observe any term, provision, covenant or agreement to be performed or
observed by Buyer pursuant to this Agreement the remedy for which survives the
Closing, (ii) except to the extent that Buyer would be entitled to be
indemnified in respect thereof pursuant to subsection (a)(iii) above (without
giving effect to Section 8.3, Section 8.4(h) and Section 8.4(i)), any of the
Assumed Liabilities and any Liabilities of the Transferred Business Companies
arising out of the Transferred Business or the Transferred Assets (other than
Retained Liabilities) whether arising prior to or after the Closing, (iii)
except to the extent that Buyer would be entitled to be indemnified in respect
thereof pursuant to subsection (a)(iii) above (without giving effect to Section
8.3, Section 8.4(h) and Section 8.4(i)) or that such Liabilities arise from or
are related to willful misconduct by a DuPont Indemnified Party, any Liabilities
of DuPont or DPI arising from or related to its status as a holder of
partnership interests of DPC, and (iv) any breach, or failure to be true, as of
the date of this Agreement or as of the Closing Date, of any representation of
Buyer set forth in Article IV of this Agreement.
(c) Notwithstanding anything herein to the contrary, any
indemnification claims relating to any Seller Environmental Liabilities shall be
made exclusively under Sections 8.4(a)(i), 8.4(a)(iii) (but only insofar as
Section 3.12 is concerned) or Section 8.5.
113
(d) Any calculation of Losses for purposes of this Section 8.4
(including for purposes of determining the amount of Losses for purposes of
sub-sections (h) and (i) below) or any indemnity payments made under Article VI
hereof shall be (i) net of any insurance recovery made by the Indemnified Party
(whether paid directly to such Indemnified Party or assigned by the Indemnifying
Party to such Indemnified Party) and (ii) (x) increased to take into account any
net Tax cost incurred by the Indemnified Party arising from the receipt or
accrual of indemnity payments hereunder (grossed-up for such increase) and (y)
reduced to take account of any net Tax benefit realized by the Indemnified Party
arising from the deductibility of any such Losses or Taxes. Any indemnification
payment hereunder shall initially be made without regard to this paragraph and
shall be increased or reduced to reflect any such net Tax cost (including
gross-up) or net Tax benefit only after the Indemnified Party has actually
realized such cost or benefit. For purposes of this Agreement, an Indemnified
Party shall be deemed to have "actually realized" a net Tax cost or a net Tax
benefit to the extent that, and at such time as, the amount of Taxes payable by
such Indemnified Party is increased above or reduced below, as the case may be,
the amount of Taxes that such Indemnified Party would have been required to pay
but for the receipt or accrual of the indemnity payment or the deductibility of
such Losses or Taxes, as the case may be. The amount of any increase or
reduction hereunder shall be adjusted to reflect any Final Determination with
respect to the Indemnified Party's liability for Taxes and, if necessary, DuPont
or Buyer, as the case may be, shall make payments to the other to reflect such
adjustment. Any indemnity payment under this Agreement shall be treated as an
adjustment to the Purchase Price, for Tax purposes, unless a Final Determination
with respect to the Indemnified Party or any of its Affiliates causes any such
payment not to be treated as an adjustment to the Purchase Price for Tax
purposes. Each of the parties shall notify the other parties if it receives
notice that any Tax Authority proposes to treat any indemnity payment under this
Agreement as other than an adjustment to the Purchase Price for Tax purposes. A
party (and its Affiliates) shall not be deemed to have suffered a "Loss" with
respect to an item to the extent such party was actually compensated therefor by
reason of an increase in the amount otherwise paid to it or a reduction in the
amount otherwise paid by it pursuant to Section 2.4 hereof.
(e) No Action, claim or setoff for Losses subject to
indemnification under this Section 8.4 shall be brought or made with respect to
claims for Losses resulting from a breach of any covenant contained in this
Agreement, or in any representation, after the date on which such covenant or
representation shall terminate pursuant to Section 8.3 hereof; and PROVIDED,
HOWEVER, that any claim made after the Closing with reasonable specificity by
the party seeking indemnification (the "INDEMNIFIED PARTY") to the party from
which indemnification is sought (the "INDEMNIFYING PARTY") within the time
periods set forth in Section 8.3 shall survive (and be subject to
indemnification) until it is finally and fully resolved.
114
(f) (i) Upon receipt by the Indemnified Party of notice from a
third party of any action, suit, proceeding, claim, demand or assessment against
such Indemnified Party which might give rise to a claim for Losses under Section
8.4, the Indemnified Party (or DuPont or Buyer on behalf of an Indemnified
Party) shall promptly give written notice thereof to the Indemnifying Party
indicating the nature of such claim and the basis therefor; PROVIDED, HOWEVER,
that failure to give such notice shall not affect the indemnification provided
hereunder except to the extent the Indemnifying Party shall have been actually
prejudiced as a result of such failure. A claim to indemnity hereunder may, at
the option of the Indemnified Party, be asserted as soon as Losses have been
threatened by a third party orally or in writing, regardless of whether actual
harm has been suffered or out-of-pocket expenses incurred; PROVIDED, HOWEVER,
the Indemnified Party shall first have reasonably determined that it may be
liable or otherwise incur such Losses. However, payments for Losses for Third
Party Claims which are otherwise covered by the indemnification obligations
herein shall not be required except to the extent that the Indemnified Party has
expended out-of-pocket sums. The Indemnifying Party shall have the right, at its
option, to assume the defense of, at its own expense and by its own counsel, any
such matter involving the asserted liability of the Indemnified Party as to
which the Indemnifying Party shall have acknowledged its obligation to fully
indemnify the Indemnified Party. If any Indemnifying Party shall, in accordance
with the preceding sentence, undertake to compromise or defend any such asserted
liability, it shall promptly notify the Indemnified Party of its intention to do
so, and the Indemnified Party shall agree to cooperate fully with the
Indemnifying Party and its counsel in the compromise of, or defense against, any
such asserted liability; PROVIDED, HOWEVER, that the Indemnifying Party shall
not settle any such asserted liability without the written consent of the
Indemnified Party; PROVIDED, FURTHER, HOWEVER, that the immediately preceding
proviso shall not apply in the case of any settlement which releases the
Indemnified Party completely in connection with such matter and which provides
relief consisting solely of money damages borne by the Indemnifying Party.
Notwithstanding an election to assume the defense of such action or proceeding,
such Indemnified Party shall have the right to employ separate counsel and to
participate in the defense of such action or proceeding. The Indemnifying Party
shall bear the reasonable fees, costs and expenses of one such separate counsel
in each jurisdiction (and shall pay such fees, costs and expenses at least
quarterly), if, but only if, (i) the defendants in, or targets of, any such
action or proceeding include both an Indemnified Party and the Indemnifying
Party, and such Indemnified Party shall have reasonably concluded that there may
be legal defenses available to it or to other Indemnified Parties which are
different from or additional to those available to the Indemnifying Party (in
which case the Indemnifying Party shall not have the right to direct the defense
of such action or proceeding on behalf of the Indemnified Party); (ii) the
Indemnifying Party shall not have employed counsel reasonably satisfactory to
such Indemnified Party to represent such Indemnified Party within a reasonable
115
time after notice of the institution of such action or proceeding; or (iii) the
Indemnifying Party shall authorize such Indemnified Party to employ separate
counsel at the Indemnifying Party's expense. In addition, the Indemnifying Party
shall be liable for the fees and expenses of counsel employed by the Indemnified
Party for any period during which the Indemnifying Party has not assumed the
defense thereof. In any event, the Indemnified Party and its counsel shall
cooperate with the Indemnifying Party and its counsel and shall not assert any
position in any proceeding inconsistent with that asserted by the Indemnifying
Party; PROVIDED, HOWEVER, that the foregoing shall not prevent the Indemnified
Party from taking the position that it is entitled to indemnification hereunder.
All out-of-pocket costs and expenses incurred in connection with an Indemnified
Party's cooperation shall be borne by the Indemnifying Party. In any event, the
Indemnified Party shall have the right at its own expense to participate in the
defense of such asserted liability.
(ii) In the event any Indemnified Party should have an
indemnification claim against any Indemnifying Party under this Agreement that
does not involve a claim by a third party, the Indemnified Party shall promptly
deliver notice of such claim to the Indemnifying Party in writing and in
reasonable detail. The failure by any Indemnified Party to so notify the
Indemnifying Party shall not relieve the Indemnifying Party from any liability
that it may have to such Indemnified Party, except to the extent that the
Indemnifying Party has been actually prejudiced by such failure. If the
Indemnifying Party does not notify the Indemnified Party within 20 Business Days
following its receipt of such notice that the Indemnifying Party disputes such
claim, such claim specified by the Indemnified Party in such notice shall be
conclusively deemed a liability of the Indemnifying Party under this Article
VIII and the Indemnifying Party shall pay amount of such liability to the
Indemnified Party on demand, or in the case of any notice in which the amount of
the claim is estimated, on such later date when the amount of such claim is
finally determined. If the Indemnifying Party disputes its liability with
respect to such claim in a timely manner, the Indemnifying Party and the
Indemnified Party shall proceed in good faith to negotiate a resolution of such
dispute and, if not resolved through negotiations, such dispute shall be
resolved by litigation in the appropriate court of competent jurisdiction.
(g) The indemnification provisions of this Article VIII (i)
shall, in the case of the representations and warranties, be the exclusive
remedy following the Closing with respect to breaches thereof, (ii) shall apply
without regard to, and shall not be subject to, any limitation by reason of
set-off, limitation or otherwise and (iii) are intended to be comprehensive and
not to be limited by any requirements of Law concerning prominence of language
or waiver of any legal right
116
under any Law (including, without limitation, rights under any workers
compensation statute or similar statute conferring immunity from suit). The
obligations of the parties set forth in this Section 8.4 and in Section 8.5
shall be conditioned upon the Closing having occurred.
(h) Notwithstanding anything to the contrary set forth herein,
except with respect to breaches of Sections 3.1, 3.2, 3.3, 4.1 and 4.2 (as to
which none of the provisions of this Section 8.4(h) shall apply), neither DuPont
nor Buyer shall be required to provide indemnification under Sections
8.4(a)(iii) and 8.4(b)(iv) to the Buyer Indemnified Parties or DuPont
Indemnified Parties, respectively, unless the aggregate amount of Losses
incurred by the Buyer Indemnified Parties or DuPont Indemnified Parties, as
applicable, with respect to such breaches (in the aggregate), exceeds $100
million (the "BASKET"), in which case the obligation to provide indemnification
under Sections 8.4(a)(iii) and 8.4(b)(iv) to the Buyer Indemnified Parties or
Seller Indemnified Parties, as the case may be, shall only apply with respect to
such amounts that are in excess of the Basket; PROVIDED, HOWEVER, that Losses
covered by the indemnification provisions of Article VI or Section 8.5 hereof
shall not be applied, or be subject, to the Basket.
(i) Notwithstanding anything to the contrary set forth herein,
except with respect to breaches of Sections 3.1, 3.2, 3.3, 3.15, 4.1 and 4.2 (as
to which none of the provisions of this Section 8.4(i) shall apply), neither
DuPont nor Buyer shall be required to provide indemnification to Buyer
Indemnified Parties or the Seller Indemnified Parties, respectively, under
Sections 8.4(a)(iii) and 8.4(b)(iv) when the amount of Losses paid by DuPont or
Buyer, as applicable, with respect thereto exceeds 30% of the Purchase Price
(the "CAP"); PROVIDED, HOWEVER, that Losses covered by the indemnification
provisions of Article VI or Section 8.5 hereof shall not be applied, or be
subject, to the Cap.
8.5 ENVIRONMENTAL MATTERS.
(a) CERTAIN DEFINITIONS. For purposes of this Section 8.5, (i)
"TRANSFERRED ENVIRONMENTAL ASSETS" shall mean (A) the Transferred Assets, (B)
all other Assets of any of the Transferred Business Companies acquired from and
after the Closing or used in the operation or conduct of the Transferred
Business from and after the Closing, and (C) all Assets and businesses listed on
Schedule 8.5(a)(i); and (ii) "RETAINED ENVIRONMENTAL ASSETS" shall mean (A) the
Assets of DuPont and the Retained Subsidiaries following the consummation of the
transactions contemplated by this Agreement, (B) the Former DPC Assets, and (C)
all Assets of DuPont and the Retained Subsidiaries acquired from and after the
Closing and used in the operation or conduct of the Retained Business from and
after the Closing, but, in each case of this clause (ii), excluding all
Transferred Environmental Assets.
117
(b) On the terms and subject to the conditions set forth in
this Agreement, DuPont agrees to indemnify, defend and hold harmless the Buyer
Indemnified Parties from and against and shall reimburse such Indemnitees with
respect to all Losses, other than those relating to matters set forth in
Schedule 3.12, arising out of or related to, directly or indirectly, those
Losses with respect to all Environmental Claims and requirements of
Environmental Laws (whether or not under applicable Law DuPont or any Retained
Subsidiary would have a right of contribution against any Transferred Business
Company therefor) set forth below (the "SELLER ENVIRONMENTAL LIABILITIES"):
(i) Losses with respect to the Transferred Environmental
Assets arising from or in connection with the generation, manufacturing,
transporting, storage, handling, treatment, storage, spill, discharge, or
disposal of any Hazardous Substances prior to the Closing, including but
not limited to Losses arising from the presence of Hazardous Substances
at, on or under any of Transferred Environmental Assets prior to the
Closing or at, on or under any property or facility not located on any of
the Transferred Environmental Assets into which Hazardous Substances from
any of the Transferred Environmental Assets were disposed prior to the
Closing;
(ii) Losses arising from the failure of the Transferred
Environmental Assets to be in compliance prior to the Closing with any
Environmental Laws or Environmental Permits in effect as of and
enforceable as of the Closing whether or not such failure is the subject
of notification from a Governmental Authority either before or after the
Closing;
(iii) Losses relating to any Environmental Claim to the
extent arising from actual or alleged pre-Closing exposure to or Release
of Hazardous Substances at or from the operations of the Transferred
Environmental Assets; and
(iv) Losses with respect to the Transferred
Environmental Assets arising after the Closing and emanating from, or in
any way related to, the operation of any of the Retained Environmental
Assets.
(c) The indemnity in Section 8.5(b) shall be subject to the
following limitations: (i) if the costs of cleanup or correcting non-compliance
with Environmental Laws or Environmental Permits subject to indemnity by Buyer
and its
118
Subsidiaries are increased after the Closing Date due to an act or omission by a
Person other than DuPont and its Subsidiaries, their agents, contractors and
subcontractors, acting on their own or under the supervision or direction of any
Governmental Authority, to the extent not resulting from a change in
Environmental Laws after the Closing, DuPont and its Subsidiaries shall not be
responsible for any such increase in costs incurred; (ii) if DuPont or any of
its Subsidiaries are performing their obligations pursuant to Section 8.5(b),
DuPont and its Subsidiaries shall not be responsible for the costs associated
with Buyer's oversight of DuPont and its Subsidiaries' performance, including
the cost of Buyer's oversight of DuPont and its Subsidiaries' legal counsel,
consultants, or employees; and (iii) in performing the obligations under this
Section 8.5(b), DuPont and its Subsidiaries shall not be responsible for any
costs that are incurred by Buyer and its Subsidiaries due to any change related
to the Transferred Environmental Assets resulting or arising from (a) the
closure or sale of a facility or business, (b) the construction of new
structures or equipment, or the modification to existing structures or
equipment, (c) a change in use of any facility to a use substantially unrelated
to that at Closing, or (d) capital improvements or repairs and modifications to
capital improvements, PROVIDED THAT DuPont shall be responsible for any such
capital improvements, repairs and modifications to or associated with the
Transferred Environmental Assets to the extent required to allow the facility to
meet pre-Closing requirements of Environmental Laws or Environmental Permits at
levels of production substantially equivalent to those at Closing or
necessitated by any condition existing on or related to the Transferred
Environmental Assets prior to Closing.
(d) On the terms and subject to the conditions set forth in
this Agreement, Buyer agrees to indemnify, defend and hold harmless the Seller
Indemnified Parties from and against and shall reimburse such Indemnitees with
respect to all Losses arising out of or related to, directly or indirectly,
those Liabilities with respect to all Environmental Claims and requirements of
Environmental Laws (whether or not under applicable Law DuPont would have a
right of contribution against Buyer or any of its Subsidiaries) set forth below
(the "BUYER ENVIRONMENTAL LIABILITIES"):
(i) Liabilities arising from or in connection with the
generation, manufacturing, transporting, storage, handling, treatment,
storage, spill or discharge of any Hazardous Substances at the Transferred
Environmental Assets or otherwise arising from the operation of the
Transferred Environmental Assets after the Closing;
(ii) Liabilities arising from the failure of the
Transferred Environmental Assets after the Closing to be in compliance
with any Environmental Laws; and
119
(iii) Liabilities arising from the matters set forth in
Schedule 3.12 hereto.
(e) As between the parties to this Agreement, (i) Buyer will
have full authority to control, direct, manage and implement remediation and to
determine its scope, and conduct all negotiations, meetings and settlements with
Governmental Authorities with respect to Buyer Environmental Liabilities;
PROVIDED, HOWEVER, that Buyer may contract with DuPont on mutually agreeable
terms for DuPont to perform any such activities with respect to Buyer
Environmental Liabilities on Buyer's behalf, for such reasonable period of time
until an orderly transfer of such activities to Buyer can be arranged, and (ii)
DuPont will have authority to control, direct, manage and implement remediation
and to determine its scope, and conduct all negotiations, meetings and
settlements with Governmental Authorities with respect to Seller Environmental
Liabilities; PROVIDED, HOWEVER, that DuPont may contract with Buyer on mutually
agreeable terms for Buyer to perform any such activities with respect to Seller
Environmental Liabilities on DuPont's behalf, for such reasonable period of time
until an orderly transfer of such activities to DuPont can be arranged, and
PROVIDED, FURTHER, that Buyer, either directly or through its designee, will
have the right to participate in all discussions, negotiations and settlements
with any Governmental Authority concerning any remediation or other activity
relating to the Transferred Environmental Assets, including receiving in a
timely fashion copies of all communications, correspondence and data relating to
such remediation and activity, and the right to comment directly and
independently to the pertinent Governmental Authority on any matter that could
affect ongoing operations at any of the Transferred Environmental Assets; and
PROVIDED, FURTHER, that if Buyer or any of its Subsidiaries are performing their
obligations pursuant to Section 8.5(d), they shall not be responsible for any
costs associated with DuPont's oversight of Buyer, including costs attributable
to oversight of Buyer's and its Subsidiaries' legal counsel, consultants or
employees.
(f) Any claim for Indemnity by a Buyer Indemnified Party
seeking indemnification under Section 8.5(b) must be received by DuPont within
five years of the Closing, except that there shall be no time limit for claims
brought under 8.5(b)(iii) relating to toxic tort claims. If a claim is not
received within the applicable time period, it shall no longer constitute a
Seller Environmental Liability and shall become a Liability of Buyer and Buyer
shall indemnify DuPont and its Subsidiaries against any Liability arising from
such a claim.
(g) Notwithstanding any provisions of Environmental Laws or
the provisions or principles of any other statutory or common law including,
without limitation, the Comprehensive Environmental Response, Compensation and
Liability Act, as amended, and state law analogues, the provisions of this
Section 8.5
120
and, to the extent relating to environmental matters, Section 8.4, shall
constitute the parties' exclusive remedy with respect to each other for all
Environmental Claims and Liabilities under Environmental Laws arising from the
ownership of, or conduct of business with respect to, the Transferred
Environmental Assets or the Retained Environmental Assets. The obligations of
the parties set forth in this Section 8.5 shall be conditioned upon the Closing
having occurred.
(h) Except as otherwise provided in this Section 8.5 or as
would be inconsistent herewith, the provisions of Sections 8.4(d), (f) and (g)
shall apply to this Section 8.5 and claims for indemnification hereunder.
ARTICLE IX
MISCELLANEOUS
9.1 AMENDMENT AND MODIFICATIONS. This Agreement may be amended,
modified or supplemented at any time by the parties hereto, but only by an
instrument in writing signed on behalf of the parties.
9.2 EXTENSION; WAIVER. At any time prior to the Closing, the parties
hereto entitled to the benefits of the respective term or provision may (a)
extend the time for the performance of any of the obligations or other acts of
the parties hereto, (b) waive any inaccuracies in the representations and
warranties contained herein or in any document, certificate or writing delivered
pursuant hereto or (c) waive compliance with any obligation, covenant, agreement
or condition contained herein. Any agreement on the part of a party to any such
extension or waiver shall be valid only if set forth in an instrument in writing
signed on behalf of the party not entitled to the benefits of such extension or
waiver. No failure or delay on the part of any party hereto in the exercise of
any right hereunder shall impair such right or be construed to be a waiver of,
or acquiescence in, any breach of any representation, warranty or agreement
herein, nor shall any single or partial exercise of such right preclude other or
further exercise thereof or any other right.
9.3 REPRESENTATIONS AND WARRANTIES; ETC. (a) Buyer hereby
acknowledges and agrees that neither DuPont nor any Subsidiary thereof nor any
of their Representatives is making any representation or warranty whatsoever,
express or implied, except those representations and warranties explicitly set
forth in this Agreement and the Related Agreements.
(b) DuPont hereby acknowledges and agrees that neither Buyer nor any
Subsidiary thereof nor any of their Representatives is making any
121
representation or warranty whatsoever, express or implied, except those
representations and warranties explicitly set forth in this Agreement and the
Related Agreements.
9.4 ENTIRE AGREEMENT; ASSIGNMENT. This Agreement, together with the
Related Agreements, (a) constitutes the entire agreement among the parties with
respect to the subject matter hereof and supersedes all other prior agreements
and understandings, both written and oral, among the parties with respect to the
subject matter hereof (other than the Confidentiality Agreement) and (b) shall
not be assigned by operation of law or otherwise; PROVIDED, HOWEVER, that Buyer
may assign its rights and obligations to any wholly owned Subsidiary of Buyer
(unless to do so would restrict or delay the consummation of the transactions
contemplated by this Agreement), but no such assignment shall relieve Buyer of
its obligations hereunder.
9.5 VALIDITY. The invalidity or unenforceability of any provision of
this Agreement shall not affect the validity or enforceability of any other
provisions of this Agreement, each of which shall remain in full force and
effect.
9.6 NOTICES. All notices, requests, claims, demands and other
communications hereunder shall be in writing and shall be deemed to have been
duly given if delivered personally, telecopied (which is confirmed) or sent by
registered or certified mail (postage prepaid, return receipt requested) to the
parties at the following addresses:
If to Buyer, to:
Xxxxxxx-Xxxxx Squibb Company
000 Xxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attn: General Counsel
With a copy to:
Cravath, Swaine & Xxxxx
Worldwide Plaza
000 Xxxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attn: Xxxxx Xxxxxxx, Esq.
122
If to the Sellers or DPC, to:
E.I. du Pont de Nemours and Company
0000 Xxxxxx Xxxxxx
Xxxxxxxxxx, XX 00000
Attn: Xxxx X. Xxxx, Esq.
Corporate Counsel - Mergers & Acquisitions
With a copy to:
Skadden, Arps, Slate, Xxxxxxx & Xxxx LLP
Xxxx Xxxxx Xxxxxx
Xxx Xxxx, XX 00000
Attn: Xxx X. Xxxxx, Esq.
or to such other address as the Person to whom notice is given may have
previously furnished to the others in writing in the manner set forth above
(PROVIDED that notice of any change of address shall be effective only upon
receipt thereof).
9.7 GOVERNING LAW. This Agreement shall be governed by and construed
in accordance with the laws of the State of Delaware, regardless of the laws
that might otherwise govern under applicable principles of conflicts of laws
thereof.
9.8 SPECIFIC PERFORMANCE. The parties hereto agree that if any of
the provisions of this Agreement were not performed in accordance with their
specific terms or were otherwise breached, irreparable damage would occur, no
adequate remedy at law would exist and damages would be difficult to determine,
and that the parties shall be entitled to specific performance of the terms
hereof, in addition to any other remedy at law or equity.
9.9 PUBLICITY. Each of the parties to this Agreement hereby agrees
with the other party hereto that, except as may be required to comply with the
requirements of any applicable Laws, and the rules and regulations of each stock
exchange upon which the securities of one of the parties is listed (in which
case the party so required to make such release shall use its reasonable best
efforts to allow the other party reasonable time to comment thereon in advance
of such issuance), no press release or similar public announcement or
communication shall, if prior to the Closing, be made or be caused to be made
concerning the execution or performance of this Agreement unless the parties
shall have agreed in advance with respect thereto.
9.10 JURISDICTION; FORUM, ETC. (a) The parties hereto agree that the
appropriate, exclusive, and convenient forum for any disputes between any of the
parties hereto arising out of this Agreement or the transactions contemplated
hereby
123
shall be in any state or federal court in the State of Delaware. The parties
hereto further agree that the parties will not bring suit with respect to any
disputes arising out of this Agreement or the transactions contemplated hereby
in any court or jurisdiction other than the above specified courts; PROVIDED,
HOWEVER, that the foregoing shall not limit the rights of the parties to obtain
execution of judgment in any other jurisdiction; PROVIDED, FURTHER, HOWEVER,
that the foregoing shall not limit (i) DuPont's or any of its Subsidiaries'
ability or right to join, implead or otherwise bring any third-party claim
against Buyer or any of its Subsidiaries in an action brought against DuPont or
any of its Subsidiaries by a third party in a jurisdiction outside of the State
of Delaware and Buyer agrees that, pursuant to Sections 9.10(b) and 9.10(c), it
(and its Subsidiaries, as applicable) will submit to such jurisdiction or (ii)
Buyer's or any of its Subsidiaries' ability or right to join, implead or
otherwise bring any third-party claim against DuPont or any of its Subsidiaries
in an action brought against Buyer or any of its Subsidiaries by a third party
in a jurisdiction outside of the State of Delaware and DuPont agrees that,
pursuant to Sections 9.10(b) and 9.10(c), it (and its Subsidiaries, as
applicable) will submit to such jurisdiction. The parties hereto further agree,
to the extent permitted by law, that final and unappealable judgment against a
party in any action or proceeding contemplated above shall be conclusive and may
be enforced in any other jurisdiction within or outside the United States by
suit on the judgment, a certified or exemplified copy of which shall be
conclusive evidence of the fact and amount of such judgment.
(b) (i) By the execution and delivery of this Agreement, Buyer
(A) irrevocably designates and appoints CT Corporation (the "AGENT") as its
authorized agent upon which process may be served in any suit or proceeding
arising out of or relating to this Agreement, and (B) agrees that service of
process upon the Agent shall be deemed in every respect effective service of
process upon Buyer in any such suit or proceeding. Buyer further agrees, at its
own expense, to take any and all action, including the execution and filing of
any and all such documents and instruments, as may be necessary to continue such
designation and appointment of the Agent in full force and effect so long as
this Agreement shall be in effect. The foregoing shall not limit the rights of
any party to serve process in any other manner permitted by law.
(c) To the extent that any party hereto has or hereafter may
acquire any immunity from jurisdiction of any court or from any legal process
(whether through service or notice, attachment prior to judgment, attachment in
aid of execution, execution or otherwise) with respect to itself or its
property, each such party hereby irrevocably (i) waives such immunity in respect
of its obligations with respect to this Agreement, and (ii) submits to the
personal jurisdiction of any court described in Section 9.10(a).
124
(d) THE PARTIES HERETO AGREE THAT THEY HEREBY IRREVOCABLY
WAIVE AND AGREE TO CAUSE THEIR RESPECTIVE SUBSIDIARIES TO WAIVE, THE RIGHT TO
TRIAL BY JURY IN ANY ACTION TO ENFORCE OR INTERPRET THE PROVISIONS OF THIS
AGREEMENT.
9.11 DESCRIPTIVE HEADINGS. The descriptive headings herein are
inserted for convenience of reference only and are not intended to be part of or
to affect the meaning or interpretation of this Agreement.
9.12 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which
shall constitute one and the same agreement.
9.13 EXPENSES. Whether or not the transactions contemplated by this
Agreement are consummated, and except as otherwise expressly set forth herein,
all legal and other costs and expenses incurred in connection with the
transactions contemplated by this Agreement shall be paid by the party incurring
such expenses.
9.14 PARTIES IN INTEREST. This Agreement shall inure to the benefit
of and be binding upon the parties hereto and their respective successors and
permitted assigns. Nothing in this Agreement, express or implied, is intended to
confer upon any Person other than DuPont, Buyer (and their respective
Subsidiaries) and their successors or permitted assigns, any rights or remedies
under or by reason of this Agreement, it being understood that the foregoing
shall not limit the right of DuPont Indemnified Party or a Buyer Indemnified
Party to bring claims for indemnification under Section 8.4 or Section 8.5 in
respect of Losses.
9.15 INTERPRETATION. An item arising with respect to a specific
representation or warranty shall be deemed to be "reflected on," "set forth in"
or "given effect in numbers on" a balance sheet, to the extent any such phrase
appears in such representation or warranty, to the extent that (a) there is a
reserve, accrual or other similar item underlying a number on the face of such
balance sheet that relates to the subject matter of such representation or (b)
such item is otherwise specifically set forth on the face of such balance sheet
or in the notes thereto.
When a reference is made in this Agreement to Sections, such
reference shall be to a Section of this Agreement unless otherwise indicated.
The headings contained in this Agreement are for reference only and shall not
affect in any way the meaning or interpretation of this Agreement. Wherever the
words "include," "includes" or "including" are used in this Agreement, they
shall be deemed to be followed by the words "without limitation."
125
9.16 SCHEDULES. The disclosure of any matter in any Schedule to this
Agreement shall expressly not be deemed to constitute an admission by DuPont or
Buyer, or to otherwise imply, that any such matter is material for the purpose
of this Agreement.
126
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first above written.
E.I. DU PONT DE NEMOURS AND COMPANY
By:
----------------------------------------
Name:
Title:
DUPONT PHARMA, INC.
By:
----------------------------------------
Name:
Title:
DUPONT PHARMACEUTICALS COMPANY
By:
----------------------------------------
Name:
Title:
DUPONT ELECTRONIC MATERIALS, INC.
By:
----------------------------------------
Name:
Title:
DUPONT DIAGNOSTICS INC.
By:
----------------------------------------
Name:
Title:
XXXXXXX-XXXXX SQUIBB COMPANY
By:
----------------------------------------
Name:
Title:
